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Abstract  
Cancer Chemotherapy treatment involves the administration of drugs to patients, these 
drugs mainly work by interacting with the cell cycle or inhibiting DNA synthesis. 
Unfortunately, the toxicity of these chemotherapy drugs is severe and can have serious 
side-effects on different tissues and organs of the body. In chemotherapy treatment 
about 85% of cancer patients exhibit some degree of liver or kidney damage. Therefore, 
the aim of this study was to investigate the cytotoxicity of some of the most commonly 
used chemotherapy drugs; Methotrexate (MTX), Etoposide, Cisplatin and Doxorubicin 
(DOX) on liver and kidney cell lines (HepG2, Huh7.5, COS-7 and HK2). Therefore, our 
focus were on studying the molecular mechanism by which these drugs cause cell death 
in liver and kidney cells. This study also investigated the effects of some Ca
2+
 binding 
proteins (RGN, SERCA1, SERCA2b, SPCA1a, SPCA2) to test their ability to decrease 
the toxicity of these chemotherapeutic drugs in liver and kidney cells. The results 
showed that Etoposide, Cisplatin and DOX induce cell death in both kidney and liver 
cell lines via several different pathways such as apoptosis, necrosis, and autophagy. The 
results presented here also showed that several of the drugs used induced cell death by a 
novel new autophagic pathway in liver and kidney cells. Our data also suggested that 
regucalcin (RGN) and the endoplasmic reticulum Ca
2+
 pumps (SERCA1 and 
SERCA2b), but not the secretory pathway Ca
2+
 pumps (SPCA1a and SPCA2) were able 
to protect against different types of chemotherapy-induced toxicity in liver and kidney 
cells. These new observations will help to build up our awareness of the diverse effect 
of these drugs have on liver and kidney cells and may also  help to develop protective 
interventions and strategies in the future to reduce hepatotoxicity and nephrotoxicity 
caused by these drugs. 
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CHAPTER 1 
Introduction
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1 Introduction 
1.1 Chemotherapy 
It is now known that cancer is one of the major health problems of the developed world 
and causes one of the most deaths in the human population (Ma and Yu, 2006). Cancer 
can be simply defined as uncontrolled cell division; many abnormal cells that undergo 
division can lead to tumor formation in the body. Some tumor cancer cells can easily 
spread to distance locations within the body through the vascular system and 
consequently lead to secondary tumor growths or metastasis (Lodish et al., 2000).  
In spite of the different causes of cancer, i.e. genetic inheritance, environmental factors, 
age, lifestyle and nutrition, medical research over many years has developed a variety 
of different treatments. These include treatments such as radiation therapy, surgery, 
targeted therapy, immunotherapy and chemotherapy (Baskar et al., 2012). Surgery is 
usually considered the most effective option compared to other types, and if possibly is 
applied in the early stages of cancer development and diagnosis, while radiation therapy 
can be applied before or after surgery to damage / kill cancer cells. On the other hand, 
when cancers cells have spread in the body through metastasis, chemotherapy 
treatment is usually considered the main option (Baskar et al., 2012).  
Chemotherapy is a type of cancer treatment that uses medicines and drugs in order to 
prevent, slow and/or stop tumor cancer cells multiplying. Chemotherapy drugs are also 
commonly given to patients (orally or intravenously), in order to destroy any remaining 
cancer cells following surgery (Skeel and Khlief, 2011). This form of therapy mainly 
acts either by interacting with the cell cycle or inhibiting DNA replication (Payne and 
Miles, 2008).  
Approximately 60% of the commonly used anti-cancer agents are derived from natural 
resources (Cragg et al., 2005). These potential anti-cancer agents have been derived 
from plants, microorganisms, and marine organisms (Butler, 2004). The biochemical 
diversity of the natural world has in the past been a great source for developing of new 
anti-cancer agents compounds. In fact about 100 naturally derived drugs have been 
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discovered for the treatment of various cancers during the last five decades (Wagner et 
al., 2002).  
As an ideal way to improve a patients’ prognosis and life expectancy, some 
chemotherapy treatments are given in combination. This enhances the potential of such 
drugs to cause remission (Frei and Eder, 2003, Yardley, 2013). However, on the other 
hand, the toxicity of these drugs is increased. Chemotherapeutic drugs either singly or 
in combination have the ability to damage blood cells which causes by anemia, 
fatigue and immuno-supression (Groopman and Itri, 1999). Other common side effects 
of chemotherapy drugs are mouth sores, diarrhea that is the result of mucous 
membrane damage, and hair loss, which is caused by destruction of hair root and 
follicles (Raji, 2005, Lenz, 2012). Some chemotherapeutic drugs can also specifically 
damage some organs.  
The toxic effects of some of these drugs to healthy cells will induce severe side-effects 
(Kuo, 2008). Therefore, with chemotherapy treatment, unfortunately about 8% of 
cancer patients exhibit some degree of liver damage (Ramadori and Cameron, 2010). 
Some chemotherapy drugs can cause severe liver injury and even liver failure (Moar 
and Malnickls, 2013). Furthermore, some of these drugs can also affect kidney and 
heart function and causes nephrotoxicity and cardiotoxicity (Cornelison and Reed, 
1993, Christenson, 2015). This may mean that the patients are not able to continue their 
chemotherapy treatment due to serious damage caused by these hepatotoxic and 
nephrotoxic drugs that prohibit cells from performing their normal metabolic functions 
(King and Perry, 2001, Lawrence et al., 1973). 
1.2 Classes of Chemotherapy drugs 
Chemotherapy Agents are classified in several ways; they can be classified according to 
their biochemical mechanisms, chemical structures, and their interaction with each 
other. Hence, according to their mechanism of action, chemotherapy drugs can be 
divided in to some of the following types; alkylating agents, antimetabolites, anti-tumor 
antibiotics and topoisomerase inhibitors. 
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1.2.1 Alkylating Agents 
Common alkylating agents include Nitrogen mustards, Triazines, Nitrosoaureas, 
Ethylenimines and Alkyl sulfonates. These kinds of drugs mainly attack cancer cells 
through binding covalently to DNA. Unlike other chemotherapeutic agents, alkylating 
agents are not ‘phase- specific’ and have the ability to modify the DNA throughout 
their cell cycle (Warwick, 1963, Swift and Golsteyn 2014) (Figure 1.2.1A). 
 
 
Figure 1.2.1 A; stages of the cell cycle. Where G1 means cell growth and protein 
synthesis takes place (time periods, 18-30 hrs). S, is where DNA replication takes place 
(time period, 18-20 hrs). G2, is where secondary cell development and genetic code 
checking take place before M phase (time period, 2-10 hrs), and M is where all Mitosis 
stages taken places (i.e. prophase, metaphase, anaphase and telophase, etc.) and 
formation of  2 new cells (times period, 30-6- hrs) (Adapted from Cooper, 2000). 
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Nitrogen mustards alkylating agents consist of Mechorethamine, Ifosfamide, 
Melphalan, Cyclophosphamide and Chlorambucil. Mechorethamine was the first to be 
used as an anti-cancer agent (Gilman and Philips, 1946). This radiomimetic chemical 
drug is used to treat Hodgkin's disease and other lymphomas (De Alencar et al., 2014). 
Ifosfamide is also a nitrogen mustard derivative, which is used to treat solid tumors.  
This anti-agent is most often used in combination with other drugs such as Cisplatin, 
Etoposide, and Doxorubicin (Kawasaki et al., 2014). Furthermore this anticancer-drug 
is commonly used to treat sarcoma and lung cancer, but it has been known to cause 
damage to nervous system (Brunello et al., 2007) and is therefore neurotoxic (Imtiaz 
and Muzaffer, 2010).  
Melphalan has been mainly used in the treatment of multimyeloma and ovarian cancer 
(Falco et al., 2007). But Cyclophosphamide is highly recommended for treating various 
types of lymphomas in combination with other drugs (Yu, 2015), Leukemia (Assouline 
et al., 2015) and many other types of cancer. Like many other chemotherapy drugs, 
Cyclophosphamide has many side-effects and is known to cause pulmonary damage 
(Bhattacharjee et al., 2015) and is hepatotoxic (Koler and Forgren, 1958). On the other 
hand, Chlorambucil is used to treat follicular lymphoma (Herold et al., 2015). Besides 
that, this anti-cancer agent is the standard drug of choice for chronic lymphocytic 
leukemia (Goede et al., 2014) when a proportion of the lymphocytes are in the bone 
marrow. Unfortunately, many patients who have taken this drug are often diagnosed 
with liver damage as well as damage to the spleen and lymph nodes (Kolar and Forgen 
1958).  
Triazinas drugs include Decarbonize and Temozolomide. Temozolomide has been used 
in combination with other anti-cancer agents to treat Hodgkin lymphoma 
(Gandikota et al., 2015) and melanomas (Ferrucci et al., 2015, Hill and Hill, 1979). 
However, patients can suffer from   hepatic   failure   during   Temozolomide-treatment 
(Frosch et al, 1979). Decarbonize is widely used to treat brain tumors such as gliomas 
(Van Rijn, 2000).  
Nitrosoaureas is another class of alkylating agent and consist of three main drugs: 
Carmustin, Lomustin and Streptozotcin. Carmustin has been used for a long time for 
treating metastatic brain tumors (Ewend et al., 2007) and for lymphomas when used in 
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combination with Etoposide, Cytarabin and Melphalan (Martin et al., 2015). Lomustin 
is used for treating Glioblastomas and relapsed lymphoma (Harvey et al., 2015, Moore, 
1999). Recently this drug has also shown to cause hepatotoxicity (Musser et al., 2012). 
Streptozotcin is a diabetagenic compound that induces beta cell cytotoxicity when 
injected into mice and causes insulitis (Rossini et al., 1977). This drug was originally 
discovered as an antibiotic in 1959 (Vavra et al., 1959). Recently this drug h a s  been 
used in many research studies as a diabetes inducer (Oztürk et al., 2015, Zhu et al, 
2011). Streptozotcin and Carmustin can both cause irreversible changes to liver and 
kidney cells after only a few doses of treatment and changes to liver and kidney 
function  have occurred in 15% to 67% of patients, respectively,  given these drugs 
(Schein et al., 1974).  
The Ethylenimines class of chemotherapeutic drugs include; Thiotepa and 
Hexamethylmelamine. Thiotepa is a known human carcinogen (Proctor et al., 2007) and 
is used in bone marrow and stem cell transplantation. This agent can be used to treat a 
range of different cancers including; lymphoma, leukemia, and other soft and solid-
tumors (Davies, 2001). However, there have been reports of a direct correlation 
between Thiotepa and toxicity, such as mucositis, hepatitis and brain toxicity (Nieto and 
Vaughan, 2004). Hexamethylmelamine has replaced cisplatin as a better anti-cancer 
agents drug for the treatment of ovarian cancer (Rosen et al, 1987).  Furthermore, 
Hexamethylmelamine has been successfully used to treat metastatic breast cancer 
(Henderson and Shapino., 1991).  
Busulfan is the only alkylating sulfonate drug. In spite of the lung changes it causes 
during therapy (Brittig et al., 1993), busulfan is still useful to treat leukaemia 
(Underwood et al., 1971, Nagler et al., 2014).  
The platinum anticancer- drugs (e.g. Cisplatin, Carboplatin and Oxaliptin) are most 
often used with alkylating agents as they work in the same way but they are likely to be 
less immunosuppressive than the other alkylating agents (Kufe et al., 2003). Many 
researchers have suggested that the cytotoxicity of platinum drugs are different. 
Oxaliptin has less toxic side effects, while carboplatin is more myelotoxic than the 
others. Cisplatin appears to be the most neurotoxic and nephrotoxic of the platinum 
drugs (Cavaletti, 2008). Cisplatin is known as cis- diamminedichloroplatinum (CDDP) 
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and considered the first metal complex that has been used as a chemotherapy drug. It 
consists of platinum ion and is surrounded by four ligands arranged in a square; two 
are amines and two chlorides (Figure 1.2.1 B). Once cisplatin enters the cell, it loses 
these two chloride ions and binds to DNA bases (Goodsell, 2006). Cisplatin is 
commonly used in testicular cancer as well as many other epithelial malignances such  
as  ovary,  bladder,  cervix,  head,  neck,  prostate,  lymphoma,  and  carcinomas  of 
esophageal (Oyanagi, et al., 2015, Rozencweig et al., 1977). Cisplatin and other 
anticancer- agents for instance Etoposide, Doxorubicin, Vinblastine etc.,  has shown a 
potential advance in the 5 year survival rate for non-small-cell lung carcinoma (Molina 
et al., 2008). Drug distribution studies suggest that about 10% of Cisplatin dose can pass 
into the blood serum then interact with the cancer cells, while 90% of the drug 
binds to plasma proteins and therefore has no effect on cancer cells (Michael et al, 
1990, Deconti, et al., 1973). It has strongly been suggested that platinum drugs can 
accumulate in primary sensory neurons and are therefore neurotoxic, although the 
mechanism is not fully understood (Shord et al., 2002, Cavaletti et al., 2001, 1998, 
1992). Furthermore, Cisplatin also causes liver toxicity as a side effect (Waseem et al., 
2015).  
As mentioned previously, the mechanism of toxicity for this drug is complicated 
because Cisplatin has the ability to bind to various biomolecules (DNA, RNA, protein, 
and phospholipids). However, its interaction with DNA could be the most critical factor 
for inducing toxicity inside the cells (Zamble and Lippared, 1995), and apoptosis could 
be the major mechanism for this due to DNA-cross linking (Goodsell, 2006, Zhen et al., 
1992).  
As research continues, efforts have been taken to determine whether cell death by 
Cisplatin is specifically by apoptosis (Victor et al., 2001). Based on several research 
studies, cell populations treated with Cisplatin shows both pathways of cell death ie 
apoptosis and necrosis are involved (Pestell et al. 2000). Many other hypotheses of cell 
death have been suggested since for instance some leukemia cells showing apoptotic 
cell death lacked many of the morphological and biochemical features that are 
distinctive of   apoptosis (Segal-Bendirdjian and Jacquemia- Sablon, 1995). Therefore, 
necrosis cell death has been suggested the main form of cell death induced by Cisplatin, 
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However, this depends on Cisplatin concentration, cellular condition and energy 
availability (Victor et al., 2001). 
 
Figure 1.2.1 B: the structure of Cisplatin  
(Adapted from Messori and Merlino, 2016) 
 
1.2.2 Antimetabolites 
Antimetabolites drugs generally work by affecting DNA and RNA, either by 
incorporating into these genetic materials or by inhibiting their biosynthesis. These 
types of drugs damage cells during S phase and are widely used to treat variety of 
cancers (Von Hoff et al., 2003).  
Some common examples of Antimetabolites drugs include; Methotrexate, 5-
fluorouracil, 6- mercaptopurine, Capecitabine, Cladribine, Gemcitabine, Hydroxyurea 
Clofarabine, Floxuridine, Fludarabine,  Pemetrexed, Pentostatin, Thioguanine and 
Cytarabine.  
Both 5-fluorouracil and Capecitabine are commonly used in treating breast cancer 
(Asara et al., 2012, Mrozek-Orlowski et al., 1999), colorectal cancer (Twelves et al., 
2012), gastric cancer (Kang et al., 2014, He et al., 2015), pancreatic cancer (Short et 
al., 2013, Kruger et al., 2015) and colorectal cancer (Petrelli et al., 2012). 
Unfortunately, these two drugs are still considered as substantially toxic because of 
their cardiotoxicity affects (Segalini et al., 1987, Tutkun et al., 2001 and Fontanella et 
al., 2014).  
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Methotrexate (MTX) (Figure 1.2.2) is an antimetabolite agent and acts as an inhibitor of 
tetrahydrofolate reductase, which blocks tetrahydrofolate formation, a necessary 
component for nucleotide biosynthesis and thus inhibits cell division (Warlick et al., 
2000).  
 
 
Figure 1.2.2; the structure of methotrexate (Alcăntara, et al., 2010) 
 
MTX was the first antimetabolites discovered in the 1940’S (Cuellar and Espinoza, 
1997). It is also one of the most commonly used anti-rheumatic drugs and has also 
been used for decades for treatment of Psoriasis, Spondyloarthropathy, and Vasculitis,   
etc. (Laohapand,et al., 2015). This anticancer-agent has attracted physician’s attention 
for many different reasons. For instance, rheumatoid arthritis requires long term 
therapy, however, there are also many factors which increase MTX toxicity such as age, 
diabetes, obesity, hepatitis B or C  virus infection, alcohol consumption, etc. 
(Malatjalian, et al.,1996, Rheumatol 1995, sotoudehmanesh, 2010 and Bath et al., 
2014). Although MTX is widely used as anti-cancer agent, it should be used with 
monitoring due to its hepatotoxicity and haematological toxicities that it could exert 
(Gilani et al., 2012). MTX hepatotoxicity might be related to its effects on the retinoid 
receptor (Ewees et al., 2015).  MTX leads to necrosis when directly applied to 
hepatocytes (Lee, 2003). Other reports have suggested that MTX can also cause liver 
fibrosis (Jaskiewicz et al., 1996). In addition, others body organs have been shown to be 
affected during MTX therapy. Some examples are acute renal failure (Isoda et al., 
2007), lung toxicity (Kaplan, 2014), neurotoxicity (Taylor et al., 2015) 
Myelosuppresion (Hayashi, 2010), skin disorders or alopecia (Weiss et al., 1986), ocular 
irritation (Doroshow et al., 1981), men and women fertility problems (Shamberger 
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et al., 1981, Elise and Durham, 1991). For this reason, MTX therapy is closely 
monitored and avoiding daily MTX dosage (Jones and Patel, 2000). 
 
1.2.3 Anti-tumor Antibiotics 
This chemotherapy drug group can be divided into anthracyclines, (eg Daunorubicin, 
Doxorubicin (Adriamycin®), Epirubicin, Idarubicin) and non-anthracyclines groups, 
(Actinomycin-D, Bleomycin, Mitomycin-Co).  
Anthracyclines antibiotics were considered one of the most effective anticancer drugs 
ever developed when first used (Weiss, 1992). In the 1960S, the first anthracyclines, 
Daunorubicin and Doxorubicin were isolated from Streptomyces peucetius 
(Lomovskaya et al., 1999).  
The anti-cancer mechanisms of these anthracyclines is still controversial, as numerous 
papers have been published that indicate different modes of action. These includes,   
inhibition of DNA function after DNA intercalation, damaging of DNA as a result of 
free radical formation, causing alkylation, inhibiting topoisomerases II (involved in 
DNA replication), inducing apoptotic cell death and unwinding of DNA by affecting 
helicase activity (Gewirtz, 1999).  
In terms of structure there is not much difference between Daunorubicin and 
Doxorubicin, Daunorubicin terminates with methyl while Doxorubicin, terminates with 
primary alcohol.  
Doxorubicin (DOX) is a throcyclin antibiotic anti-cancer drug. Chemically, it consists 
of an amino-sugar daunosamine which is bound to C7 of the tetracycline ring structure 
(Carvalho, 2009) (Figure 1.2.3). Biochemically, DOX reacts and interferes with DNA 
and the other nucleic acids, DNA polymerases at phase G1 and G2 of the cell cycle (Lal 
et al., 2010). This interaction inhibits topoisomerase II and stops nucleic acid 
replication and transcription (Tan et al., 2009). DOX is considered one of the most 
potent chemotherapeutic drugs that is used (Carvalho, 2009), because this drug has the 
ability to damage DNA by alkalation and also inhibit enzymes that produce DNA 
and RNA by free-radical damage (Minotti et al., 2004).  
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Figure 1.2.3; the structure of Doxorubicin (Arcamone, 1981) 
Furthermore, DOX interacts with plasma membrane proteins and electron transfer 
process to causes highly reactive hydroxyl free radical formation (Cardosol et al., 
2008). In spite of these side effects, DOX is a powerful anticancer drug, either in 
isolation or in combination, for treating ovary, haematological malignance, breast, 
stomach, liver, and prostate cancers (Tacer and Dass 2013).  
In addition to what has been previously mentioned, DOX has effects on many 
biological molecules either directly or indirectly, which can lead to cell death. Cyclic 
Adenosine monophosphate (cAMP) -activated protein kinase can be activated via 
DOX in embryonic ventricular myocardial Hac2 rat cells as well causing  reactive 
oxygen species accumulation (Chen 2011). DOX has been shown to affect 
mitochondrial function which might cause elevation of reactive oxygen species 
(Armstrong and Dass, 2015). The suppressor tumor protein p53 is known to be a cell 
cycle regulator and activate DNA repair mechanisms, as well as being involved in 
angiogenesis (Sionov et al., 2000). Under certain forms of cellular stress p53 induces 
apoptosis to stop uncontrolled cell growth (Lee et al., 2002, Brooks and Gu, 2010). 
Several studies have shown that DOX induces p53 activation leading to apoptosis 
in both normal and tumor cells (Wang et al., 2004). Cell death via apoptosis during 
DOX therapy is not limited to p53 activation but also includes decreasing Bcl2 and 
increasing Bax, which leads to cytochrome c release from the mitochondria and which 
ultimately, leads apoptosis via caspase 3 activation (Leung and Wany, 1999). Once 
caspase-3 is activated it leads to the activation of caspase-6 and -7 which can also 
contribute to apoptosis cell death (Ueno et al., 2006). However, other research has 
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shown that DOX can additionally induce caspase-independent cell death (Youn et al., 
2005), by an unknown mechanism.  
 
1.2.4 Topoisomerase inhibitors 
Topoisomerases  are  a  group  of  enzymes  that  play  a  crucial  role  in  DNA  
synthesis  and replication (Andersen et al., 1996). These enzymes help in DNA strands 
separation during mitosis and cell division. As Topoisomerase II has different roles and 
modes of action compared to topoisomerase I, a number of clinical chemotherapy 
drugs have been developed, which inhibit the different types of Topoisomerases. 
These drugs include Topotecan and Irinotecan, which are Topoisomerase I inhibitors, 
while Etoposide, Teniposide and Mitoxantrone are Topoisomerase II inhibitors (Sinha, 
1995). Although, both Etoposide and Teniposide are podophyllotoxin derivatives, the 
mechanism of action of these two drugs are different from the parent compound. 
Etoposide and Teniposide arrest cells in late S and G2 phase and have no influence on 
tubulin assembly, while podophyllotoxin affect cells during mitosis by disorganizing 
tubulin polymerisation (Wozniak and Ross 1983, Loik and Horwitiz 1976, Chen et al., 
2013). Generally, Topotecan has been used to treat a number of cancers such as 
ovarian cancer (Wei et  al.,  2015), cervical  cancer  (Musa  et  al.,  2013) and  lung  
cancer (Tiseo et  al.,  2014). Mitoxantone has also been prescribed to treat breast 
cancer (Stuart-Harries et al., 1984) and lymphomas (Zinzani et al., 2013).   
Etoposide inhibits topoisomerases II and causes DNA breakage (Baldwin and 
Osheroff, 2005), however, once Etoposide treatment has stopped the DNA damage is 
quickly repaired (Teixeira et al., 2009). Etoposide is a plant–derived natural product; it 
is a podophyllotoxin derivative and is considered to be one of the most important and 
commonly used anticancer drugs (Figure 1.2.4).  
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Figure 1.2.4; the structure of Etoposide (Minev, 2011) 
 
In the early 1940s podophyllatoxins were shown to have effects on benign tumours. 
Later acyclic acetate derivatve which is prepared from 4’- demethylepipodophllotoxin 
P-D-glucopyranoside and acetaldehyde and was synthesised and tested which led to the 
development of Etoposide. This drug arrests cells on G2 phase and leads to apoptosis 
(Walker et al., 1991). Many factors are involved in apoptosis induced by etoposide, 
such as presence of certain oncogene products, growth factors, and p53, (Lowe et al., 
1993, Kamesaki et al., 1993). The cytotoxic effects of Etoposide have been 
demonstrated in many different cell lines (Hart well and Checker, 1985). Etoposide 
therapy requires careful supervision, when administered to patients, as some reports 
have shown that patients exposure to 10 µg/ml for 1 hour showed 100-fold less 
cytotoxicity compared to 1 µg/ml Etoposide given in one go (Hande,1996). At 
standard doses, this anti-cancer drug has no hepatotoxic effects, while at higher doses it 
has been shown to cause hyperbilirubinemia, elevated blood aminotransferases and 
alkaline  phosphatase  during a three  week period  of  treatment indicating of liver 
damage  (Tran  et  al.,  1991). Etoposide has been shown to have proven efficiency in 
treating various cancers, ovarian cancer (Thavaramara et al., 2009, lung cancer 
(Souhami et al., 1997), testicular cancer (Leohrer, 1991), Leukaemia (Papiez, 2013), 
Kaposiʼs sarcoma (Chagaluka et al., 2014) and lymphomas (Toyoda et al., 2014). 
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1.2.5 Other Types of chemotherapy drugs 
Numerous anti-cancer drugs are being developed using a personalized/targeted therapy 
approach. Some of these drugs are classified as chemotherapy drugs such as, L-
asparaginase  treatment  (Yeh  et  al.,  2004),  Corticosteroid  (such  as Prednisone) (Liu 
et al., 2013) and  mitotic inhibitors (such as Taxanes, Epothilones, Vinca alkaloids  and  
Estramusting  (Carvaja  et  al.,  2005). Non- chemotherapeutic drugs are considered to 
be less toxic and mainly target cancer cells and not normal healthy cells (Torrisi et al., 
2011).  
These new non typical-chemotherapeutic drugs  can be divided in to Targeted 
therapies (Shore, 2014),  hormonal  therapy  (Shore,  2014),  immunotherapy  (Van  der  
Most  et  al.,  2005). Targeted therapies are used for attacking cells with mutant versions 
of specific oncogene, or cells that are expressing too many copies of certain genes. 
Imasatinib, gefinibs, unitinib and bortezomib can be listed as targeted therapy 
(Ciavarella et al., 2010). Hormone therapy is a category of drugs that attacks cancer 
cells which are usually grown in response to natural hormones, such as some breast, 
prostate, endometrial cancers (Liu et al., 2004). However, these drugs are sex 
hormones and influence the production of female or male hormones or prevent cancer 
cells from using specific hormones that are necessary for growth (Henderson and 
Feigelson, 2000) (e.g. Anti-estrogen, Aromatase inhibitors, Progestins, Estrogen, Anti-
androgens and Gonadotropin-realising hormone). Finally, Immunotherapy is a group of 
drugs used to increase the natural immune-system in order to recognize and fight 
cancer cells (Liu et al., 2004). Some of these drugs are called ‘Active’ 
immunotherapies, which boosts or increases the body’s own immune-system to attack 
cancer cells, whilst ‘Passive’ immunotherapy provides the body with synthetic 
antibodies. Some examples of this immunotherapy agents include; Rituximab, 
alemtuzumab, and Herceptin (which are themselves antibodies) as well as BCG, 
thalidomide and interferon- Alfa which boost the immune-system (Neves and Kwok, 
2015). 
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1.3 Cell Death  
Vogt in 1842 observed and described a first form of cell death, ie the destruction of 
notochord cells, although at that time the term cell death was not used. A more rigorous 
approach to experimentally investigating cell death really started in the middle of 
twentieth century, where other researchers reported morphological changes associated 
with the death of individual cells (Saunders, 1966, Ellis and Horvitz 1986). The most 
published studies of cell death at that time were histological studies, where commonly 
noted specific morphological  features  of  cell  death  were  observed  and  later  
identified  as  hallmarks  of apoptosis (a term coined by Andrew Wyllie in the 1972) 
(Clark and Clark 1995). As this field developed, cell death, under certain circumstances, 
was viewed more as a biological control process and the term “programmed cell death” 
began to be used. Subsequently, John Kerr, was the first researcher who clarified the 
complete characteristic features of programmed cell death  starting  with  cell  rounding,  
shrinkage,  blebbing,  and  other  cytoplasmic  changing, leading to nuclear component 
alterations (Kerr, 1971, Kerr and Harman, 1991). 
1.3.1 Major Forms of cell death 
Histologically and according to the morphological observations, cell death has been 
categorized to three major types, Apoptosis, Necrosis, and Autophagy (Green, 2011).  
1.3.2 Apoptosis  
The term “apoptosis” was first coined in 1972 by Kerr, Wyllie and Currie to 
characterize the morphological and biochemical feature of programmed cell death (Kerr 
et al., 1972). These morphological features can be summarized by; Plasma membrane 
blebbing, chromatin condensation, DNA laddering, and formation of apoptotic bodies 
(Wyllie et al, 1980) (Figure 1.3.2A). Whilst, the biochemical   changes can include, 
increases in mitochondrial permeability, phosphatidylserine externalisation, and DNA 
degradation (Martin et al., 1995, Hengartner, 2000). Once these features occur, 
neighbouring cells or macrophages can distinguish these plasma membrane changes and 
engulf the apoptotic cells without any inflammatory response taking place (Jacobson et 
al., 1997). More recently, a number of other forms of programmed cell death have been 
described, which differ in some of these features and there could also be some others 
still to be elucidated (Formigli et al., 2000, Debnath et al., 2005).  
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Figure 1.3.2 A; morphological changes observed in apoptotic cell death. Cell death 
starts with the cell becoming rounded and chromatin condensation. This is followed by 
membrane blebbing and finally, fragmentation of cell into small bodies called apoptotic 
bodies (Imajoh et al., 2004).  
Apoptosis can be defined as programmed cell death involving specific gene expression 
to remove all unwanted (damaged) cells under internal or external responses (Savill 
and Fadok, 2000). Apart from removing damaged cells, apoptosis cell death maintains 
homeostasis, and plays a role in development and in the pathogenesis of some diseases 
such as cancer, human immunodeficiency virus infection, cardiovascular disorder, and  
acute neurodegeneration (Stroke, Alzheimer’s diseases) (Raffray and Coher, 1997). 
Genetic control of programmed cell death was initially identified in 1986 in the 
nematode c. elegans with the finding that ced-3, ced-4, ced-9 genes, being essential for 
the death of the cell (Ellis and Hovaritz, 1986). Several factors have now been reported  
for  cell  death  activation  including;  steroid  hormone  activation,  DNA  damage, 
growth factor withdrawal, stress (both physically and chemically induced) and death 
receptor activation (Zhou et al., 1995, Baehrecke 2002, Nowsheen and Yang 2013).  
Upon studying the molecular mechanism of programmed cell death. It was identified 
that a number of ced homologues were also identified in mammals and were found to 
belong to a family of cysteine-aspartate proteases which were named “caspases” and 
which specially cleaves protein substrates after an aspartic acid residue (Alnemri et al., 
1996).  
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According to their function, these caspases can be categorized as “initiator” caspases 
such as caspase-8, and -9, which activate the “effectors” caspase, and effector the 
caspases such as caspase-3,-6 and -7, which directly activates apoptosis (Chang and 
Yang, 2000). These caspases work together to form a caspases cascade (Cohen, 1997).  
Apoptosis has been shown to be a major cell death pathway induced by toxicological 
and chemotherapeutic drugs, a huge number of chemicals have been described which 
induce apoptotic  cell death either directly or indirectly (Kerr et al., 1994). 
 
Mechanisms of cell death  
Cells to undergo apoptosis, through intrinsic and extrinsic pathways (Figure 1.3.2B). 
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Figure 1.3.2 B; summary of the two main apoptotic pathways. Both extrinsic and 
intrinsic pathways, the extrinsic pathway starts with the ligand binding to the TNF 
receptor (a death receptor), which then activates FADD. This then activates caspase-8 
and subsequently, caspase-3. In the intrinsic pathway, the mitochondria release 
cytochrome c through the MPTP probably as a result of Bax activity or Ca
2+
 overload. 
Cytochrome c is then released and in association with Apaf1 and procaspase-9 forms 
the apoptosome which activates caspase-9 and then promotes procaspase-3 cleavage, 
leading eventually to cell death. However, caspase-8 can activate Bid to tBid, which 
connects the two pathways (Adapted from Woo et al., 2000).  
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1.3.2.1 Extrinsic apoptotic pathway 
The extrinsic apoptotic pathway is usually initiated by a specific transmembrane 
receptor interaction, which are known as death receptors, these include; Fas receptor 
(FasR), tumor necrosis factor receptor (TNFR), death receptors (DR3, DR4 and DR5), 
which are activated by FasL, TNF-α and TRAIL ligands, respectively (Locksley et al., 
2001). When Fas receptors bind the Fas Ligand, the FasR cytoplasmic domain 
reorganizes and recruits a complex involved in propagating the death inducing 
signalling pathway called fas associated death domin (FADD). FADD activates 
caspase-8, which then activates other initiator caspases such as caspase-2 and 10. These 
caspases in turn cleave the effector caspase, procaspase-3 to caspase 3 (Chang and 
Yang, 2000).  
Calcium channels may also participate in the apoptotic pathway, since calcium ion plays 
a major role in the signal transduction regulation in both cell proliferation and cell death 
(Yang et al., 2010). It is clear that the extrinsic apoptotic pathway plays an essential role 
in homeostasis and responding to external signals. Other factors also have the ability to 
trigger the extrinsic apoptotic pathway, such as bacteria, virus, RNA fragmentation and 
DNA damage (Obregόn-Henao et al., 2012), However, it is still unclear how.  
1.3.2.2 Intrinsic apoptotic pathway 
The intrinsic pathway, is also commonly referred to the mitochondrial pathway. This 
pathway is controlled via mitochondria through a family of regulator proteins known as 
Bcl2, which regulate the permeability of mitochondria membrane pores (Cory and 
Adams, 2002). Bcl2 family proteins can regulate mitochondria permeability and can 
either be pro-apoptotic or anti-apoptotic (Tsujimoto, 1998). To date, some of the Bcl2 
family proteins can be controlled by the tumour suppressor p53 (Chipuk et al., 2003). 
Generally, Bcl2 family proteins can be classified to three categories, the first category 
includes anti-apoptotic family includes Bcl2, Bcl-xl, Bcl-w and Mcl-1 proteins. The 
second category includes the pro- apoptotic proteins such as Bax, Bak and Bok. The 
third category includes BH3-domain proteins and includes a number of pro-apoptotic 
proteins such as Bid, Bim, Bik, Bad, Baf, and others (Tzifi, et al., 2012). Bax and Bak 
are essential for mitochondrial pore formation, whilst, Bid and Bad are apoptotic 
promoters since they bind to the active Bax and Bak. However, the anti-apoptotic Bcl2 
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family proteins have a role in mitochondrial permeabilization protection (Green, 2006). 
Therefore, all these proteins participate together and control mitochondrial cytochrome 
c release (Donovan and Cotter 2004, Lukovic et al., 2003). Furthermore, mitochondrial 
release of Smac/DIABLO proteins, can control this cascade by reversing inactived 
caspases (Laken and Leonard, 2001). Beside these proteins, reactive oxygen species 
(ROS) also contributes to this pathway. Increasing level of ROS also increases 
mitochondria membrane permeability. ROS also elevates polyADP ribose polymerase 
(PARP-1), an essential apoptosis-inducing factor (AIF) (Kang et al., 2004). 
Subsequently, cytochrome c, Apaf-1 and ATP enhance apoptosome formation, which 
then leads to caspase- 9 activation and apoptotic cell death. Although these pathways 
have different caspase cascades, they are not independent from each other, as caspase 8 
can cleave Bid to tBid which can then activate Bax and lead to the release of 
cytochrome c (Candẻ et al., 2002). 
Furthermore, mitochondria plays an vital role in intracellular Ca
2+ 
homeostasis, 
signalling and intracellular Ca
2+
 communication as well as cell survival (Cerella et al., 
2010). Mitochondria matrix, is a Ca
2+
 reservoir, which is helps in the accumulation of 
large amounts of Ca
2+
 (Csordas et al., 2006, Kass and Orrenius, 1999). The 
mitochondria allows the removal of excessive Ca
2+
 ions from cytosol, and therefore 
maintains Ca
2+
 cell homeostasis and signalling functions (Walsh et al., 2010). However, 
Ca
2+
 overload of the mitochondria when exceeding capacity, can lead to the 
Mitochondrial Permeability Transition Pores (MPTP) opening (Qian et al., 1999, 
Michelangli and East, 2011). Once MPTP is opened, it increases mitochondrial inner 
membrane permeability and then causes cytochrome c release. This apoptotic pathway 
is Bax translocation independent (Qian et al., 1999, Zorov et al., 2000, Mullauer et al., 
2009). Subsequently, cytochrome c activates caspase and leads to apoptotic cell death 
(Richter, 1993).   
More recently another apoptosis pathway has been identified which is called Perforin/ 
Granzymes pathway. Granzymes (granule enzymes) belong to the serine protease 
family and that are present in cytotoxic T cells. Perforin is a pore forming protein, and 
initiates rapid granzymes endocytosis, which can begin apoptosis either directly or 
indirectly (Lieberman, 2003). Perforin possibly with the help of the Ca
2+
 binding 
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protein calreticulin creates pores in the surface of the target cells, which then allow the 
granzymes to enter the cell membrane. This then allows granzyme release from 
endocytic vesicles (Figure 1.3.2 C) (Fraser et al., 2000, Shi et al., 1997). Granzyme 
A can also induce caspase-independent apoptosis via targeting the endoplasmic 
reticulum- associated complex (SET complex), which consists of p53, pp32 and NM23-
H, the nucleosome-assembly protein SET (DNA-binding protein HMG2) and APE1 
repair enzyme (Fan et al., 2002). This type of cell death induction does not involve 
mitochondria or cytochrome c activity. In contrast, Granzyme B, can induce caspase-
dependent apoptosis via caspase3/CPP32 activation (Wang et al., 1996), as well as the 
possible involvement of caspase-6,-7,-8,-9 and -10 as determined from in vitro studies 
(Preedy, 2015). Once caspase-3 becomes activated, it can cleave other pro-apoptotic 
substrates, such as poly (ADP-ribose) polymerase (PARP) and causes activation of 
caspase activated DNase, followed by morphological alteration and DNA degradation. 
For activation of both Granzyme A and B, selective proteolysis takes place, carried by 
cathepsin C/dipeptidyl peptidase I (DPPI), which is a part of pro dipeptide domine 
serine protease complex (Mc Guire, 1992, Mc Guire et al., 1993). 
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Figure 1.3.2 C; the perforin/granzyme cell death pathway in cytotoxic T cells. 
Perforin and granzyme bind to the cell surface and perforin permit granzymes to inter 
the target cell. The granzymes then induce cell death either by the extrinsic caspase 
cascade or through mitochondrial induced apoptosis (Adapted from DeFranco et al., 
2007). 
1.3.3 Necrosis cell death 
Originally necrosis was viewed as an “accidental” form of cell death and refers to 
extreme structural modifications such as cell membrane damage, which are easily 
visible under a microscope (Major and Joris, 1995). Various factors can initiate 
necrosis, which are most likely to be physical factors such as heat, diseases, Ischemia, 
oxidative stress etc. (Rani and Yadav, 2014). Necrosis is characterized by cell   
swelling, impairment of the cell membrane, cytoplasmic enzyme release, and 
inflammation of the surrounding cells and tissues (Figure 1.3.3) (Proskyuryakov et al., 
2003). Once necrosis begins, the cells secrete a variety of pro-inflammatory factors, 
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which activate the immune effector cells via the pathogen recognition receptors (PRRs) 
to initiate the inflammatory reaction this is then followed by phagocytosis via 
macrophage cells. These pro- inflammatory factors include; histone proteins, heat-shock 
proteins (e.g. HSP27, HSP60, HSP70 and HPS90) and high mobility group box proteins 
(Zitvogel et al., 2010).  
Biochemically, the most notable hallmark of necrotic cell death is karyolysis (ie 
chromatin dissolution and nuclear fading), pyknosis (chromatin condenses and 
clumping), karyorhexis (pyknotic nuclei membrane and nuclear fragmentation) and 
also phosphatidylserine (PS) exposure on the external side of the plasma membrane 
(Hammill et al., 1999).   
There has been some dispute regarding necrosis as Major and Joris (1995), suggested 
that necrosis is not a specific type of cell death but rather the end phase of any forms of 
cell death, since both necrosis and apoptosis have several similarities in their features 
especially in the advanced phase (Leist and Jaattela, 2001). Nevertheless, as apoptotic 
cells are not always recognized by phagocytes cells, this consequently led to the term of 
secondary or apoptotic necrosis (Sanders and Wide, 1995).  
 
Figure 1.3.3; Necrosis cell death. Necrosis starts with swelling of cell and organelles, 
cellular membrane rupturing and some blebbing and then ends with total cell digestion 
via cellular enzymes that releases pro-inflammatory factors into the surrounding tissues 
(Fink and Cook, 2005).  
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1.3.4 Necroptosis 
Necroptosis can be generally defined as a   regulated form of necrosis, and therefore 
shares many of the same morphological characteristics of necrosis (cellular organelle 
swelling, cellular leakage, etc.) (Hirosova and Gores, 2015).  
Cytokine tumour factors, such as TNF, play a vital role in the necroptosis pathway, 
triggering cell death and involved in immune system function (Kawasaki et al., 2002). 
Induction of regulated necrosis occurs through many different receptor families, in 
addition to TNF there are many others, such as cluster differentiation (CD 95 L) 
(which includes FASL and apoptotic antigen receptors APO-1L), receptor induction 
protein kinases (TRAIL) such as APO-2L (Holler et al., 2000), TWEAK receptor 
(Wilso and Browning 2002), T cell receptor (Chen et al., 2008). Cell inflammation 
can also be induced by genetic stress (Huang, 2013), anticancer drugs (Tenev et al., 
2011) and DNA- dependent activator of TNF-regulator factors. Once necroptosis is 
activated, the necrosome complex is formed, which consists of the receptor-inducing 
protein kinases (RIPK1), RIPK2, and caspase -8 (Berghe et al., 2014), The Fas- 
associated death domain (FADD) can also be involved in necrosome activation. Inside 
the cells, caspase -8 then recruits a series of other caspases that results in cell death. 
Alternatively, the mixed lineage kinases domain-like (MLKL) mediates events that 
ultimately leads to necroptosis without caspase -8 activation (Degterev, et al., 2005). 
Furthermore, the chemical inhibitor Necrostatin (NEC1) plays a role in blocking 
RIPK activation thereby stopping regulated necrosis (Degterev, et al., 2012).  
1.3.5 Autophagy 
Autophagy can be defined as a catabolic process involving the removal and degradation 
of unused or long lived cellular components with a view to maintaining cellular energy 
levels (Levine and Kroemer 2008). Although this process was identified in 1950’s, it 
has still not been fully elucidated (Tooze, 2012). Autophagy plays an important role in 
cell homoeostasis because it recycles unwanted amino acid, metal ions and sugars, 
thereby it helps to maintain the cells energy (Paglin et al., 2001). Furthermore, 
autophagy (which is sometimes referred to as type II programmed cell death) is initiated 
as a result of nutrient starvation, therefore the deficiency of any essential nutrient can 
trigger autophagy (Levine and Kroemer, 2008). However, autophagy, has also been 
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shown to be involved in development since it is demonstrated to cause inter-segmental 
muscle formation during embryogenesis (Daniel and Korsmeyer, 2004). According to 
its physiological roles and its removal mechanisms, autophagy can be divided in to 
three subdivisions: macroautophagy, chaperone-mediated autophagy and 
microautophagy (Kurz and Terman, 2008). Macroautophagy (commonly referred as 
classical autophagy) starts with the degradation of a portion of cytoplasm (cargo) by 
forming a double membrane organelle (autophagosome), which then fuses with 
lysosomal vesicles to form an autolysosome (Figure 1.3.5A). In chaperone-mediated 
autophagy, the cargo delivery performs by a specific sequences signal starting from 
cytoplasm, towered lysosomal membrane (Cuervo and Dice1996). However, in 
microautopgagy the lysosomal membrane itself pinches off a portion of the cytoplasm 
and then digests it via the action of lysosomal hydrolases (Ahlberg et al., 1982).   
Autophagy is initiated through activation of a series of proteins such as 
phosphoinositide 3- kinses (PI3K), Beclin 1 complex, ATGs 1, 3, 5, 7, 10, 12 and 16 as 
well as microtubule associated protein 1 light chain 3 (LC3) and 
phosphatidylethanolamine conjugation. These interactions lead to the formation of the 
phagophore which then matures into the autophagosome. The mature autophagosome  
then fuses  with  the lysosome to  form  the autolysosome  and cytoplasmic material 
encapsulated within it is subjected to digestion and degradation  (Kando et al.,   2005), 
and finally peptide units and energy produce from this process shift back to cytoplasm 
to be reused (Mizushima,  2007).   
Many  studies  on  yeast  have  helped  clarify  the  molecular  mechanisms  of  
autophagy (Klionsky, 2004) and  approximately 30 autophagy genes have so  far  
been discovered (commonly abbreviated as ATGs).  Atg1 or ULK2 (the mammalian 
Homologue) induces autophagy by binding to Atg13 controlled via phosphorylation 
which causes the Atg1-Atg13 complex to increase (Kamada et al., 2000). Furthermore, 
Beclin 1 activates the autophagy signal pathway by binding to class III 
phosphatidylinositol-3 kinases VPS34 (Kamada et al., 2000). VPS34 is associated with 
VPS15, and bind to Beclin1, which can be inhibited by the anti-apoptotic proteins 
Bcl2/Bcl-XL (Tassa et al., 2003). Beclin1 is activated to form the autophagosome by 
additionally binding the Ambra protease as well, two other proteins UVRAG and 
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endophilin B1 (Bif-1) to promote VPS34 activity, (Figure 1.3.5B) (Takahashi et al., 
2007).   
One of the biggest debates amongst scientists in the field is whether autophagy is a cell 
death mechanism as well as a cell surviving mechanism. However, some studies have 
reported that some cytotoxic agents can trigger autophagy cell death in such cells 
treated with caspases inhibitors, or expressing high levels of Bcl2 or Bcl-XL (Shimizu 
et al., 2004, Yu et al., 2004), or with caspases genetically knocked out (Wong et al, 
2013). This mechanism may also be regulated by Ca
2+
 (Wang et al, 2009).  
 
Figure 1.3.5A; macroautophagy formation process in mammalian cells. Autophagic 
isolation membrane (phagophore) encloses a portion of cytoplasm forming 
autophagosome and then the lysosome fuses with autophagosome to form autolysosome 
(Mizushima et al., 2002). 
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Figure 1.3.5 B; the Beclin-1-Vps34 complex. Beclin-1, UVRAG, Bif-1 and Ambra 
activate VPS34 lipid kinase, while Bcl2 and Bcl-XL inhibit autophagy when it binds to 
Beclin-1. The lipid tail attached to VPS15 helps the complex to anchor the 
autophagsome membrane (Adapted from Funderburk et al., 2010).  
1.4 Regucalcin 
In  1978,  regucalcin  (RGN/SMP30)  was  discovered  as  an  abundant  liver  cytosolic 
Ca
2+ 
binding protein (Yamaguchi and Yamamoto, 1978). The name, regucalcin, was 
proposed for this protein because it has the ability to regulate various liver Ca
2+ 
dependent enzymes. Although RGN   is able to bind Ca
2+ 
it does not have an EF hand 
which might be expected to form a  part of protein in order to bind Ca
2+ 
(Figure 1.4) 
(Yamaguchi, 2000). RGN is a 299 amino acid polypeptide which has a 33 MW of kDa 
and has an intracellular location in both the cytoplasm and nucleus (Omura and 
Yamaguchi, 1999, Yamaguchi and Yamamoto, 1978). RGN is a multifunctional protein 
that is involved in number of cellular processes including; calcium homeostasis by 
regulating Ca
2+ 
binding protein activity such as Ca
2+ 
ATPases, calmodulin kinase and 
PKC (Karota and Yamaguchi, 1997). Furthermore, RGN has an established defence role 
in Ca
2+ 
mediated stress protection. RGN has been shown to be an important ageing 
marker protein in many organisms, as it increases its expression through the neonate 
stage into early adulthood and then drops significantly in old age (Ishigami, 2010, 
Maruyama et al., 2010). Therefore, RGN is also refers to as senescence marker protein -
30 (SMP30) (Fujita et al., 1996). Overexpression of RGN can inhibit L-type Ca
2+ 
channels (Nakagawa and Yamaguchi, 2005) and the Ca
2+ 
sensing receptor in NRK52E 
cells (Yamaguchi, 2013). While the low levels of RGN in mice has been shown to be 
linked with X-linked muscular dystrophy (Doran et al., 2006).  Besides its effects on 
Ca
2+ 
signalling it also has other functions such as in the synthesis of vitamin C in some 
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mammals as it acts as a gluconolactonase enzyme as well as acting as a detoxifying 
enzyme in liver cells (Kondo et al., 2004). Moreover, RGN depletion can increase the 
oxidative stress within brain cells (Son et al., 2006).  
Subcellular localisation of RGN has to be found in the cytosol, nucleus (Nakagawa and 
Yamaguchi, 2008) and to a much lower levels in mitochondria (Yamaguchi et al., 
2008) and is predominately found in tissues such as kidney, liver and brain (Yamaguchi, 
2000a). The expression level of RGN protein in the liver appears to be age-dependent 
(Hong et al., 2012). Moreover, mRNA of this protein has been reported in cerebrum and 
lung, testis and heart (Mori et al., and Doran et al., 2006). More recently RGN mRNA 
has also been detected in both mammary and prostate gland of rats, as well as pancreas 
(Maia et al., 2008, 2009, Yamaguchi, 2015).  
Therefore it is very likely that RGN, which is a multifunctional and multi-locational 
protein, could be associated with many pathological conditions, such as cancer, 
osteoporosis and Alzheimer's disease (Sun et al., 2006).  Other age-related disorder such 
as hearing loss (Kashio et al., 2009), liver lipid accumulation (Yamaguchi, 2010) and 
decreases intolerance to glucose have also been identified in the RGN knockout mouse 
(Hasegawa et al., 2010). Moreover, RGN may play a role as in reducing oxidative stress 
and apoptosis (cell death) within cells (Misaka et al., 2013).  
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Figure 1.4; the solved crystal structure of RGN (SMP30). The ribbon structure of 
RGN with Ca
2+ 
(purple sphere) is the binding position, in the centre of six--propeller    
barrel fold (Chakraborti and Bahnson, 2010).  
 
1.4.1 Transcription Regulation of Regucalcin expression 
Principally, NF1-A1 and AP-1 nuclear transcription factors, predominantly influence 
RGN expression level (Yamaguchi, 2005), along with,   a novel transcription   protein 
factor known as RGPR-p117, regucalcin gene promoter region related protein, which 
binds to TTGGC(N)6CC sequences and participates in regucalcin mRNA expression in 
NRK52E cells (Misawa and yamaguchi, 2001). The RGPR-p117 gene  product has 
been shown to be expressed in human, fish and yeast, as well as various animals, for 
instance bovine, rabbit, cow, dog and others (Misawa and Yamaguchi, 2002). 
Moreover, the RP11-6501 sequence has been used to confirm RGPR-p117 gene 
structure, thus the results shows that RGPR-p117 transcription factor consist of 26 
exons spanning approximately 4.1 kbp (Misawa and Yamaguchi, 2001). 
Overexpression studies in liver and kidney cells, demonstrated the RGPR-p117 is 
sensitive to [Ca
2+
] levels within liver cells (Misawa and Yamaguchi, 2002), and this 
study also described the essential role of RGPR-p117 in regulating the expression of 
regucalcin in kidney cells and on inhibiting DNA and protein synthesis. Some studies 
have also shown that, RGPR-p117 over-expression alone cannot significantly alter RGN 
mRNA levels and that hormonal control is also required (Yamaguchi, 2009).  
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A significant increase in RGPR-p117 mRNA expression has been noticed after calcium 
elevation in rat liver (Yamaguchi, 2009), therefore some studies have suggested that 
this change is mediated through a Ca
2+
 elevation-induced secondary factor, but not 
related directly to Ca
2+
, during gene expression. A related study also reported the 
stability level of RGPR-p117 to different physiological changes such as aging, Fasting 
or re-feeding (Yamaguchi, 2009). However, RGPR-p117 has been shown to have 
suppressor effects on many cell death factors including, tumour necrosis factors- 
(TNF-), lipopolysaccharide (LPS) and cell death induced by Bay k 8644 in NRK52E 
cells (Yamaguchi, 2007). RGPR-p117 also reduces death in NRK52E cells in the 
presence of apoptosis stimulation factors such as caspase-3,-9,-8 and Fas-associated 
death domain protein (FADD) (Yamaguchi, 2007).  
1.4.2 Regucalcin and apoptosis 
Regucalcin has been shown to have an effect on cell function via supressing intracellular 
Ca
2+
 homeostasis as well as Ca
2+
- dependent and independent enzyme activity, cell 
signalling, protein production and nuclear signalling (Yamaguchi, 2012). 
1.4.2.1 Regucalcin role in suppressing cell death and apoptosis in liver cells 
Many studies have reported the apoptotic effect of TNF-α and Nitric oxide on 
hepatocytes rat cells (Abou-Elella et al., 2002, Belloma et al., 1992). Furthermore, 
TNF-α induced cell death in mammalian adenocarcinoma cells has been shown to be 
by increasing cytoplasmic [Ca
2+
] concentration level and DNA fragmentation (Belloma 
at al., 1992). TNF-α also causes significant cell death in the hepatoma cell line H4-II-E 
by apoptosis, however overexpression of regucalcin in these cells was shown to protect 
against apoptosis even with high concentrations of TNF-α (Izumi and Yamaguchi, 
2004). Likewise, the regucalcin anti-apoptotic properties has been reported in RGN-
transfected H4-II-E cells, after treating cells with lipopolysaccharide (LPS), caspase-8 
modulator and an apoptotic inducer.  
Further studies have indicated the suppressive role of regucalcin on apoptosis cell death. 
It is known that, apoptosis induction is correlated to protein kinases, since both 
dibucaine, Ca
2+ 
dependent kinases protein inhibitor, and PD98059, an inhibitor of 
extracellular signal-regulated kinases, causes H4-II-E cell death. However, such an 
effect was not detected when H4-II-E cells transfected with regucalcin (Izumi and 
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Yamaguchi, 2004). Regucalcin may affect Bcl2 stimulation or caspase inhibition, since 
dibucaine acts on various caspases, including caspase-3,-6,-8 and -9 and has the 
ability to change membrane depolarization and release cytochrome c (Arita et al., 
2000). PD89059 is known to activate Bcl2 and increases Bcl2 phosphorylation in 
human prostate cancer cells (Zelivianshi et al., 2003). Over expression of regucalcin 
decreases liver cell death when cells are treated with both PD89059 and dibucaine 
(Yamaguchi, 2005). Furthermore, regucalcin has been shown in NRK52E kidney cells 
to cause a rise in Bcl2 mRNA expression (Nakagawa and Yamaguchi, 2005). 
Additionally, a high Ca
2+ 
concentrations might causes cell death through apoptosis 
(Cohen and Duke, 1984), and the calcium pump inhibitor such as thapsigargin causes 
apoptosis in many different cells by causing DNA fragmentation (Izumi and 
Yamaguchi, 2004). Likewise, there is evidence to demonstrate the suppressor effect of 
regucalcin on cell death and apoptosis caused by nitric oxide (Izumi and Yamaguchi, 
2004, Izumi et al., 2003) (see figure 1.4.2.1). 
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Figure 1.4.2.1; the suppressive effect of Regucalcin on cell death and apoptosis. 
This is mediated by the inhibition of NO synthase, caspase-3 or Ca
2+
-dependent 
endonuclease, and activation of Bcl2. This cell death is induced by many factors (Bay 
K866, dibucaine, IGF-1, Insulin, LPS, PD89059, Thapsigargin, TNF- or Sulforaphane 
(Adapted from Yamaguchi, 2012).  
 
1.4.3 Regucalcin protein and Ca2+ Homeostasis 
Calcium ion plays a significant role in a variety of critical cellular functions, such as 
cell divisions  and  gene  expression,  as  well  as  hormonal  secretion  and  muscle  
contraction. Calcium ions are also fundamental to neurotransmission and metabolism 
(Berridg et al, 2000). Regucalcin is a calcium- binding protein, which can binds Ca
2+ 
as 
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well as other divalent mental ions such as Mn
2+
 (Chakraborti and Bahnson, 2010). 
Regucalcin can affect a number of different Ca
2+ 
or Ca
2+
/Calmodulin-dependent 
enzymes in liver cells (Yamaguchi and Mori, 1988, Yamaguchi and Shibano, 1987). 
Fujita and his colleagues reported that regucalcin could decrease intracellular [Ca
2+
] 
levels and modulate plasma membrane Ca
2+ 
pumping activities in Hepatic cells (Fujita 
et al., 1998). Regucalcin was also found to control Ca
2+ 
ATPase activity in renal cortex 
of rat kidneys and also helps re-absorption of Ca
2+ 
in the nephron kidney cortex (Agus 
et al., 1997). Regucalcin has been shown to regulate ER Ca
2+ 
pumps (Yamaguchi, 
2000) through an as yet unknown mechanism and to increase SERCA Ca
2+ 
pump 
expression in kidney cells (Lai et al., 2011). Ca
2+ 
homeostasis role of regucalcin has 
also been studied on both heart and brain cells (Akhter et al., 2006). 
 
1.5 Cytoprotection 
Chemotherapy drugs are defined as a toxicant, natural or synthetic, chemicals that 
generate harmful side effects on the living organism. These can be toxic at specific 
doses and most of these drugs are also carcinogens such as antitumor antibiotic, 
antibiotic antimetabolites and nitrogen mustarded.  Some drugs can have epigenetic 
affects such as Diethylstilbestrol which has shown to causes a cervix and vagina cancer 
in the off spring of women treated with it (Hodgson, 2004).  
Once drugs affect the body, a variety of defence mechanisms and barriers can initiated 
to reduce their toxic effects. Chemotherapy drugs can easily enter the blood stream, 
because these drugs are usually administrated by intravenous, intra-muscular injection, 
subcutaneous injection or orally, which are then easily distributed via vascular system 
(Hodgson, 2004). Cancer chemotherapy drugs have been specially designed to kill 
cells, both cancerous and normal cells, by affecting   cellular   activity   such as 
proliferation, differentiation and cell death. Genes called proto-oncogenes, have a 
powerful associating with tumor formation and cell transformation. Once these genes 
are activated (sometimes, through the action of toxicants), the oncoproteins produced 
influence signal transduction pathways and an example of that is the reactive oxygen 
species (ROS) gene and tumor suppressor genes (Hodgson, 2004), to minimize cell 
death.  
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Reactive oxygen species (ROS) contribute to many cell functions for instance cell 
growth, differentiation and cell signalling. ROS at high levels is also a mediator of cell 
death. Therefore, the ROS levels are controlled by different proteins such as catalase   
and   superoxide dismutase (SOD). The high levels of ROS have been correlated to 
neurodegenerative disorder, DNA damage and cancer (Loft et al., 2008).  
The most noted forms of ROS are hydroxyl radicals, peroxides and superoxides. 
Antioxidants such as vitamin E, C and K, dietary flavonoids, polyphenols, e.g.  
resveratrol, quescitin etc., can neutralize ROS directly or indirectly (Thompson and Van 
Bel, 2012).  
The  tumor  suppressor  p53  plays  an  important  role  in  the  prevention  of  mutation  
and inhibition of abnormal cell growth. p53 activation occurs during cellular stress, 
and affects cell  cycle  progress.  During such circumstances, p53 acts by blocking the 
cell cycle or inducing cell death. Furthermore, p53 contribute to both DNA repair and 
angiogenesis inhibition (Thoreen, 2009). Poly (ADP-ribose) polymerase (PARP) has 
been shown to be involved in p53 activation and regulation. This polymerase plays a 
positive role in DNA damage detection and DNA repair (Serpi, 1999). p53 has the 
ability to activate cell death autonomously via sub-cellular translocation as well as 
stimulation of  pro-apoptotic Bcl2-2 family members. Different factors can trigger p53 
activation for example, DNA damage, and radiation, hypoxia, as well as chemotherapy 
drugs.  
Cytoprotective heat shock proteins such as Hsp60 and Hsp70 (Morimoto  and Santoros, 
1998), also plays a vital role in protein folding, blocking caspase activation and 
protecting against oxidative stress (Bellmann et al., 1996), inflammation (Klosterhalfen 
et al., 1996) and ischemia (Mestril et al., 1994). Apart from this role, changes in Ca
2+
 
concentration levels have on many biochemical and biophysical processes, large 
increases in [Ca
2+
] levels can also contributed to ischemia and therefore affect survival. 
Hence, some drugs have been developed which have the ability to alter cellular Ca
2+ 
concentrations inside cells such as Dantrolene and Ursodeoxycholic acid (Thompson 
and Van Bel, 2012). As mentioned before, regucalcin has also been shown to affect 
Ca
2+ 
homeostasis, by possibly affecting Ca
2+ 
levels. Therefore, we hypothesize that 
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regucalcin, can act as a cytoprotector protein which helps reduce abnormality of high 
[Ca
2+
] levels caused by cell stress and then prevents or reduces cell death.  
 
1.6 Calcium 
It is now widely recognized that Ca
2+
 ions and Ca
2+ 
homeostasis have a crucial role to 
play in most biological systems (Berridge et al., 2000). The importance of Ca
2+
 ions was 
first identified as playing a key physiological role in the 19
th
 century (Ringer, 1882). 
Ca
2+
 is essential to many cellular functions in all prokaryotic and eukaryotic cells. In 
higher organisms Ca
2+ 
are involved muscle contraction, fertilization, cell division, 
proliferation, development, learning and memory, secretion, metabolism, and cell death 
(Brini and Carafoli, 2009).  
Ca
2+
 concentration inside the cytoplasm needs to be strongly controlled. In cells, resting 
cytosolic Ca
2+ 
concentration is kept very low, roughly 100 nM and approximately 
10,000 fold less than outside the cell. When stimulated to undertake normal cellular 
function this concentration could increase to 10-100 fold which can then be utilised a 
variety of Ca
2+ 
dependent enzymes and proteins to initiate biochemical changes 
(Michelangli et al, 2005). Very high concentrations of Ca
2+
 in some cells, like  
hippocampal neurons cells can causes cell death instead of carrying out normal 
stimulation (Randal and Thayer, 1992) by causing both apoptosis and necrosis to take 
place (Berridge et al., 2000; Carafoli et al., 2001). Inhibition of Ca
2+ 
channels can also 
reversibly inhibit proliferation in some cancer cells (Kohn et al, 1996). The highly 
regulated Ca
2+
 homeostasis is controlled by the cooperation of many Ca
2+
 channels and 
pumps activity in both plasma membrane and other intracellular Ca
2+
 stores membrane 
(Berridge et al., 2000, Michelangeli et al., 1999)(figure 1.6).  
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Figure 1.6; mechanisms of calcium signalling. Agonists stimulate cells to form second 
messengers which induce the Ca
2+
 release from the ER through the IP3R. In addition; 
some agonists can activate the extracellular Ca
2+
 entrance through plasma membrane 
channels. A high percentage of cytosolic Ca
2+
 is bound to Ca
2+
 binding proteins which 
can causes biochemical changes inside the cell. Various pumps and exchangers act to 
remove Ca
2+
, including NCX and plasma membrane Ca
2+–ATPase (PMCA) that remove 
the Ca
2+
 from the  cell and the SERCA which pumps take Ca
2+
 back to the ER. The Ca
2+
 
release to cytoplasm by mitochondria can occur through the mitochondrial permeability 
transition pore (MPTP) (Adapted from Rosado et al., 2004).  
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1.6.1 Ca2+ channels and pumps 
There are three main types of  Ca
2+
 channels which regulate intracellular [Ca
2+
] level 
and control Ca
2+
 influx on the cell; these are Voltage-operated Ca
2+
 channel (VOX), 
store-operated Ca
2+
 channel (SOCs) and  receptor-operated Ca
2+
 channel (ROCs) 
(Bootman et al., 2001). The cell membrane also contains several more protein 
transporters that move Ca
2+
 to the outside the cells, such as Na
2+
/Ca
2+
 exchanger (NCX), 
and plasma membrane Ca
2+
 -ATPase (PMCA) (Michelangli et al, 2005). Inside cells are 
Ca
2+
 storage organelles, such as ER, mitochondria, nucleus, lysosome etc. (see figure 
1.6.1). These organelles contain number of Ca
2+
 channels such as, inositol-1,4,5-
triphosphate receptor (IP3R), nicotinic acid adenine dinucleotide phosphate receptor 
(NAADPR) and ryanodine receptors RyR, which are the second messenger-operated 
Ca
2+
 channels (SMOCs) (Calcraft et al., 2009). These organelles are involves in 
decreasing intracellular [Ca
2+
] level also promoting Ca
2+
 movement in the opposite 
direction by the activation of transporters, namely (Sarco) endoplasmic reticulum 
(SR/ER) Ca
2+_
ATPase (SERCA), mitochondrial Ca
2+
 uniporter (MCU) and H+/Ca 
exchanger (HCX) (Michelangli et al, 2005).  
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Figure 1.6.1; Ca
2+ 
Channels, Exchangers and Pumps in a typical Cell. The diagram 
shows the organelles that act as a Ca
2+
 stores inside the cell and the associated Ca
2+
 
transport (ER- Endoplasmic Reticulum, G- Golgi Apparatus, L- Lysosomes, M-
Mitochondria, N-Nucleus, SR-Sarcoplasmic Reticulum, V-Vacuoles). Also listed are 
some Ca
2+
 transporters associated with the various organelles (Adapted from 
Michelangeli et al., 2005).  
1.6.1.1 Inositol 1, 4, 5-triphosphate receptors (IP3Rs) 
IP3Rs consist of four subunits, have a molecular mass of about 1200KDa, and are 
located on the ER membrane and belong to the family of second-messenger operated 
ion channels (SMOC) (Berridge et al., 2000). There are three isoforms of IP3Rs, namely 
type 1 (IP3R1), type 2 (IP3R2) and IP3R type 3 (IP3R3) (Patel et al., 1999, Dyer and 
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Michelangeli, 2001). These receptors are activated by inositol, 1, 4, 5-trisphosphate 
(IP3).  
The IP3R can be opened typically by activating the cell through the binding of an 
agonist to a G protein couple receptor (GPCR) which in turn activates a membrane G 
protein. This then activates an enzyme phospholipase C (PLC) and the enzyme cleaves 
the bond phospholipids of phosphatidyl inositol, 4,5-bisphosphate (PIP2) in to both 
diacylglycerol  (DAG) and IP3 (Berridge et al., 2000). Once IP3 binds to IP3R it affect 
its Ca
2+
 sensitivity and opens to produces higher Ca
2+
 concentration in the cytoplasm of 
a normal cell (Kasri et al., 2004).  Phosphorylation or dephosphorylating of IP3 to IP4 or 
IP2 then takes place to remove the second messenger. An inactivation process on the 
channel can also take place to restore IP3R to its unstimulated state (Dyer and 
Michelangeli, 2001). 
 Many protein kinases can causes in IP3R phosphorylation such as PKG, PKA and 
CaMKII (Ferris et al., 1992; Wojcikiewicz and Luo, 1998; Szado et al., 2008, Dyer and 
Michelangeli, 2003), and regulate its activity.  
1.6.1.2 Ryanodine receptors (RyRs) 
RyRs is one of the largest heterotetrameric Ca
2+
 channels, which is located in the 
endo(sarco) plasmic reticulum of different types of cells (Fill and Cappello,2002). RyRs 
are made up of four subunits (monomers) each one being 565 KDa in size. In Mammals, 
there are three different isoforms and each one encoded by a different gene. This Ca
2+
 
channels plays a central role in muscle excitation-contraction coupling through 
regulating Ca
2+
 mobilization from the sarcoplasmic reticulum (Fleischer, 2008). RyR1 is 
found in skeleton muscle, RyR2 is highly expressed in cardiac muscle, while low levels 
of expression of RyR3 is present in neuronal and other tissues (Fill and Cappello, 2002). 
These different RyRs isoforms have different properties that may allow them to perform 
different functions (Fill and Cappello, 2002). Isolated hepatocytes express 
RyR1receptors, but not type 2 or type 3 (Pietrobon et al., 2006). While RyR2 has been 
detected in rabbit kidney (Tunwell and Lai, 1996). The sequence analysis shows two 
functional domains of RyR proteins, a large N-terminal cytoplasmic domain and C- 
terminal domain, which forms part of the channel. The N-domian includes a variety of 
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proteins binding sites for various ligands such as Calmodulin (CaM), FK-506 Binding 
proteins, as well as kinase-dependent phosphorylation sites (Williams et al., 2001).  
1.6.1.3 Mitochondrial permeability transition pore channels (MPTP) 
MPTP is a channel located on the inner mitochondrial membrane, this pore are very 
sensitive to many physiological conditions such as calcium concentration, and ROS 
formation as well as in the regulation of physiological pH (Lapidus and Sokolove, 
1994). Once these pores open it becomes highly permeable to solutes and under some 
circumstances the osmotic gradient between cytosol and matrix causes the mitochondria 
to swell and then release cytochrome c (Zoratti and Szabo, 1995). Cytochrome c is an 
apoptosis regulator, associated with caspase-9 which activates caspase-3 and then leads 
to apoptosis (Gustanfsson and Gottlieb, 2003, Halestrap et al., 1997). The MPTPs are 
usually regulated by pro-apoptotic members of Bcl2 (BAK and Bax), which also 
contributed to apoptotic cell death (Gustanfsson and Gottlieb, 2003, Tsujimoto and 
shimizu, 2009).   
1.6.2 Ca2+ Pumps 
P-type ATPase pumps are ion transport pumps which form as a large family of 
membrane protein. Within mammalian biological membranes there are three types of 
Ca
2+
 ATPase pumps; Plasma membrane Ca
2+_ 
ATPase (PMCAs) (Niggli, et al., 1982, 
Shull and Greeb, 1988, Carafoli, 1994). Sarco (endo) plasmic Ca
2+
-ATPase (SERCAs) 
(MacLennan 1970; Burk et al., 1989, Rossi and Dirksen, 2006) and secretory pathway 
Ca
2+
-ATPase (SPCAs) ( Gunteski-Hamblin et al., 1992; Ton et al., 2002; Wuytack et 
al., 2003; Shull et al., 2003; Van Baelen et al., 2001; Wootton et al., 2004). These 
pumps are characterized by their ability to undertake ATP-dependent phosphorylation 
during the reaction cycle and Ca
2+
 transport (Palmgren and Axelsen, 1998). Ca
2+
 
ATPase pumps are composed of a single polypeptide chain and consist of 10 
transmembrane helices and 3 cytosolic domains (nucleotide-binding (N), actuator (A), 
and phosphorylation (P) domain) (see figure 1.6.2) (Dileve et al., 2008).  
40 
 
 
Figure 1.6.2; structure of the Ca
2+
-ATPase in the conformational state, E1. Show 
the three domains, nucleotide-binding (N), actuator (A), and phosphorylation (P) 
domain. Ca
2+
 binding occurs close to the membrane region (Adapted from Lervik et al., 
2012).  
1.6.2.1 Overview of the Sarco (endo) plasmic reticulum Ca2+ -ATPase (SERCAs) 
SERCAs belong to the P-ATPase family (Toyoshima et al., 2000 and Moller et al., 
1996) which serve as the main Ca
2+
 pumps in the ER. SERCAs are single poly- peptide 
with molecular mass 110 KDa (MacLenran, 1985) consist of three cytoplasmic 
domains, actuator (A) domain, phosphorylation (P) domain and nucleotide or ATP- 
binding  (N) domain and 10 -helices transmembrane domain. Both, phospho Lamban 
and sarcolipin are protein modulators of SERCA (Lytton at al., 1991; Periansamy and 
Kalyanasundaram, 2007). In mammals, three separate genes encode SERCA pumps 
(SERCA1, SERCA2, and SERCA3) with more 10 spliced variants. SERCAs can 
transport two Ca
2+
 ions which bind co-operatively to the transmembrane region per one 
ATP hydrolysed (Moller et al., 2005, Lee, 2002). The main expression of SERCA1 is in 
skeleton muscles, which has two spliced variants; SERCA1a is expressed in adult tissue 
and SERCA 1 b is exclusively expressed on foetal tissue (Brandle et al., 1986). SERCA 
2 exists in three different spliced variants with different expression locations, SERCA2a 
is mainly expressed in mammalian heart cells, whereas SERCA2b is located in most 
other tissues at least at low levels. SERCA2c is expressed in cardiac and skeletal muscle 
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tissues (Lompre et al., 1994). SERCA3 has up to six spliced variants found in both 
smooth muscle and non-muscle tissues (Bobe et al., 2004; Hovnanian, 2007; 
Periansamy and Kalyanasundaram, 2007, Chemaly et al., 2013). 
1.6.2.1.1 SERCA kinetic cycle 
Many intermediate conformations are involved during catalysis and transport of Ca
2+
 
through the transmembrane region of SERCA Ca
2+
 pumps with the main ones being the 
E1 and E2 conformations (Post eta l., 1972; Toyoshima at al., 2000; Danko st al., 2004, 
Michelangli and East, 2011). Initially, the catalytic cycle involves, the Ca
2+
-ATPase 
being in a high affinity Ca
2+
 binding E1 state, which binds to Ca
2+
 and ATP  (Ca2E1-
ATP) (Sorensen et al., 2004; Toyoshima et al, 2004), This then  activates the  N and P 
domains, to come together and transfer P from ATP to the P domain (ASP351) and also 
causes the occlusion of Ca
2+
 ions (Ca2 E1~P.ADP) (Jensen, 2006; Sorensen et al., 
2004). At this stage, this triggers the conformation to the low affinity Ca
2+
 E2 state. 
Upon this, Ca
2+
 is then released from the binding site and passes through the ATPase in 
to the SR lumen as a result of the decreased Ca
2+
 affinity (Inesi, 1985; Toyoshima and 
Inesi 2004) (See figure 1.6.2.1.1).  
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Figure 1.6.2.1.1; scheme of Ca
2+
 transport cycle of SERCA. 
 
1.6.2.1.2 SERCA Ca2+ pumps inhibitors 
Several chemical agents have been used as a SERCA Ca
2+
 pumps regulators in 
mammalian cells (Michelangeli and East, 2011). These inhibitors helped elucidate the 
mechanism of Ca
2+
 entry to ER (Wictome et al., 1992b; Wotton and Michelangeli, 
2006). The most well-known inhibitors are, thapsigargin (Tg)  (Laytton et al., 1991, 
Estrogen agents, such as bis-phenol A (BPA), butylated hydroxyanisole(BHA) ,3,5-
dibutyl-4-hydroxytoleuene (BHT), 4-n-nonylphenol (NP), 1,1,3,3-
tetramethylbutylphenol, diethystibestrol (DES) (Khan, 2001), quercetin, as well as many 
others (Sokolove et al., 1986; Shoshan and MacLennan, 1981). Thapsigargin (Tg), 
however, is a highly lipophilic compound and has good penetration of the cell 
membrane. Tg is an extremely potent inhibitor with an LC50 of less than nanomolar 
(Wotton and Michelangeli, 2005). The inhibition controlled by Tg cause changes in 
Ca
2+
 ATPase binding affinity to Ca
2+
, which locks the ATPase in to the low affinity 
rather than high affinity state (Sagara and Inesi et al., 1991; Wictome et al., 1995). 
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Furthermore, inhibitory effects of SERCA have dramatic effects on cells and can cause 
cell death (Michelangeli 2008). 
 
1.6.2.2 Overview of secretory pathway Ca2+ –ATPase (SPCAs) 
SPCAs also belong to the P-ATPase family and consist of two isoforms (SPCA1 and 
SPCA2). These are encoded by two genes (ATP2C1 and ATP2C2) in mammals (Van 
Baelen et al., 2004). As mentioned earlier, PMCAs remove excess Ca
2+
 from the cytosol 
to the extracellular space, while SERCA and SPCA transfer Ca
2+
 back to sarco (endo) 
plasmic reticulum and Golgi complex, respectively (Reinhardt et al., 2009). The 
similarity of amino acid sequence between human SERCAs and SPCAs are more 
similar than PMCAs. Early studies on SPCA were undertaken in yeast Sacchromyces 
cerevisiae, where it was first identified (Rudolph et al., 1989). Later, SPCA was also 
identified in rat brain, testes and stomach tissue and most other tissue which suggest that 
SPCA likely has housekeeping roles in most cell types (Gunteski-Hamblin et al., 1992). 
Furthermore, SPCA pumps are present only in Golgi apparatus, but not in ER. 
Differently to SERCA, SPCAs also have a very affinity for Ca
2+
 or Mn
2+
 and only 
translocate one Ca
2+
 (or Mn
2+
) ion per each hydrolysed ATP, compared to SERCA 
pumps which bind to two Ca
2+
 ions. Moreover, SPCA has less potential charged 
residues in Ca
2+
 binding site to bind protons (Van Baelen et al., 2004). As, SPCA has no 
specific inhibitor, this has prevented our understanding of the specific role of SPCA in 
cellular homeostasis (Lai and Michelangeli, 2012). Many biochemical studies on this 
protein have been dependent on the overexpression experiments or studies on 
keratinocytes obtained from Hailey-Hailey skin diseases patients (Hu et al., 2000, 
Sudbrak et al., 2000) since they have mutation in SPCA1 (Behne e al., 2003). Generally, 
three different splice variants SPCA1a, SPCA b, and 1c have been found. These spliced 
variants, except SPCA1c, are functional (Dode et al., 2006). 
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1.6.2.2.1 The multifunctions of SPCA in Eukaryotic cells 
SPCA1 can be involved in many cellular processes. In the studies with HeLa cells, 
SPCA1 showed it could affect cytosolic Ca
2+
 signalling due to the reduction of 
histamine-induced baseline Ca
2+
-oscillations in SPCA knockdown cells (Van Baelen et 
al., 2004). A similar effect of SPCA was also seen in insulin secreting cells (Mitchell et 
al., 2004). The decreased resistance to oxidative stress was observed in c.elegans with 
SPCA1 knockdown (Cho.et al., 2005). Furthermore, the role of SPCA1 in affecting Ca
2+
 
uptake within vascular smooth muscle has been suggested in the diabetic state (Lai and 
Michelangeli, 2009). More recently, SPCA has been shown to involved protein 
synthesis, ER stress, lactation, brain development, and other Ca
2+
 homeostasis functions 
(Vandecaetsbeek, 2011). SPCA2 has also recently been implicated to play a role in 
breast cancer by regulating Ca
2+
 entry into the cell (Fengre et al, 2010).   
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1.7 Aims of this study  
1. To determine which chemotherapeutic drugs are most toxic to a range of human 
liver and kidney cell lines. To determine their mechanisms of cell death, i.e. 
whether this is involves apoptosis, necrosis or autophagy. 
 
2. Determine the level of RGN in some human liver and kidney cell lines and then 
transfecting these cells with a RGN plasmid to increase its expression, followed 
by testing these cells for toxicity with known hepatotoxic and nephrotoxicity 
chemotherapeutic drugs. This will help us to determine whether human liver and 
kidney cells manipulated to increase their expression of RGN can afford 
cytoprotection against these chemotherapeutic drugs. 
 
3. Transfecting cells with SERCA and SPCA plasmids followed by testing cell 
toxicity with known hepatotoxic and nephrotoxicity drugs. This will help us to 
investigate whether human liver and kidney cells manipulated to increase their 
expression of SERCA and SPCA and can give some protection against these 
chemotherapeutic drugs.  
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CHAPTER 2 
Materials and Methods 
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2 Materials and Methods  
2.1 Materials 
 Etoposide; (Calbiochem) 
 Cis-Diammineplatinum II dichloride; ( Sigma- Aldrich) 
 Methotrexate; (Sigma- Aldrich) 
 Doxorubicin hydrate; (Sigma-Aldrich) 
 Dulbecco’s  Modified Eagle Media (DMEM).high  glucose(4,5g/l)with  L-
glutamine (with and without phenol red); (PAA) 
 Foetal bovine serum (FBS); (PAA) 
 Penicillin Streptomycin; (PAA) 
 Non-essential amino acids; (PAA) 
 Dulbecco’s phosphate buffered saline (DPBS); (Lonza) 
 Trypsin +5% EDTA; (PAA) 
 Absolute ethanol; (Fisher Chemicals) 
 Absolute Methanol; (Fisher Chemicals) 
 Dimethyl Sulfoxide (DMSO); (Sigma-Aldrich and Fisher Scientific) 
 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT); 
(Calbiochem) 
 Hexabromocyclododecane (HBCD); (Sigma-Aldrich) 
 Caspase-3 Inhibitor III; (Sigma-Aldrich) 
 BAPTA/AM; (Calbiochem) 
 Necrosis inhibitor; (Calbiochem) 
 Hydrogen peroxide (H2O2); (Fisher Chemicals) 
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 Precept; (Jounson) 
 LB agar; (Sigma-Aldrich) 
 LB Broth; (Sigma-Aldrich) 
 Ampicillin; (Sigma-Aldrich) 
 Minipreb Kits; (Qiagen) 
 Maxipreb Kits; (Qiagen) 
 Fast Digest SfaAI restriction enzyme; (Thermo Scientific) 
 DNA ladder; (New England Biolabs ®) 
 Transfection reagent; Turbofect (Thermo Scientific) 
 RGN plasmid cDNA; (OriGene) 
 PCDNA3.1; (Thermo Scientific) 
  pEGFP-LC3  (Gift from Prof. Tamotsu Yoshimori) (Addgene plasmid 
21073) 
 SERCA1-EGFP (Gift from Prof. J.M. East, University of Southampton) in 
PCDNA3.1  
 SERCA2b-EGFP (Gift from Belgium, Loven University) in PCDNA6.2   
 SPCA1-EGFP (Gift from Belgium, Loven University) in PCDNA6.2   
 SPCA2-EGFP (Gift from Belgium, Loven University) in PCDNA6.2   
 N-Acetyl-Asp-Glu-Val-Asp-p (Sigma-Aldrich) 
 Nucview 488 Caspase-3 substrate (Biotium) 
 DH5TM  Competent Cells (Invitrogen TM) 
 SYBR®   Safe DNA Gel stain (Invitrogen TM) 
 MitoTracker ®  Deep Red FM (Cell Signalling) 
 Kanamycin (Sigma-Aldrich) 
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 Propidium Iodine (Sigma-Aldrich) 
 Hoechst 33258 pentahydrate stain (InvitrogenTM) 
 Hypomount agar (National  Diagnostics) 
 RGN 045 antibody (Previously made in Prof. Frank Michelangeli group ) 
 Y1F4 pan SERCA (Gift from Prof. J.M. East, Univesity of Southampton) 
 Donkey anti-mouse IR DYE 800 - LiCOR 
 LMPA agar (Promega) 
 NMPA (Sigma-Aldrich) 
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2.2 Methods 
2.2.1 Cell culture technique 
All cells culturing was completed in an aseptic environment, using a lamina flow hood, 
and Ethanol (70% v/v) was used to sterilize all materials in the hood. Cells were 
incubated in CO2 incubator at 5% v/v CO2 and 37 °C. Finally waste solutions were 
treated with precept before being discarded. All materials were sterilized either as 
purchased or autoclaved at 110-120 °C for 20 min.  
2.2.2 Mammalian cells culture and subculturing 
All four types cell lines (two livers cell lines; HepG2, Huh7.5, and two kidney cell 
lines; HK2, COS-7) were grown in sterile 25 cm
2  
and 75 cm
2 
cell culture flasks, with 
DMEM supplemented with 10% FBS, 1% v/v Essential amino acid, 1% 
Penicillin/streptomycin and 2 mM glutamine. The media was changed every 2 days. 
When cells reached 70-80% confluency, the cells were sub cultured, by removing the 
old media and washing the cells with DPBS three times, then 2 ml Trypsin –EDTA (for 
75 cm
3
) was added. The cells were incubated in the CO2 incubator for about 2-4 min, 
then gently agitated to fully detach the cells, the cell  suspension was split to 1 in 2 
(COS-7, HK2 and Huh7.5) to 4 (HepG2) in new culture flasks for re-culturing. The 
cells were usually grown in 10 ml media, when seeded in a 75 cm
2 
culture flask.  
 
2.2.3 Mammalian cells freezing and thawing 
At +80% confluent, some cells were trypsinzed and frozen for the future work. The 
suspension of cells was centrifuged for about 5 min at 1000 rpm, the media removed 
followed by adding 10% DMSO in full culture medium to the pelleted cells at 
approximately 1/10 of original volume. After gentle re-suspension the cells were 
aliquoted in 1ml fractions in to cryovials and stored at -80 °C in an isopropanol 
container for 24 hrs. Next day, all the frozen cryovials were moved to be store on -
196 °C on the liquid nitrogen storage tank. Thawing procedure starts with thawing cells 
in a water bath at 37 °C, and then cells diluted with fresh new media and centrifuged at 
1000 rpm for 5 min, after removing the media the cell re-suspended and cultured in 
25 cm
2
 flasks containing 5 ml full culture medium. Dependent upon the cell line, the 
cells reached the full confluency after 2-4 days.  
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2.2.4 Mammalian cells counting Via a Haemocytometer 
A haemocytometer was used to estimate cell number, a 10 µl of suspended cells 
was added to the slide and sealed with cover slip. Under X100 magnification light 
microscope the number of cells were counted within the grid and repeated three 
times. Then the averages were taken to calculate the number of cell in 1 ml, based on 
the number of cells within the 0.1 µl grid. The number of cells required (depends on 
the type of well plates used). The number of cells and the volumes of growth media 
used in the different plates are given in Table 2.2.4 (www.Invitrogen.com). Cells 
were left for attachment for about 24 hrs, and then the experiments were undertaken. 
 
Table 2.2.4, the number of cells and the volumes of growth media used in this study. 
Culture plates (ml) Surface Area (cm
2
) Seeding Density    Growth media 
 
6-well 9 
 
0.3x10
6
 
 
3-5 
 
12-well 4 
 
0.1x10
6
 
 
1-2 
 
24-well 2 
 
0.05x10
6
 0.5-1 
48-well 1 9.5x10
4
 0.2-0.5 
 
2.2.5 Cell viability assay (MTT Assay) 
Cells were seeded in (12, 24) well-plates and allowed to grow and reach 80-90% 
confluencey at 37 °C. Drug treatment was applied with different concentrations and 
periods (24-48, 72 hrs). The cells viability was measured by using MTT solution 
made in Hank’s and/or PBS buffer (0.5 mg/ml, final concentration). The MTT assay 
is a metabolic assay that measures the mitochondria activity by following formazan 
formation in live cells. Cells were incubated for about 40-60 min and after removing the 
MTT solution the cells were dissolved in 1 ml DMSO. The cells suspension was placed 
into 96 well plates and the cells viability were measured using spectrophotometers using 
an ELISA plate reader at 590 nm and subtracting light scattering if necessary at 650 nm 
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(Hughes et al., 2000). The percentage of cell viability was calculated dependent on the 
following equation: 
% viable cells =
Absorbance difference of treated cells (A590 − A650) 
Absorbance difference of untreated cells (A590 − A650)
 ∗ 100 
In most experiments the cells were mostly near-confluent (70-80%), however, in 
proliferation experiments with MTX, sub-confluent cell cultures of about 20 to 30% 
was used. 
2.2.6 Stock solution preparation 
Both, Doxorubicin and Cisplatin were dissolved in 0.9% w/v saline and made as 
10 mM stock solution. In contrast, DMSO was used as the solvent for Etoposide and 
MTX, and made in 0.25 M, 20 mM, 10 mM stocks. Because of the slight toxicity with 
DMSO the final concentration of DMSO  used was as low as possible and tested on the 
cells in order to minimize its effect on cell viability, hence the concentration of DMSO 
was always less than 0.4% v/v. DMSO was also used to dissolved caspase inhibitor, 
necrosis Inhibitor and BAPTA-AM. 
2.2.7 Caspase activity assay 
Caspase enzyme activity was tested with caspase inhibitor Caspase -3 inhibitor (N-
Acetyl-Asp-Glu-Val-Asp-p). Cells were seeded in 48 well plates and incubated at 37 °C 
overnight. The day after the media was replaced with 0.5 ml of serum-free DMEM and 
the cells treated with 60 µM of the caspase -3 inhibitor and incubated for 5-4 hrs. Cells 
were then treated with different drugs and incubated for 48 hrs. MTT assays were 
performed to measure the cell viability using a Multiskan
® 
Microplate 
spectrophotometer at 570 nm and 650 nm.  
2.2.8 Caspase-3 substrate activity 
Apoptotic cell death was assayed with Nucview 488 caspase-3. Cells were incubated in 
the presence of DMEM media in 24 well plates and left to attach for 24 hrs. After 24 
hrs, cells were treated with the different drugs for 24 hrs in 0.5 ml serum free DMEM 
media at 37 °C. 2 µM of caspase substrate in PBS was prepared and 170 µl of the 
substrate added to the cells after serum-free was removed. The cells were then incubated 
for 40 min at 37 °C. The number of cells that appeared green using the fluorescence 
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microscope (Nikon Eclipse TS100) with FITC cube were counted and the % of 
fluorescence vs non-fluorescence cells (under white light) were calculated. 
2.2.9 Necrosis inhibitor 
Necrosis cell death was detected with the use of the necrostatin inhibitor. Cells were 
seeded in 48 well plates and incubated at 37 °C overnight. The day after, 10 µM of 
necrostatin was added to the cells in free serum media and incubated for 4-5 hrs. Cells 
were then treated with the different drugs and incubated for up to 48 hrs. MTT assays 
performed to measure the cell viability of control and treated cells.  
2.2.10 Lactate Dehydrogenase (LDH) activity 
Cells were seeded in to 6 well plates overnight, the following day, the drugs were added 
to several wells and left for 24 hrs. 10% Triton alone was also added to some of the 
wells and incubated for 30 min (100%, positive control), cells media were collected and 
centrifuged at 1,500 rpm for 5 min, then 50 µl of each was added to the cocktail buffer 
(1 ml) (100 mM potassium phosphate, 0.66 mM sodium pyruvate, 0.25 M NADH pH 7) 
and the rate of oxidation of NADH was followed at 340 nm in spectrophotometer 
pharmacia ultraspes 1000.  
2.2.11 LC3-GFP Autophagy transfection 
Cells were seeded in 12 well plates and incubated at 37 ˚C to allow for attachment. The 
next day cells were transfected with a plasmid for Autophagosome marker LC3 with a 
green fluorescence protein (GFP), in different conditions (1 µg plasmid/2 µl TR, 1 µg 
plasmid/4 µg TR, and 2 µl plasmid/4 µg TR) in 1000 µl of serum-free media. The cells 
were left for upto 48 hrs to increase transfection efficiency. After LC3-GFP transfection 
for 48 hrs the cells were treated with the drugs for about 3-4 hrs. Images were taken 
using the Nikon TS 100 fluorescence microscope (with FITC-Cube) and the numbers of 
fluorescent cells with and without distinct punta were calculated for both control and 
treated cells and converted to percentages. 
2.2.12 Flow cytometry and cell viability 
COS-7 Cells were plated into 48 well plates, and then cells were treated with Etoposide 
for 48 hrs. Cells were then washed with PBS twice and then incubated with 0.05% 
trypsin-EDTA for 4-5 min. Once the cells detached, complete media was added and 
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cells then centrifuged for 2 min at 1000 rpm. The cell pellet was again washed with PBS 
and suspended in 2% Propidium Iodine (PI) in PBS and incubated in room temperature 
for 40-50 min. FACS Calibur was used and set at 488 nm to detect PI. Cells suspensions 
were transferred to FACS tube and run directly through the machine without any others 
additions. Data collected and analysed with the Weasel (FACS dedicated) software.  
2.2.13 Comet Aassay  
Cells (200,000/well) were seeded in 6- well plates, and incubated overnight at 37 ˚C. 
Cells were then treated with the drugs for 6 and 24 hrs in 2 ml of free-serum media. 
-slide preparation 
Slides were prepared 48 hrs prior to the start of the comet assay. Clean slide were coated 
with normal melting point agarose (NMPA), and left to dry at room temperature for 
48 hrs. Serum-free media was replaced with PBS and the cells were washed again with 
PBS and trypsinized with 1 ml Trypsin-EDTA and centrifuged for about 1 min at 1000 
rpm. The cells were re-suspended in 150 µl of PBS and 150 µl of pre-warmed low 
melting point agarose (LMPA) mixed with 15 µl of the cell sample and then added to 
the NMPA-coated slide. The slides were covered with coverslips and left over an iced- 
metal tray for 20 min tray to allow solidification to occur. 
 -Lysis 
Once solidified, the cover slips were removed carefully and the slides placed in Coplin 
jars containing lysis buffer (146.4 g NaCl, 37.2 g Na2EDTA, 1.21 g Tris-Base, 33.3 ml 
sodium laurylsarcosinate, in 1liter of dH2O pH 10). The jars were covered and foiled 
and stored for 1 hr in the cold room.  
-Electrophoresis and Staining 
Cells were transferred to a large electrophoresis tank containing buffer ( NaOH, 9 M, 
Na2 EDTA, 20 mM in dH2O) and left for 20 min in the tank, then the slides 
electrophoresed at 32 V (~300 mA) for an additional 20 mins. For staining, slides were 
washed for 5 min with neutralisation buffer (Tris Base, 0.4 M in dH2O pH 7.5) 3 times 
and then washed with dH2O one min each time. Slides were stained with 50 µl SYBR 
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gold solution followed by adding the coverslips, slides were placed in a moist box and 
stored overnight in cold room. 
 
-Counting 
Cells were scored (100 cells/slide) and comet assay IV software used to analyse the 
data. 
2.2.14 Protein estimation 
2.2.14.1 Preparation of Cell lysates 
HepG2, Huh7.5, COS7 and HK2 were grown to 80-90% confluency in 6 well plates, 
then the media removed and 400 µl of lysis buffer (50 mM Tris-HCI, 1 mM EDTA, 
1 mM PMSF, 150 mM, NaCl, 1% w/v sodium deoxycholate, 0.1% w/v SDS and 
1% v/v Triton X100, pH 7.4) was added to each well for 10 min at room temperature. 
Homogenisation was performed by passing the cell suspension through a narrow gauge 
needle (25 G) and 1 ml syringe about 10 times, followed by centrifugation at 2400 g for 
5 min. The supernatant was collected and aliquoted into eppendorf tubes and stored at -
20 °C, until required. 
2.2.14.2 Bradford protein concentration determination assay 
The amount of protein in the cell lysates was estimated using the Bradford assay 
(Bradford, 1976). Standard calibration curve was constructed from three replicate, with 
950 µl Bradford reagent (Sigma) and using 1mg /ml of Bovine Serum Albumin (BSA) 
as the protein standard stock and varying in amounts between 0-50 µg BSA to give a 
final volume 1 ml by adding the relevant volume of deionised water. The absorbance of 
the samples was read at 590 nm using spectrophotometer in order to estimate the protein 
concentration values.  
2.2.14.3 SDS_PAGE 
BIORAD miniPROTEAN
®3
 system was used according to the manufacturer’s 
instructions. The pre-made (Biorad) gel was added to the tank and the Running Buffer 
(192 mM glycine, 25 mM Tris and 0.1 % w/v SDS) was used to fill the electrophoresis 
tank. The protein samples (typically at 2 mg/ml) were mixed with an equal volume of 
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the loading solubilizing buffer, (125 mM Tris. 4.6% w/v SDS and 20% w/v glycerol, 
pH 6.8) and to this buffer was added 2-mercaptoethanol mixed at a ratio 20:1 (5%) 
and a trace  amount of bromophenol blue. Each sample was heated at 100 °C for 5 min 
before being loaded into the wells of the gel. The gel was electrophoresed for about 45 
min at 120 Volts and then the plates carefully separated and the gel either stained with 
EZBlue
TM 
staining reagent for protein visualization, or directly used for transfer onto 
nitrocellulose membranes for Western blotting. 
2.2.14.4 Western blotting 
The gel was transferred onto nitrocellulose membranes using a sandwich assembly 
(Figure 2.2.8.4) and the Biorad Semidry transfer apparatus manufacturer’s instructions 
followed. Once transferred, the membrane was washed with dH2O and the membrane 
was marked on right face with a pencil. The membrane was blocked for the non- 
specific protein binding sites using milk solution (5% w/v semi-skimmed milk powder 
in TTBS buffer (25 mM Tris-HCl (pH 8.0), 150 mM NaCl and 0.05% v/v tween 20). 
The membrane was left at -4 ˚C overnight with gently agitation. ATBS (20 mM Tris 
and 137 mM NaCl at pH 7.6) was prepared to dilute the primary and secondary 
antibodies. After 1.5–2.0 hrs of incubation of the nitrocellulose with the primary 
antibody, the membrane was washed 3 times for 5 min with dH2O, followed by another 
blocking step for 30 min and incubation with a fluorescently tagged secondary 
antibody for 1.5–2 hrs (IRDye). After washing the membrane 3 times with TBST high 
salt and dried on filter paper, the membrane was viewed using the Odyssey LiCor 
infrared scanner (Li-Biosciences) to detect the fluorescent antibody labelled bands. 
 
Figure 2.2.8.4, western and blotting sandwich assembly. The transfer is done using 
an electric field oriented perpendicular to the surface of the gel. The sandwich from 
cathode to anode includes sponges, Filter papers, gel, nitrocellulose membrane, filter 
paper and sponges.  
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2.2.15 Transfection 
2.2.15.1 Making Luria-Bertani (LB) and Agar Plates 
A sceptic conditions were used throughout. 20 ml of  2% LB media and  1.5% Agar  
were  made  and  autoclaved,  then  heated  on  microwave  for  3 min (medium power). 
The LB agar was allowed to cool down, followed by addition of 10 µl of Ampicillin 
(100 mg/ml), avoiding any bubbles. The LB agar was poured in to 10 cm diameter petri 
dishes and allowed to set.  
2.2.15.2 DH5 cells transformation and RGN plasmid preparation 
50 µl of DH5 cells were thawed on ice for 10 minutes and 1 µl of 0.1 µg/µl of Human 
RGN cDNA clone (Pcmv6 AC-GFP-RGN with C-terminal GFP tag) added to cells, the 
mixture placed on ice for 30 min. After that, cells heat shocked at 42 °C for 
30 seconds. Cells where then placed on ice for 5 min, and then 950 µl of LB media 
added to the mixture at room temperature, and cells incubated for 60 min at 37 °C. A 
serial of 10-fold dilutions were made and 50 µl of each dilution used to spread the plates 
and incubate cells at 37 °C overnight. Next day, three single colonies were transferred to 
three LB media tubes (5 ml) and grown overnight in an orbital shaker at 37 °C. 
Following the manufacturer’s instruction, RGN plasmid DNA was isolated using 
QIAprepᴿ Spin Miniprep. In order to possess a high DNA plasmid amount, QIAfilter 
Plasmid Midi and Maxi Kits was used, after overnight grown of 500 ml bacterial cell 
cultures. 
2.2.15.3 Estimation of plasmid RGN DNA quantity 
Measurement of the DNA plasmid concentration and purity were performed by 
NanoDrop (ND-1000) spectrophotometer. The 260/280 (A260-A280) absorbance ratio 
was also measured to assess DNA purity.  
2.2.15.4 Transfection of COS-7 cells 
COS-7 cells were seeded in 24 well plates at 37 °C, with 1ml of DMEM media, 
supplemented with glutamine, Non-esssential amino acids, 10% FBS and 1% 
penicillin/streptomycin. Three transfection conditions were used to optimize the 
transfection efficiency each done in triplicate. The transfection reagent used was 
Turbofect as used following the manufacturer’s recommended instructions. After 
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24 hrs and  when  cells  reached  40-50% confluence,  DMEM media without FCS 
with the solution of plasmid (SERCA1-GFP, SERCA2b-GFP, RGN-GFP, SPCA1a-
GFP, SPCA2-GFP and PCDNA 3.1) and transfection reagent was added to cells and 
incubated for 24, 48, 72 hrs, after 24 hrs the media was removed and new DMEM 
media with FCS was added to the cells and the fluorescent microscopy images (20x 
magnification power) was used after each 24 hrs to estimate the transfection efficiency 
for the GFP-tagged  expressed  proteins  for each  condition. White light and 
fluorescence images for the same field were taken and routine cell counting was 
performed to calculate the total cell transfection percentage.  
The mammalian expression plasmids for the Ca
2+
 ATPases used were as follows:  
pcDNA3.1 Rabbit SERCA1b-N-GFP (Newton et al., 2003, Wotton, PhD thesis 2005, 
Al-Mousa, PhD thesis, 2010) 
pcDNA6.2 Human SERCA2b-N-GFP (Baron et al., 2010) 
pcDNA6.2 Human SPCA1a-N-GFP (Baron et al., 2010)  
pcDNA6.2 Human SPCA2-N-GFP (Baron et al., 2010)                          
The plasmid identities were confirmed through diagnostic restriction enzyme analysis. 
2.2.15.5 Co-Localization of RGN 
COS-7 cells were seeded on to sterilized coverslips in 6 well plates overnight at 37 ˚C 
for attachment to occur. Cells were then transfected with RGN-GFP in 2ml media 
(serum free DMEM) and viewed under the fluorescence microscope after 48 hrs to 
determine that the expression level was at least 35-45%. Cells were then treated with 
DOX (20 µM) in 2 ml serum free media for 2 hrs. Cells were washed with PBS 3 times 
and treated with (0.5 µM) Mitotracker® Deep RedFM in 2ml DMEM media and 
incubated for 30-40 min. Cells then were washed with PBS, 2 times and then the 
DMEM media replaced by 4% paraformaldehyde (PFA) in PBS pH 7.4 to allow the 
cells to be fixed. After 20 min, cells were washed with PBS twice and 1 µg/ml of 
Hoechst 33258 was added to the cells, covered in foil and then incubated for 30 mins. 
Finally cells were washed again with PBS twice more. The coverslips were removed 
from the slide gently and 70 µl of Hypomount agar was added to the side and left in the 
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dark to allow air drying to occur. Then the cells were viewed with transmission, Red, 
Blue, Green channels of Leica SP2 or Nikon Eclipse Ti microscope.  
2.2.15.6 Cell proliferation and crystal violet assay  
100 µl of cells were seeded on to 96 well plates and the cell allowed to attach overnight. 
Next day the cells were transfected with the plasmids and the cells were incubated for 
24 hrs. The media was changed and cells were left for more 24 hrs. The day of assay, 
cells were washed with PBS (PH 7.4) after media aspiration, then cells were fixed with 
100 µl of 4% paraformaldehyde in PBS for 15 min. After that, paraformaldehyde was 
replaced with 100 µl of 0.5% crystal violet (in 10% ethanol, 90% dH2O) for 20 min. The 
cells were again washed three times with dH2O to remove any access dye and cells left 
to dry, 100 µl of 10% acetic acid was added for 20 min to allow the dissolution. An 
additional dilution of 1:2 with 10% acetic acid was used and then absorbance measured 
at 595 nm with the plate reader.   
2.3 Statistical Analysis 
The data taken from chapter 1 and 5 have been analyzed using sigma plot version 12.5, 
mean and standard division (SD) were calculated with Microsoft Excel. p values, two 
tailed equal variation t-test were applied. Weasel.Jar software used to analyze flow 
cytometry data.  
2.4 Image analysis 
LI-COR Odyssey used to detect the western blot bands, ImagJ was used to measure the 
bands intensities on chapter 4 and 5, ImagJ JACOP’s plugin used for colocalization 
analysis (Bolte & Cordelières, 2006).  
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CHAPTER 3 
Mechanisms of cell death by 
chemotherapeutic drug
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3 Mechanisms of cell death by chemotherapeutic drug   
3.1 Introduction 
As cancer is considered one of the major causes of death, research over many years have 
developed a variety of different treatments, such as radiation therapy, surgery and 
chemotherapy. Although, chemotherapy can be an effective treatment for killing cancer 
cells, chemotherapy can affect normal dividing cell as well (Debatin, 1997), due to their 
cytotoxic nature. Therefore, with chemotherapy treatment, unfortunately 85% of cancer 
patients exhibit some degree of liver damage (Ramadori and Cameron, 2010), 
furthermore, these drugs can affect kidney function and causes nephrotoxicity 
(Cornelison and Reed, 1993). This may mean that they are not being able to continue 
their chemotherapy treatment due to serious damage caused by these hepatotoxic and 
nephrotoxic drugs that prohibit cells from performing their normal functions (King and 
Perry, 2001 & Lawernce et al., 1973).  
The work presented in this chapter investigates the molecular mechanisms of cell death 
of four chemotherapy drugs (Methotrexate, Etoposide, Cisplatin, and Doxorubicin), 
which are often used in clinical treatment of some forms of cancer. Furthermore, four 
various cell lines were used from kidney and liver cells (COS-7, HK2, HepG2 and 
Huh7.5) to investigate the effect of these drugs on cells derived from these particular 
susceptible organs. An investigation of apoptosis, necrosis and autophagy cell death 
mechanisms was the main focus in this chapter.  
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3.2   Cell viability and DMSO concentration    
3.2.1 Cell viability with MTT assay  
MTT cell viability experiments were performed to show that the absorbance measured 
is directly correlated to cell number. Different numbers of HepG2 cells were plated in 
24 cell culture plates. Cells were incubated 24 hrs in CO2 incubator at 37 °C, then 
the MTT protocol performed, as described in section 2.2.5 and the results presented in 
figure 3.2.1. As can be seen a linear correlation between the cell number (or cell 
viability) and the absorbance values is observed.  
 
Figure 3.2.1; the correlation between absorbance at 590 nm using an MTT 
assay and cells number. The data represented is mean ± SD of between 3-4 
determinations.  
 
3.2.2 Cell Viability with Flow Cytometry 
COS-7 cells were treated with trypsin/EDTA and cells were stained with PI, used in 
order to measure the viability of these cells using flow cytometry. As shown in figure 
3.2.2, 95% of cells were considered live cells (i.e. having lower levels of PI 
fluorescence), while only 5% where labelled cells which were considered dying cells 
(As they showed high levels of PI fluorescence).   
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Figure 3.2.2; shows the percentage of cell viability of COS-7 cells. Cells were 
labelled with propidium iodide and run through a flow cytometry (Calibure16). Dead 
cells with very low side scatter were excluded prior to analysis. The results showed two 
populations of cells with the required cell size, with one population considered positive 
for PI staining (therefore indicating dieing cells). This plot is typical of at least three 
experiments.  
 
3.3 The effect of chemotherapy drugs on the viability of liver (HepG2, 
Huh7.5) and kidney cells (COS-7, HK2) 
3.3.1 The effect of chemotherapy drug Methotrexate on the viability of kidney 
cells (COS-7, HK2) and liver cells (HepG2, Huh7.5) using the MTT assay  
A number of liver and kidney cells were monitored with different concentrations of 
Methatrexate (MTX) drug to determine the nephrotoxicity and hepatotoxicity, b y  
measuring cell viability. As DMSO was used as a solvent for MTX and Etoposide 
drugs, the effects of DMSO on cell viability was first determined. As shown in figure 
3.3.1 the total concentration for DMSO should be kept to less than 0.4% (v/v) in HepG2 
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cells. As this causes no significant effect on cell death. This was also similar for the 
other cell lines tested.  
 
Figure 3.3.1; shows the cell viability using MTT assay with different 
concentrations of DMSO (0-1.5% v/v) in HepG2 cells. The data represented is mean 
± SD of between 3-4 determinations.  
Figure 3.3.1.1 A-D; shows the dose-dependent effects of a range of concentrations of 
MTX (0 to 200 µM) on kidney cells COS-7 (A), HK2 (B) and liver cells HepG2 (C), 
Huh7.5 (D). The cells were incubated for 48 hrs with the drug at 37 ºC and the cell 
viability was measured via MTT assays and compared with control DMSO alone 
treated cells. All data represented the mean and the standard deviation (mean ± SD) of 
3-4 replicates. It can be seen that this chemotherapy drug shows the little toxicity with 
the liver cell lines compared to the kidney cells. Both kidney cell lines showed that 
about 50% of the cells were very sensitive to low µM concentration of MTX, while 
about 50% were relatively in-sensitive to MTX. In contrast, both HepG2 and Huh7.5 
cells show little or no effect on cell viability even with high concentrations of MTX 
(100 to 200 µM). As a result, COS-7 and Huh7.5 cells at low confluency (20%) were 
treated with high concentrations of MTX (200µM) and the cells were left for 96 hrs in 
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order to determine whether MTX drug reduced the rate of cell proliferation. Figure 
3.3.1.2 shows the effect of MTX on COS-7 (A) and Huh7.5 (B) cell proliferation, 
compare to DMSO treated cells which were used as a control. The MTT assay was 
carried out after 4 days. COS-7 cells showed a reduction of about 40% in the rate of 
cell proliferation as compared with DMSO control, while Huh7.5 cells showed a 30% 
reduction in cell proliferation compared to DMSO.  
 
 
Figure 3.3.1.1 A-D; shows the effects of MTX on the viability of COS-7 (A), HK2 
(B) HepG2 (C), and Huh7.5 (D) cells. The cells incubated with MTX over a range of 
concentrations for 48 hrs at 37 ºC and then cell viability measured using the MTT 
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assay. The data represented is mean ± SD of between 3-4 determinations. 
 
 
Figure 3.3.1.2A and B; shows the effect of MTX (200 µM) on COS-7 (A) and 
Huh7.5 (B) on cell viablility. As +/- DMSO treated cells were used as a control, COS-
7 and Huh7.5 cells were incubated with MTX on 37 ºC for 96 hrs and the MTT assay 
was performed. All data represent the mean ± SD of between 3-4 determinations.  
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The results suggested that MTX plays a role in reducing cell proliferation and therefore a 
range of MTX concentrations (0, 50, 100, 200, 300, 400, 500 µM) were used to treat 
(COS-7, HK2 and HepG2) cells at low 20% confluency (9 replicates). Cells were 
incubated in 5% CO2 and 37 ºC, then MTT assays were performed for 3 replicates after 
24 hrs, the other 6 replicates were treated with MTX, and after 72 hrs three replicates 
were used to measure the cell viability. Again after then the MTX drug was removed 
and cells incubated for a further 48 hrs to investigate the effect of MTX removal on cell 
proliferation. Figure 3.3.1.3 shows the effects of different concentrations of MTX drug 
on the different cells lines. COS-7 cells showed no cell growth at < 100 µM or higher, 
while HK2 cells showed some slight cell growth, which decreased with increasing drug 
concentrations. In contrast, HepG2 cells showed clear cell proliferation even at 500 µM 
MTX concentration. Once the MTT assays were performed, after 48 hrs of removing 
the MTX, all cell lines showed some restoration of cell growth.  
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Figure 3.3.1.3 A-C; shows the inhibition effects of MTX on COS-7 (A), HK2 (B) 
and HepG2 (C) on cells proliferation. The MTT assay was carried out, before and 
after drug administration as well as after removing MTX after 72 hrs. Cells were 
incubated at 37 °C and MTT assay carried out after 24 hrs of cell seeding, 72 hrs after 
drug exposure, and 48 hrs after removing the drug. All data represent the mean ± SD of 
up to 9 determinations.  
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3.3.2 The effect of chemotherapy drug Etoposide on the viability of kidney (COS-
7, HK2) and liver cell lines (HepG2, Huh7.5) as performed using the MTT 
assay  
A series of liver and kidney cell lines viability measurements were monitored at 
different concentrations of etoposide to determine its nephrotoxicity and hepatotoxicity. 
Figure 3.3.2 A-D;  shows  the  dose-dependent  effects  of  a  range  of  concentrations  
of  Etoposide (0 to 2000 µM) on kidney cell lines (COS-7 (A), HK2 (B) and liver cell 
lines (HepG2 (C), Huh7.5 (D). The cells were incubated for 48 hrs with the drug at 
37 ºC and cell viability was measured via the MTT assay and compared with control, 
(DMSO alone), all data represents the mean and the standard deviation (mean ± SD) 
of 3-4 replicates. In figure 3.3.2 it can be seen that both kidney and liver cell lines are 
sensitive to Etoposide drug with LC50 values of 50±6, 120±6.4 and 150±9.1 µM for 
HK2, HepG2, and COS-7 cells, respectively. While Huh7.5 shows a much higher LC50 
(1000±11.1 µM).Figure 3.3.2 the insert confirmed that 150 µM Etoposide also causes 
about 50% cell death in COS-7 cells as measured using PI and flow cytometry (Figure 
3.3.2 inset) ( BD FACS caliber).  
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Figure 3.3.2 A-D; shows the effect of Etoposide on the viability of COS7 (A), HK2 
(B), HepG2 (C), and Huh7.5 (D), cell lines. Cells where incubated for 48 hrs at 37 ºC. 
The data represents the mean ± SD of between 3-4 determinations. The flow cytometry 
graph (inset) above that shows COS-7 cells (47% live cells and 53% dead cells) after 
cell treated with 150 µM etoposide for 48 hrs. For control compare this with figure 
3.2.2.  
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3.3.3 The effect of chemotherapy drug Cisplatin on the viability of kidney cell 
lines (COS-7, HK2) and liver cell lines (HepG2, Huh7.5), as performed 
using the MTT assay 
Figure 3.3.3 A-D; shows the dose-dependent effects of a range of concentrations of 
Cisplatin (0, 0.1, 10, 100, 1000 µM) on kidney COS-7 (A), HK2 (B) and liver cells 
HepG2 (C), Huh7.5 (D)). The cells were incubated for 48 hrs with drug at 37 ºC and 
the cell viability was measured via MTT assay and compared with control, all data 
represents the mean and the slandered deviation (mean ± SD) of 3-4 replicates. Figure 
3.3.3 shows differences between the different cell lines used. HK2 cells is the most 
sensitive cell lines for cisplatin (LC50 was 20±7 µM) compared to other cell lines 
HepG2, COS-7 and Huh7.5 (with LC50 were 35, 46, 90 µM), respectively.  
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Figure 3.3.3 A-D; shows the effects of Cisplatin on the viability of COS-7 (A), HK2 
(B) (HepG2 (C), and Huh7.5 (D). Cells were incubated for 48 hrs at 37 ºC with drug. 
The data represented is mean ± SD of between 3-4 determinations. 
 
3.3.4 The effect of chemotherapy drug Doxorubicin (DOX) on the viability of 
kidney (COS-7, HK2) and liver cells (HepG2, Huh7.5) as performed using 
the MTT assay 
Figure  3.3.4  A-D; shows the dose-dependent effect of a range of concentrations of 
DOX (0, 0.01, 0.1, 10,100 µM) on kidney cell lines COS-7 (A), HK2 (B) and liver cell 
lines HepG2 (C), Huh7.5 (D). The cells were incubated for 48 hrs with the drug at 
37 ºC and the cell viability was measured via MTT assay and compared with control, 
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all data represent the mean and the standard deviation (mean ± SD) of 3-4 replicates. 
Dox causes cell death in all the cell lines used with similar LC50 values, in low µM 
concentration (See table 3.3).  
 
 
 
 
Figure 3.3.4 A-D; shows that DOX reduces viability of COS-7 (A), HK2 (B), 
HepG2 (C), and Huh7.5 (D). Cells were incubated for 48 hrs at 37 °C. The data 
represented is mean ± SD of between 3-4 determinations.  
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Table 3.3 summarizes concentration that causes 50% cell death (LC50) for cell 
viability of these chemotherapy drugs, it is clear that DOX is the most potent anti-
cancer drug compared to other drugs test here. In contrast, MTX showed its little effect 
on rate of cell proliferation, and Etoposide was only weakly toxic with an LC50 
1000±11.2 µM on Huh7.5 cell.  
Table 3.3; comparison of lethal concentration 50 (LC50) values of different anti- 
cancer drugs. All data represent the mean ± SD of between 3-4 determinations.  
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3.4 Detection of apoptosis induced by MTX, Etoposide, Cisplatin, and                             
Doxorubicin using caspase 3 inhibitors and the fluorogenic substrate (488 
Nuc caspase-3) on kidney and liver cell lines  
These experiments were carried out to determine whether cell death by these anti-
cancer drugs, at least is part, involved the apoptosis pathway. Therefore, a caspase 
inhibitor was used to see if they affected cell viability in the presence of these drugs. 
The fluorogenic substrate (488 Nuc caspase-3) was also used to determine if caspase 
activity was directly affected, within intact cells. 
3.4.1 Detection of apoptosis by caspases caused by Etoposide, Cisplatin, and 
Doxorubicin using a caspase 3 inhibitor to detect the effects on cell 
viability  
3.4.1.1 Effect of caspases inhibitor on Etoposide induced cell death 
From the figure 3.4.1.1 A-D; it can be seen the caspase -3 is involved in kidney and 
liver cell death, where the cells were treated with 60 µM of caspases  inhibitor for 
4 hrs before adding the etoposide (at LC50 concentration for each of the cell lines). Cells 
were incubated with the drug at 37 ºC for 48 hrs and MTT was performed.  
In figure 3.4.1.1A and 3.4.1.1B, COS-7 and HK2 cells were treated with Etoposide (at 
the following concentration 150, 50 µM, respectively). COS-7 cells showed a 
significant difference in the presence of caspase 3 inhibitor, where significantly less 
cells died compared to Etoposide alone. However, none of the other cell lines were 
protected from etoposide-induced cell death. These results would suggest that caspases 
dependent apoptosis only occurs in COS-7 cells and not the other cell tested.  
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Figure 3.4.1.1A-D; the effects of caspase 3 inhibitor on Etoposide induced cell 
death. (A) shows COS-7 cells with caspase 3 inhibitor  and  Etoposide (150 µM), (B) 
shows HK2 cells with caspase 3 inhibitor  and Etoposide (50 µM). (C) Shows HepG2 
cells with caspase 3 inhibitor with Etoposide (120 µM), (D) shows Huh7.5 cells with 
caspase 3 inhibitor and Etoposide (1000 µM). Confluent (70-80%) cells were incubated 
for 48 hrs with the drug. Values are presented as mean ± SD of 3-4 determinations. (* 
value points were significant different from the Etoposide, p ≤ 0.05), using t-test. 
3.4.1.2 The effect of caspase inhibitor -3 on Cisplatin induced cell death  
Figure 3.4.1.2A-D; shows the effect of caspase -3 on kidney and liver cells. Cells were 
pretreated with 60 µM of caspase inhibitor for 4 hrs before adding Cisplatin (at the LC50 
of each type of cell). Cells were incubated at 37 ºC for 48 hrs and then MTT assays 
performed. 
In figure 3.4.1.2A and 3.4.1.2B, COS-7 and HK2 cells were treated with Cisplatin at 46, 
20 µM, respectively. The cells showed significant protection from cell death induced by 
Cisplatin. COS-7 and HK2 cells showed increased cell viability of about 30%, while 
figure 3.4.1.2C and 3.4.1.2D shows HepG2 and Huh7.5 treated with Cisplatin (35, 
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90 µM), respectively. The results showed a significant effect of caspases 3 inhibitor on 
cell viability for both liver and kidney cells. The cell viability of Huh7.5 and HepG2 
cells increased to almost control levels using caspase 3 inhibitor .  
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Figure 3.4.1.2A-D; the effects of Cisplatin–induced death by caspase 3  inhibitor. 
(A) Shows COS-7 cells pretreated with caspase 3 inhibitor and then Cisplatin (46 µM), 
(B) shows HK2 and Cisplatin (20 µM). (C) Shows HepG2 cells with Cisplatin (35 µM), 
(D) shows Huh7.5 cells with Cisplatin (90 µM). Cells incubated for 48 hrs with the 
drug. Values are presented as mean ± SD of 3-4 determinations. p values were 
presented with caspase inhibitor followed by Cisplatin compared to Cisplatin 
treatment alone are indicated by (* p ≤ 0.05, ** p ≤ 0.01), using t-test.  
3.4.1.3 The effect of caspase inhibitor -3 on Doxorubicin induced cell death. 
Figure 3.4.1.3A-D; shows the effects of caspses 3 inhibitor on kidney and liver cell 
viability. The cells were treated with 60 µM of the caspases inhibitor for 4 hrs before 
adding DOX (at LC50 of each cell type). Cells were incubated at 37 ºC with the drug 
for 48 hrs and then MTT assays were performed.  
In figure 3.4.1.3A and 3.4.1.3B, COS-7 and HK2 cells were treated with DOX (7, 3 µM 
respectively). The cell viability was significant increased using caspase 3 inhibitor with 
COS-7, but not in HK2 cells. Figure 3.4.1.3C and 3.4.1.3D, shows HepG2 and Huh7.5 
were treated with DOX (4, 6 µM respectively). Results showed a small but significant 
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effect of caspase inhibitor on cell viability for HepG2 cells, but on the Huh7.5 cell 
viability was not, however, affected. 
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Figure 3.4.1.3A-D; the effect of caspase 3 inhibitors on DOX-induced cell death.  
(A) shows COS-7  cells pretreated with caspase 3 inhibitors  and then DOX (7 µM), (B) 
showed HK2  cells pretreated with caspase 3 inhibitors and  then DOX (3 µM). (C) 
showed HepG2 cells pretreated with caspase 3 inhibitors and then with DOX (4 µM), 
(D) shows Huh7.5 cells pretreated  with caspase inhibitor and then with DOX (6 µM). 
Cells were incubated for 48 hrs after exposure to the drug. Values are presented as mean 
± SD of 3-4 determinations (* p ≤ 0.05). 
3.4.2 Detection of apoptosis by caspase activation induced by MTX, Etoposide, 
Cisplatin, and Doxorubicin using a fluorogenic substrate (488 Nuc caspase-
3) 
In order to confirm apoptotic cell death induced by these drugs on liver and kidney cell 
lines, a second technique was used, which is fluorogenic substrate (488 Nuc caspase-3 
kit). This generates green fluorescent product inside cells if caspase 3 become activated 
within the cells (see figure 3.4.2). This method has greater sensitivity than the use of 
caspase inhibitors, because it is fluorescence based. 
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Figure 3.4.2; Illustates light and flouresence field of COS-7 cells pre-treated with 
fluorogenic substrate (488 Nuc caspase-3) and then treated with doxorubicin. 
3.4.2.1 Detection of apoptosis by caspase activation induced by MTX, using a 
fluorogenic substrate (488 Nuc caspase-3) on kidney and liver cell lines 
As MTX was shown previously to have a little or no effect on cell death but mainly 
affected cell proliferation, in order to confirm this, in vivo caspase-3 substrate was 
used. Figure 3.4.2.1(A) COS-7 cells and figure 3.4.2.1(B) Huh7.5 cells,  were treated 
with MTX 100 µM for 24 hrs, then cells were treated with 2 µM of caspase substate-3 
and incubated for a further 30-40 min. Fluorescence microscopy images were taken of 
the cells under white light and fluorescence conditions for the same field. Fluorescent 
and total numbers of cells were counted and the apoptotic cell death percentage was 
calculated for each group. As MTX was dissolved in DMSO, two controls were used 
(i.e. controls with and without DMSO). Figure 3.4.2.1(A) shows only about 10% of cells 
are fluorescence and therefore undergo apoptosis upon MTX treatment, while about 
12% of Huh7.5 cells undergo apoptotic cell death. 
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Figure 3.4.2.1A; shows the effect of MTX on apoptotic cells. COS-7 cells were 
exposed to the drug for 24 hrs. The caspase-3 substrate was monitored after 30 min of 
incubation at 37 ºC. Data represents the mean ± S.D of 3-4 determinations (* value 
points were significantly different from the DMSO control, p ≤ 0.05, ** p ≤ 0.01), using 
the t-test.  
 
Figure 3.4.2.1B; shows the effect of MTX on apoptotic cells. Huh7.5 cells were 
exposed to the drug for 24 hrs. The caspase-3 substrate was monitored after 30 min of 
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incubation at 37 ºC. Values are presented as mean ± SD of 3-4 determinations (* value 
points were significant different from the DMSO, p ≤ 0.05, ** p ≤ 0.01), using the t-test.   
 
3.4.2.2 Detection of apoptosis by caspase activation induced by Etoposide, using 
the fluorogenic substrate (488 Nuc caspase-3) on kidney and liver cell lines 
In order to confirm that cell death was induced by apoptosis, the fluorgenic caspase-3 
substrate was used. Figure 3.4.2.2 shows the effect on COS-7 (A), HK2 (B), HepG2 
(C), and Huh7.5 (D), when treated with Etoposide (150,50,120,1000 µM), respectively, 
for 24 hrs, then cells were treated with  2 µM  of  caspase  substate-3  and  incubated  
for  about  30-40  min.  Fluorescence microscopy was used and the cells imaged under 
light and fluorescence conditions for the same field of view. Fluorescence and total 
number of cells were counted and the apoptotic cell death percentage was calculated 
for each group. As etoposide was dissolved in DMSO, two control groups have taken, 
controls with and without DMSO. A significant difference of the % of apoptotic cells 
between control and treated cells, in all the four cell lines was observed. Both kidney 
cell lines showed increases in apoptotic cell numbers cell with HK2 and Huh7.5 
showing that 40-60% of the cells were apoptotic. 
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Figure 3.4.2.2A-D; shows the effect of Etoposide on apoptotic kidney and liver cell 
lines. COS-7 (A), HK2 (B) HepG2 (C), and Huh7.5 (D), cells were exposed to 
Etoposide drug for 24 hrs. The caspase-3 substrate added and the cells monitored after 
30 min of incubation at 37 ºC. Data represents the mean ± SD of 3-4 determinations.  (* 
value points were significant different from the DMSO control, p ≤ 0.05, ** p ≤ 0.01), 
using the t-test.  
3.4.2.3 Detection of apoptosis by caspase activation induced by Cisplatin, using 
the fluorogenic substrate (488 Nuc caspase-3) on kidney and liver cell lines 
In order to determine whether apoptosis was induced by Cisplatin, the fluorogenic 
caspase-3 substrate was used. Figure 3.4.2.3 shows COS-7 (A), HK2 (B), HepG2 (C), 
and Huh7.5 (D), were treated with Cisplatin (at the LC50 concentration 35, 20, 35, 
90 µM, respectively), for 24 hrs, followed by incubation with 2 µM of caspase 
substrate- for about 30-40 min. Images were then taken of the cells under white light 
and fluorescence conditions for the same field, and the number of fluorescence cells 
and total number of cells were counted such that the apoptotic cells percentage could 
be calculated for each group. All cells showed significant increases in apoptotic cell 
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numbers compared to control. COS-7 and HK2 were more sensitive to Cisplatin than 
HepG2 and Huh7.5.  
 
 
 
Figure 3.4.2.3 A-D; shows the effect of Cisplatin on apoptosis cell in different 
kidney and liver cell lines COS-7 (A), HK2 (B), HepG2 (C), and Huh7.5 (D). Cells 
were exposed to the drug for 24 hrs and the caspase-3 substrate for 30 min at 37 °C. 
Data represents the mean ± S.D of 3-4 determinations. Value that were significant with 
Cisplatin (** p ≤ 0.01), using the t-test.  
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3.4.2.4 Detection of apoptosis by caspase activation induced by Doxorubicin, 
using a fluorogenic substrate (488 Nuc caspase-3) on kidney and liver cell 
lines 
Apoptotic cells induced by DOX was monitored using the caspase substrate 488 Nuc 
caspase-3. Figure 3.4.2.4 shows COS-7 (A), HK2 (B), HepG2 (C), and Huh7.5 (D), 
treated with doxorubicin at the LC50 concentration i.e. (7, 3, 4, 6 µM, respectively), for 
24 hrs, followed by treatment with 2 µM of fluorogenic caspase substrate-3 then, 
images were taken of the cells under white light and fluorescence condition, for the 
same field. All cells exposed to DOX showed between 70-90% were apoptotic. 
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Figure 3.4.2.4A-D; shows the effect of Doxorubicin on inducing apoptotic cells in 
different kidney and liver cell lines. COS-7 (A), HK2 (B), HepG2 (C), and Huh7.5 
(D) cell lines were exposed to the drug for 24 hrs. The fluorogeneic caspase-3 substrate 
was incubated for 30 min at 37 °C. The data represents the % of apoptotic cells mean ± 
S.D of 3-4 determinations. Value points were significant different from the DOX (p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001), using the t-test.  
 
3.5  Determination of Necrosis involved in the cell death process induced by the 
chemotherapy drugs 
In order to determine whether cell death by these chemotherapy agents was, at least 
in part, due to regulated necrosis, necrostatin (an inhibitor of regulated necrosis), or 
normal necrosis leakage of cytosolic lactate dehydrogenases enzyme in to the media, 
was undertaken.  
3.5.1 Determination of necrosis using necrosis inhibitor (necrostatin by 
Etoposide, Cisplatin and doxorubicin) in kidney and liver cell lines 
3.5.1.1 Detection of regulated necrosis using necrostatin by Etoposide in kidney 
and liver cells 
Necrosis inhibitor necrostatin (10 µM) was pre-incubated with the cells, for 4 hrs, and 
then cells were exposed to Etoposide (i.e. for COS-7, 120 µM; HK2, 50 µM; HepG2, 
120 µM; and Huh7.5, 1000 µM). Cells were incubated at 37 ºC for 48 hrs then the 
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MTT assays were performed. Figure 3.5.1.1A, 3.5.1.1B, 3.5.1.1C, and 3.5.1.1C 
represents COS-7, HK2, HepG2, and Huh7.5 cells, respectively. The results show that 
the necrosis inhibitor does affect the viability of both COS-7 and HepG2 cells to a 
significant extent, but had either no effect with HK2 and Huh7 cells.  
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Figure 3.5.1.1 A-D; shows the effects of Etoposide with and without necrostatin in 
liver and kidney cells.  COS-7(A),  HK2  (B),  HepG2  (C) and  Huh7.5  (D)  cells  
were pretreated with necrostatin (10 µM) and then  exposed to the Etoposide for 48 hrs 
at 37 °C. Data represents the mean ± SD of 3-4 determinations. Values were 
significantly different from the Etoposide (p ≤ 0.05, ** p ≤ 0.01), using the t-test. 
 
3.5.1.2 Determination of regulated necrosis induced by Cisplatin in kidney and 
liver cell lines 
Necrosis inhibitor (necrostatin) (10 µM) was pre-incubated with the cells used for 4 hrs, 
and then the cells were exposed to Cisplatin (COS-7, 46 µM; HK2, 20 µM; HepG2, 
35 µM; Huh7.5,  90 µM, respectively) at 37 ºC for 48 hrs and then  MTT assays were 
undertaken. Figure 3.5.1.2A, 3.5.1.2B, 3.5.1.2C, and 3.5.1.2D represents COS-7, Hk2, 
HepG2, and Huh7.5 cells, respectively. The results showed that the necrosis inhibitor 
does affect cell viability significantly, compared to cisplatin treatment alone in all 
cells tested. 
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Figure 3.5.1.2A-D; shows the effects of Cisplatin with and without necrostatin on 
liver and kidney cell lines. COS-7(A), HK2 (B), HepG2 (C) and Huh7.5 (D), cells 
were pretreated with necrostatin and then exposed to Cisplatin for 48 hrs at 37 °C. The 
data represents the mean ± SD of 3-4 determinations. (* where value points were 
significany different from the controls, p ≤ 0.05, **p ≤ 0.01), using t-test. 
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3.5.1.3 Using necrostatin to determine whether regulated necrosis is involved in 
cell death induced by Doxorubicin in kidney and liver lines 
The necrostatin (10 µM) was incubated with the cells for 4 hrs, and then the cells; COS-
7, HK2, HepG2 and Huh7.5 were exposed to DOX (7, 3, 4, and 6 µM, respectively), 
at 37 ºC for 48 hrs. MTT assays were then performed. Figure 3.5.1.3A, 3.5.1.3B, 
3.5.1.3C, and 3.5.1.3D represents COS-7, HK2, HepG2, and Huh7.5 cells, respectively. 
Necrostatin did not affect the cell viability compared to drug alone for all the cells 
tested.   
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Figure 3.5.1.3A-D; the effects of DOX with and without necrostatin pre-
treatment in liver and kidney cell lines. COS-7(A), HK2 (B), HepG2 (C) and Huh7.5 
(D) cells were pretreated with necrostatin and then exposed to the DOX for 48 hrs and 
incubated at 37 °C. Data represents the mean ± SD of 3-4 determinations.  
3.5.2 Lactate dehydrogenases release assay to determine necrosis through plasma 
membrane leakage when kidney and liver cell lines are exposed to 
chemotherapy agents 
The current experiments were designed to determine whether cell deaths caused by 
these chemotherapy drugs are related to release of lactate dehydrogenases (LDH) 
enzymes from the cytoplasm in to the surrounding media, as a part of necrostatic cell 
death, due to increase of plasma membrane permeability.  
3.5.2.1 Detection of necrosis induced by Etoposide in kidney and liver cell lines 
using the lactate dehydrogenases release assay 
As the necrosis inhibitor studies specifically investigate regulated necrosis as a means 
of cell death, it was important to determine whether classical necrosis was a l so 
involved by measuring LDH release. Cells were treated with Etoposide (150 and 
120 µM) for both (COS-7 and HepG2, respectively) and after 24 hrs, the LDH 
assay was performed. The data in figure 3.5.2.1A and B shows COS-7 and HepG2 
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cells treated with the drug and incubated at 37 ºC for 24 hrs. Figure 3.5.2.1A show a 
small significant effect on increasing LDH releases. However, HepG2 cells show no 
significant effect compared to control.  
 
 
Figure 3.5.2.1A and B; the effect of Etoposide on lactate dehydrogenases (LDH) 
release in COS-7 cells (A) and HepG2 cells (B). Cell were treated and incubated for 
24 hrs and then LDH release assayed. Data represents the mean ± SD of 3-4 
determinations. (* values were significantly different from the controls, p ≤ 0.05), using 
the t-test.  
 
3.5.2.2 Determination of necrosis induced by Cisplatin in kidney and liver cells 
using the lactate dehydrogenases assay 
Cells were treated with cisplatin (46 µM, COS-7; 35 µM, HepG2) and after 24 hrs, the 
LDH assays were performed. The data in figure 3.5.2.2A and B show COS-7 and 
HepG2 cells treated with drugs and incubate at 37 ºC. Figure 3.5.2.2A and B shows a 
significant effect on LDH releases similar to that of the positive control (Triton). 
However, other cell lines showed a high control background (data not shown). 
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Figure 3.5.2.2A; the effect of Cisplatin on lactate dehydrogenases (LDH) release in 
kidney cells COS-7 (A) and liver cells HepG2 (B). Cells were treated with Cisplatin 
and incubated for 24 hrs and then the LDH release assays performed. Data represents 
the mean ± SD of 3-4 determinations. (* values were significantly different from the 
controls, p ≤ 0.05), using the t-test. 
 
3.5.2.3 Detection of necrosis induced by doxorubicin in kidney and liver cell lines 
using the lactate dehydrogenases assay 
Cells were treated with DOX (7 COS-7, 4 µM HepG2) and after 24 hrs, the LDH 
assays were performed. Figure 3.5.2.3A and B shows no significant effect on increasing 
LDH release.  
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Figure 3.5.2.3A and B; the effect of DOX on lactate dehydrogenases (LDH) release 
in COS-7 cells (A) and HepG2 cells (B). Cells were treated with DOX and 
incubated for 24 hrs and then LDH release assays performed. Data represents the mean 
± SD of 3-4 determinations.  
 
3.6 Autophagy detection using cytosolic LC3-GFP as a biomarker for 
autophagosome formation 
As a part of autophagosome formation, during the autophagy, LC3 protein is involved. 
LC3 usually found diffused inside the cells, but under certain forms of cell stress it is 
converted to phosplatidylethanolamine (PE)- Linked form located on the phagophore. 
Therefore, LC3 was used as a biomarker protein to monitor the initiation of autophagy 
in COS-7 and HepG2 cells treated with different chemotherapy drugs (i.e. Etoposide, 
Cisplatin and DOX). LC3-GFP when recruited to the autophagomsome gives the 
appearance of fluorescence hot spots or “punta” when visualized under the fluorescence 
microscope (Wong et al, 2013) (see figure 3.6.1, inset). 
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3.6.1 Monitoring autophagy using LC3- GFP by Etoposide in kidney and liver 
cells 
Both COS-7 and HepG2 Cells were transiently transfected with GFP-LC3 plasmid for 
48 hrs to allow the expression of this protein to be visualized under the fluorescence 
microscope and then cells were treated with etoposide [(150 and 120 µM) for both 
COS-7 and HepG2 cells]. Figure 3.6.1, shows the percentage of punta formation on both 
control/DMSO and Etoposide COS-7 (A) and HepG2 (B) treated cells for 4 hrs post 
transfection. This figure shows that COS-7 cells shown no significance difference 
between DMSO and the Etoposide group. HepG2 cells also showed a clear difference 
between the both groups where approximately 25% of cells were showing punta 
formation. 
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Figure 3.6.1; the percentage of LC3-GFP punta transfected cells treated with 
Etoposide. COS-7 (A) and HepG2 (B) cells were transfected with LC3- GFP plasmid 
for 48 hrs, then the cells were treated with Etoposide (150 and 120 µM), respectively, 
for 4 hrs. Punta formation was calculated using fluorescence microscope. Data 
represents the mean ± SD of 5-6 determinations. (* value points were significant 
different from the controls, p ≤ 0.05, **p ≤ 0.01), using the t-test. (Inset) the micrograph 
above shows the punta formation in COS-7 cells under light and fluorescence field 
following Etoposide treatment.  
3.6.2 Monitoring autophagy using LC3- GFP by Cisplatin in kidney and liver 
cells 
COS-7 and HepG2 cells were transiently transfected  for 48 hrs with LC3-GFP to allow 
expression to be visualized under the fluorescence  microscope and then cells were 
treated with the LC50 of Cisplatin (46 and 35 µM) in COS-7 and HepG2 cells, 
respectively. Figure 3.6.2 shows the percentage of punta formed on both control (i.e. 
water) and Etoposide. This figure shows that both COS-7 and HepG2 cells forms a high 
percentage of punta about 70% which is highly significance compare to control group 
with only 20% punta were observed.  
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Figure 3.6.2; the percentage of LC3-GFP punta in transfected cells treated with 
Cisplatin. COS-7 (A) and HepG2 (B) cells were transfected with LC3-GFP plasmid for 
48 hrs then the cells treated with Cisplatin (46 and 35 µM) Respectively, for 4 hrs. 
Punta formation was determind using fluorescence microscopy. Data represents the 
mean ± SD of 5-6 determinations. (* values were significant from the controls, p ≤ 0.05, 
**p ≤ 0.01), using the t-test. The micrograph above shows the punta formation in COS-
7 cells under white light and fluorescence field, during Cisplatin treatment. 
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3.6.3 Monitoring autophagy using GFP-LC3 by Doxorubicin in kidney and liver 
cells 
Cells were transiently transfected for 48 hrs with LC3-GFP plasmid and then cells were 
treated with LC50 of DOX (7 and 4 µM) with COS-7 and HepG2 cells. Figure 3.6.3 
shows the percentage of punta formation in both control and DOX, COS-7 (A) and 
HepG2 (B) treated cells for 4 hrs. Figure 3.6.3 shows that DOX causes about 45% and 
60% punta formation in COS-7 and HepG2 cells, respectively. Treated cells showed a 
significant difference of autophagosomes formation compared to control cells (water). 
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Figure 3.6.3; the percentage of punta in LC3-GFP transfected cells treated with 
DOX. COS-7 (A) and HepG2 (B) cells were transfected with LC3-GFP plasmid for 
48 hrs then cells treated with DOX (7 and 4 µM) Respectively, for 4hrs. Punta 
formation was calculated using fluorescence microscopy. Data represents the mean ± 
SD of 5-6 determinations. (* values were significantly different from the controls, p ≤ 
0.05, **p ≤ 0.01), using the t-test.  
 
3.7 Investigating DNA single strand breaks using comet assay 
The comet assay is a sensitive assay for monitoring DNA single stand breaks inside 
cells. The head represents the undamaged part of the DNA in the cell while the tail 
represents the fragmented DNA electrophoresed out of the cell. Cells were treated with 
LC50 of DOX and after (4 and 24 hrs) comet assays performed to measure the extent of 
DNA damage. In this experiment, H2O2 was used as a positive control (100 mM for 
60 min). 
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3.7.1 Comet assays for measuring DNA breaks in COS-7 cells treated cells with 
DOX 
COS-7 cells were treated with 7 µM of DOX for 4 and 24 hrs. H2O2 was added to some 
cells as a positive control. Comet assay IV software was used to calculate the tail 
intensity percentage for each group of 100 counted cells of 3 determinations. Figure 
3.7.1A shows a section of a control cells slide with intact DNA and a section of a slide 
with cells treated with DOX. Figure 3.7.1B and C shows the percentage of total 
intensity that occurs in the tail of  COS-7 cells treated with DOX (7 µM) for 4 hrs (A) 
and 24 hrs (B), respectively. Comparing the control and DOX groups, a small but 
significant difference was observed after 4 hrs, while a more significant, about 25% tail 
intensity of single stand breaks, was observed after 24 hrs. 
 
 
Figure 3.7.1A; images from Comet IV software, showing COS-7 intact nuclei and a 
damaged nuclei after DOX treatment. 
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Figure 3.7.1B and C; shows the tail intensity of control, H2O2, and DOX treated 
cells with one comet assay. COS-7 cells were treated with 7 µM of DOX and H2O2 for 
4 and 24 hrs, then comet assay was performed and Comet IV software. (* values were 
significantly different from the controls, p ≤ 0.05), using the t-test.  
 
3.7.2 Comet assay for measuring DNA breaks in HepG2 cells treated cells 
Cells were treated with (4 µM) of DOX for 4 and 24 hrs. Comet assay IV software was 
used to calculate the tail intensity percentage for each group of 100 counted cells of 3 
determinations. Figure 3.7.2A shows a section of a control cells with intact DNA and a 
section of cells treated with DOX. Figure 3.7.2B and C shows the percentage of tail 
intensity of HepG2 cells treated with DOX 4 µM for 4 hrs and 24 hrs (B), respectively. 
Comparing both the control and DOX groups, a high significant difference was 
observed after 4 hrs, and after 24 hrs. DOX causes about 25% tail intensity of single 
stand breaks at both times, which suggest that DOX is highly damaging to HepG2 cells 
even after a short period of time.  
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Figure 3.7.2A; images from Comet IV software, showing HepG2  intact nuclei and 
a damaged nuclei after DOX treatment. 
 
 
 
Figure 3.7.2B and C; shows the tail intensity of control, H2O2, and DOX treated 
HepG2 cells with one comet assay. HepG2 cells were treated with 4 µM of DOX and 
H2O2 for 4 and 24 hrs, then comet assay was performed and Comet IV software. (* 
values were significantly different from the controls, p ≤ 0.05, **p ≤ 0.01), using the t-
test.  
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3.8 Discussion 
Chemotherapy is a cancer treatment that uses medicines and drugs in order to kill 
and/or stop tumor cancer cells multiplying.  Chemotherapeutic drugs are also used   
in order to destroy any remaining cancer cells following surgery (Skeel and Khlief, 
2011). This form of therapy mainly acts either by interacting with the cell cycle, 
inhibiting DNA replication or activating cell death pathways (Payne and Miles, 2008). 
The effects of the drugs (MTX, Etoposide, Cisplatin and DOX) on cell viability of 
kidney (COS-7, HK2) and liver (HepG2, Huh7.5) cancer cell lines were studied in 
detail. 
3.8.1 The effect of Methotrexate (MTX) in Kidney (COS-7, HK2) and liver 
(HepG2, Huh7.5) cancer cell lines 
Methotrexate is an antimetabolite agent and acts as an inhibitor of tetrahydrofolate 
reductase, which blocks tetrahydrofolate formation, and which is necessary for 
nucleotide biosynthesis and therefore cell division (Warlick et al., 2000). Many studies 
have been undertaken to understand the mechanism of MTX toxicity. In order to 
investigate the cytotoxicity of MTX on kidney and liver cell lines, MTT assays were 
performed. As shown in figure 3.2.1.1 both kidney (COS-7, HK2) cell lines showed 
more sensitivity to toxicity by MTX than liver (HepG2, Huh7.5) cell lines and 
noticeably, HK2 cells were more sensitivity to MTX than COS-7 cells, with a LC50  of 
low µM. Therefore, this may indicate that different kidney cell lines are not similarly 
affected by this drug. Furthermore, the results with liver cells demonstrate that the 
toxicity of MTX has a limited effect on cell viability of liver cells even at high MTX 
concentrations (200 µM). The results are in agreement with other studies by Keefe et 
al., (1982), where murine leukaemia cells (L5178Y) exposed with ≥ 10 µM MTX for 
42 hrs did not result in any further toxicity as compared to treatment with 0.1 µM MTX.  
High MTX concentrations are usually used to treat tumours compared to the 
concentrations used for other diseases such as psoriasis and arthritis (Weinstein et al., 
1990). In this study concentrations up to 500 µM MTX was used and showed only 
limited effects with confluent cells. However, at a density of about 20% cell confluency, 
treatment with high concentrations of MTX showed suppression of cell proliferation 
(see figure 3.3.1.3 A and B). These results are consistent with other studies which have 
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shown that MTX inhibits cell growth in a vartiey of cell lines (Mazor et al., 2015, 
Seigers et al., 2010 and Jeffes et al., 2005). Furthermore, when MTX drug was removed 
from the cells, they began to show more normal cell division and growth. Therefore, 
these results could be explained by MTX mainly affecting cell proliferation rather 
than cell death, this is consistent with the fact that  MTX inhibits tetrahydrofolate 
reductase preventing the synthesis of an important nucleotide metabolites for DNA 
synthesis (Weinsterin, 1990). 
3.8.2 The effect of Etoposide in Kidney (COS-7, HK2) and liver (HepG2, Huh7.5) 
cell lines 
Etoposide is one of the most commonly used anti-cancer drugs, which inhibits 
topoisomerases II and causes DNA breakage (Baldwin and Osheroff, 2005). Etoposide 
is a plant–derived natural product; it is a podophyllotoxin derivative and is considered 
to be one of the most important anticancer drugs. However, Etoposide has toxic side 
effects at the cellular and organ level (Minev, 2011). In order to examine the 
cytotoxicity of etoposide on kidney and liver cell lines; MTT assays, caspase inhibitor, 
caspase substrates,  necrosis inhibitors, LDH assays and GFP-LC3 punta biomarker 
were used. Figure 3.3.2 A-D showed that HK2 cells are the most sensitive to 
Etoposide, with an LC50 of 50±6 µM as compared to the other cell lines which were 
much less sensitive i.e. HepG2, COS-7 and Huh7.5 with LC50 of 120±6.4 µM, 150±9.1 
µM and 1000±11.2µM, respectively. These data support other results which report a 
range of LC50 values with etoposide in different gastric cell lines (Yu, et al., 2007). 
Different methods were used to investigate the mechanism of cell death by Etoposide in 
this study. Our data suggested that Etoposide caused apoptotic cell death in COS-7 
cells, when the cell viability, of pre-treated cells with caspase-3 inhibitor, increased 
about 10-25% of cell viability compared to Etoposide alone. However, caspase-3 
substrate, which is much more sensitive could detect the involvement of caspase-3, 
more clearly in the other cell lines. This observation could be because caspase 
inhibitors are detecting cells that are either alive or dead, while, the caspase 
substrate method is assessing, all cells which are in the process of undergoing 
apoptosis and have not yet died. Dead cells in this methods are removed through the 
washing stages and so do not contribute to the cell number. Furthermore, the assay 
involves fluorescence detection is much more sensitive compared with the 
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absorbance based MTT assay. The observations presented here are in agreement with 
other studies that have shown that  Etoposide  specifically induces apoptosis  in a range 
of different cell lines (Yu et al., 2007), Hep 3B hepatoma cells [(Yoo et al., 2012), 
HL60 cell (Barry et al., 1993), Male germ cell (Lizama et al., 2011) and HEK 293 
kidney cells (Zhoa et al., 2006)]. In this chapter other experiments were undertaken to 
determine whether other mechanisms of Etoposide- induced cell death were involved. 
Etoposide was also shown to causes necrosis cell death (using necrostatin and LDH 
assays) in COS-7 and HepG2 cells but not in HK2 and Huh7.5. This effect has also been 
found in another study (Litwiniec et al., 2013) where low concentrations of Etoposide 
on A549, a human lung epithelial cells line, showed early apoptosis, late apoptosis and 
necrosis using the annexin V-PI assay. More recently, another study has suggested that 
Etoposide can induce both necrosis in HK2 cells and apoptosis after inhibition of p53 
(Kwon et al., 2015). However, our findings results shown little necrosis in HK2 cells 
exposed to Etoposide.  
In addition, HepG2 and COS-7 cells shows statistically significant differences in LC3 
punta formation when cells were exposed to Etoposide. Some studies showed not only 
apoptotic but autophagic phenotypes in Hep3B cells (Yoo, 2012), together the findings 
presented here indicate that, Etoposide induces a mixed type of cell death involving 
apoptosis, necrosis and autophagy, which appears to be cell line dependent.    
3.8.3 The effect of Cisplatin in Kidney (COS-7, HK2) and liver (HepG2, Huh7.5) 
cell lines  
Cisplatin is (cis- diamminedichloroplatinum (CDDP)), targets tumor cells of the testis 
as well as many other epithelial malignances such as ovary, bladder, cervix, head, neck, 
prostate, lymphoma, and carcinomas of esophageal (Oyanagi, et al., 2015, Rozencweig 
et al., 1977). However, Cisplatin also causes acute nephrotoxicity and can accumulate 
in microsomes, nuclei, mitochondria and cytosol of these cells (Litterst, 1981). The data 
presented here showed the cytotoxicity of Cisplatin in kidney and liver cells, to be 
different in the cell lines. As mentioned previously with other drugs, HK2 cells seems 
to be the most sensitive cell line for Cisplatin a LC50 of 20±7 µM compared with LC50 
values 35±3 µM, 46±8.7 µM for HepG2 and COS-7 cells, respectively. Recent studies 
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of cell death induced by Cisplatin have suggested that both apoptosis and necrosis are 
involved (Karadeniz et al., 2011, Sand-Dejmek et al., 2011, Pestell et al., 2000).  
The results presented here, also confirmed that Cisplatin significantly induces apoptosis 
via caspase 3 in both kidney (COS-7 and HK2) cells as well as liver cells (HepG2 and 
Huh7.5) (Figure 3.4.1.2 A-D). A recent study has shown that in HepG2 cells activation 
of caspase -3,-8,-9 in Cisplatin treated cells occurs (Chien, et al., 2015), which supports 
our finding. Our data are also consistent with the finding of activation of apoptosis in 
Cisplatin- treating cells is through caspases (Lu and Cederbaum, 2007, Barry, et al., 
1990). The results presented here show that Cisplatin is also able to induce necrosis or 
regulated necrosis in all cell lines tested. These findings are consistent with that of Lim 
et al, (2010) that reported Oxaliplatin (Cisplatin analogue) caused necrosis in HepG2 
hepatocellular carcinoma cells (Lim et al., 2010). Park et al. (2015) showed that 
Cisplatin could also induce necrosis cell death in HK2. Cisplatin at 50 µM can also 
causes nuclei fragmentation, apoptosis and necrosis features (Lau, 1999). 
Interestingly, several studies have shown that Cisplatin can induced necrosis when 
inhibiting apoptosis pathway (Zhang et al., 2008, Gonzalez et al., 2001 and Sancho- 
Martinez et al., 2011). However, in COS-7 and HepG2 cell lines used in my study, I 
have shown necrosis cell death can occur without inhibiting of apoptosis pathway. In 
fact, Cisplatin inducing necrosis rather than apoptosis could be a concentration 
dependent process (Ganzalez at al., 2001).  
The results presented here showed that Cisplatin also, causes autophagy in HepG2 and 
COS-7 cells (Figure 3.6.2 A and B). However, one study has suggested that the 
unfolded protein response (UPR) inhibits cisplatin-induced apoptosis in hepatocellular 
carcinoma cells, via heat shock protein mediated autophagy (Chen et al., 2011) 
indicating a cell survival process. This might suggest that these cells undergo autophagy 
within hours of Cisplatin exposure through a protective mechanism for cell survival 
prior to being overwhelmed and apoptosis then taking place (Periyasamy-Thandavan et 
al., 2008, Takahashi et al., 2012, Zou et al., 2012). To summarise, cisplatin has diverse 
effects on cell, causing cell death through types apoptosis, necrosis and autophagy. 
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3.8.4 The effect of Doxorubicin in Kidney (COS-7, HK2) and liver (HepG2, 
Huh7.5) cell lines 
Doxorubicin (DOX) is a anthracycline antibiotic anti-cancer drug. DOX is also 
considered one of the most potent chemotherapeutic drugs that is currently used 
(Carvalho, 2009). This drug has the ability to damage DNA and inhibit DNA and RNA 
production by free-radicals damage (Minotti et al., 2004). It was very clear that DOX 
was the most toxic chemotherapy drug compared with the other chemotherapy drugs 
used in this study. All four cell lines showed low LC50 values in contrast to Etoposide, 
Cisplatin and MTX. HK2 was the most sensitive cell line with LC50 of 3±5µM followed 
by HepG2, Huh7.5 and COS-7 cells with LC50 of 4±5, 6±7, 7±8 µM, In this study, I 
showed that this drug is highly toxic and mediates a high level of apoptosis using the 
caspase-3 substrate in all four cell lines tested (Figure 3.4.2.4 A-D). However, the results 
were not as clear with HK2, HepG2 and Huh7.5 cells using caspase-3 inhibitor. This 
finding is consistent with other studies that showed that DOX could induce apoptosis in 
renal cells (Zhang et al., 1996), in hepatoma cell lines (Lee et al., 2002) and human 
neuroblastoma cell (Rebbaa, 2003, Jin et al., 2007). With regards to necrosis, little effect 
of DOX on this was observed (figure 3.5.2.3 A and B). This disagrees with the reports of 
DNA damaged-induced necrosis through a PARP1- dependent and p53- independent 
pathway by DOX in HK2 cells (Chin et al., 2015). As no effect were seen for either the 
necrostatin inhibitor or LDH release assay, we believe that different experimental 
conditions and treatments may account for these differences. 
Autophagy, is a process involving lysosomal degradation and recycling of unwanted 
cytosolic proteins and other organelles. Activation of this might be either protective or 
destructive (i.e. causes cell death) depending on the specific pathological and 
physiological conditions (Mizushima, 2005, Levine and Yuan, 2005). DOX showed an 
increase in LC3-GFP punta with both COS-7 and HepG2 cells, indicating the potential 
for autophagy cell death. In support of this DOX has also been shown to exhibit 
autophagy in cardiomyocytes at low µM concentrations (Kabayashi, et al., 2010). The 
observation of autophagy cell death induced by DOX in both liver and kidney cells is a 
new finding and needs further study to be undertaken to determine whether this plays a 
major role in hepatotoxiciy or nephrotoxicity in patients.  
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The alkaline single cell gel electrophoresis (comet assay) was used to quantitate the 
genotoxic effects of DOX in both HepG2 and COS-7. The results showed that DOX 
causes a substantial amount of DNA single strand breaks even after a short 4 hrs 
exposure to DOX. This degree of strand breaks only increased by a smaller amount after 
24 hrs for HepG2 compare to COS-7 cells. Therefore, the early onset of DNA damage 
indicates that DOX is likely causing DNA damage directly rather than through 
apoptosis, which causes DNA damage over longer time periods. DOX also induces the 
production of reactive oxygen species in many different cells (Kim et al., 2006, Tsang, 
et al., 2003). When DOX binds to DNA it may cause oxidative damage at this site, 
therefore damaging DNA directly rather than through an indirect route (Cooke et al., 
2003). It is obvious that the four cell lines investigated showed different sensitivities to 
these drugs with, in some cases, a big difference between similar types of cells. 
However, of all the cells tested, HK2 cells appeared to be the most sensitive cell line for 
the toxicity by the drugs used. In addition, these cell lines also undergo different forms 
of cell death (with different mechanisms) when treated with the same drug (see table 
3.8.4 as a summary table), which underlines the complexity of the cell death. DOX was 
shown to be the most toxic drug compared to others used in this study. However, DOX 
showed no effect on the necrosis pathway in all four cell lines studied as compared to 
Cisplatin and Etoposide which did causes some necrosis. Finally, Caspase-3 substrate 
activity was found to be a much better method of detecting apoptosis in contrast with 
caspase inhibitors and cell viabilities, which has a limited sensitivity. 
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Table 3.8.4; summary of the different cell death pathways using variouse assay and 
different chemotherapeutic drugs used in this chapter. 
 
-            = Little or no effect 
+            = A small but significant effect 
+ +        = A substantially significant effect 
+ + +    = A strong effect 
ND        = Not determined 
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CHAPTER 4 
RGN over-expression in COS-7 and 
HepG2 cells and drugs treatment 
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4 RGN over-expression in COS-7 and HepG2 cells and drugs 
treatment  
4.1 Introduction 
During acute cell inflammation the inflammatory cytokine, tumour necrosis factor alpha 
(TNF-) is produced by macrophages and involved in various cellular signals, such as 
apoptosis or necrosis (Idriss and Naismith 2000). TNF- mediates apoptosis in rat 
hepatocytes by activating D-galactosamine, increasing the intra-nuclear free [Ca
2+
] and 
causing DNA fragmentation (Abou-Elelle et al., 2002). Overexpression of RGN shows 
a protective effect on H4-II-E liver cells which were been treated with a high 
concentrations of TNF- (10 ng/ml), and this suggested that RGN has exhibitory effects 
on cell death (Izumi and Yamaguchi, 2004). Since effect of TNF- mediated cell death 
could be inhibited by caspase inhibitors. It was suggested that RGN might also have an 
inhibitory effect on the activation of caspases in cells (Yamaguchi, 2012). This effect 
was further investigated when cells treated with thapsigargin (SERCA Ca
2+
 pump 
inhibitor and an apoptosis inducer), caused a sustained increased in cytoplasmic [Ca
2+
] 
and caused apoptosis. Treating cells with either caspase inhibitors or overexpression of 
RGN, decreased this rise of intracellular Ca
2+
 (Yamaguchi 2005; Pereira et al., 2002) 
and also decreased the nuclear DNA fragmentation, again suggesting that RGN might 
have inhibitory effects on caspase activation during apoptosis cell death (Yamaguchi, 
2012). RGN has been suggested to play a suppressor role in cell death and apoptosis in 
H4-II-E cells induced by sulforaphone, an isothiocyanate involved in cell cycle arrest 
(Gamet-Poyrastre et al., 2000). Since Sulforphane mediates the pro-apoptotic protein 
Bax expression, increases cytochrome c release from mitochondria and proteolysis of 
polymerase Hi 29, these observations suggests that RGN protection may also have an 
effect on Bax, cytochrome c, caspase and Bcl2 proteins (Cohen and Cohen, 1989). The 
suppressor effects of RGN on apoptosis does not only apply to liver cells, but has also 
been observed in kidney cells as well (Nakagawa and Yamauchi 2005). In NRK52E 
kidney cells, hormones (parathyroid hormone, aldosterone, dexamethasone) stimulate an 
increase in expression of RGN (Nakagawa and Yamauchi 2005 a). The localization of 
RGN was also more highly expressed in nucleus following hormonal stimulation 
(Nakagawa and Yamauchi 2008). The Overexpression of RGN in NRK52E kidney cells 
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was also shown to have suppressive effects on apoptotic cell death, induced by TNF-, 
LPS and thapsigargin (Nakagawa and Yamauchi 2005 b). Furthermore, the 
overexpression of RGN increased a number of key signalling pathway molecules, such 
as Apaf-1, Bcl-2 and Akt-1 (Zou et al., 1997; Vogelstein et al., 2000; Widmann et al., 
1988). In addition, the NRK25E - RGN transfected cells showed a high increase in the 
expression of Bcl-2 mRNA and Akt-1 mRNA. However, Apaf-1 mRNA and caspase3 
mRNA did not show any significant increase (Nakagawa and Yamaguchi, 2005). 
Therefore the main effect of RGN was to increase the expression of anti-apoptotic 
factors. 
The main aim of this chapter is to investigate the effects of RGN overexpression in to 
COS-7 and HepG2 cells and to determine whether this protects the cells from cell death 
induced by the chemotherapeutic drugs used in the previous chapter. 
N.B. Due to the origins of plasmids used in this chapter; SMP30 relates to the 
expression of human regucalcin, while RGN-GFP relates to the expression of human 
regucalcin that has a GFP attached to C-terminus. 
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4.2 SMP30, Over-expression, Detection, and Cytoprotection 
As mentioned previously, some studies reported that regucalcin (RGN), known as 
senescence marker protein (SMP30) is able to protect the cells from cell death (Izumi 
and Yamaguchi, 2004 and Yamaguchi and Sakuria, 1991). As we have shown in the 
chapter 3 that some of the chemotherapy drugs causes cell death to occur by different 
pathways in different cell lines, the experiments described in this chapter were carried 
out in order to determine the protective role of RGN protecting cells against cell death. 
Furthermore, two versions of RGN plamid have been used to express SMP30 and RGN-
GFP (see figure 4.2A and B), both RGN were overexpressed in COS-7 and HepG2 cells, 
for viability studies, while just RGN-GFP plamid was used in microscopy and 
localization experiments mainly for visualization purposes.  
 
Figure 4.2A and B; the restriction map for PCDNA and SMP30-PCDNA3.1- 
plasmids. The plasmid human SMP30-PCDNA3.1- was constructed by Dr. Pei Lai 
(Lai, PhD thesis, 2009). The identity of the plasmid was confirmed by diagnostic 
restriction enzyme analysis. 
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4.2.1 Over-expression and Detection of SMP30 
Cells were seeded into 6 well plates and transfected with the PCDNA 3.1 SMP30 
plasmid with different plasmid and the Turbofect reagent (TR) concentrations, as 
illustrated on section 2.2.14. After 48 hrs cell lysis was performed and the cell lysate 
were separated by SDS-PAGE and transfected on to nitrocellulose and anti-Rabbit SMP-
30 antibody was used to detect it by Western blotting.  Figure 4.2.1A and B show COS-7 
and HepG2 cell lysates were overexpressed SMP30.Both Figures show that Condition 3 
(1 µg plasmid/2 µl TR) is the best condition for COS-7 and HepG2 cells. In addition, it 
was also noticed that the untransfected cells also expressed a low level of SMP30 
naturally. It had already been reported that these cells express low endogenous level of 
SMP30 (Lai et al., 2011). 
 
 
Figure 4.2.1A and B; western blots of cell lysates overexpressing SMP30 in COS-7 
(A) and HepG2 (B). Cells were treated with different concentration of  SMP30 and the 
transfection reagent. Condition 1 (2 µg plasmid/4 µl TR), condition 2 (1 µg plasmid/4 µl 
TR), condition 3 (1µg plasmid / 2 µl TR), rat liver cytosolic fraction as a positive control 
and COS-7 and HepG2 cells alone as a ‘negative’ control. Total protein amounts loaded 
of each sample were 15 µg (COS-7) and 30 µg (HepG2) cells for each cells lysate 
condition in 6 well plates in 2 ml media. The 33 KDa SMP30 proteins were detected in 
all the lanes.    
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4.2.2 The cytoprotection of SMP30 overexpression in COS-7 and HepG2 cells 
exposed to chemotherapeutic drugs 
4.2.2.1 The cytoprotection effect SMP30 overexpression in COS-7 
COS-7 cells were transfected with either PCDNA or SMP30, 1 µg SMP30/2 µl TR and 
left for 48 hrs. Later, cells were treated with different drugs; Etoposide (A), Cisplatin (B) 
and  DOX (C) at  different concentrations and left for 48 hrs, then MTT assays were 
performed to measure the cell viability of each group. In COS-7 cells treated with 
etoposide the LC50 where shifted significantly. The LC50 was estimated to be more than 
500 µM in SMP30 transfected cells compared to the empty vector PCDNA alone 
transfected cells which had a LC50 ~200 µM. SMP30 also shows a protection effect on 
cells treated with both Cisplatin and DOX, when the LC50 increased significantly with 
Cisplatin and DOX from 50 µM to > 300 µM and from 3 µM to 20 µM, respectively 
when comparing SMP30 transfected versus PCDNA alone-transfected cells (See table 
4.2.2.1). Therefore, we could see the effect of SMP30 in protecting cells from death by a 
significant level. 
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Figure 4.2.2.1; the effects of Etoposide (A), Cisplatin (B) and DOX (C) on cell 
viability of COS-7 cells. COS-7 transfected with empty vector (PCDNA) and SMP30. 
Cells were grown in 48 well plates in 1 ml media and then cells were transfected after 
40-50% cell confluency, 1 µg of the plasmid and 2 µl of TR then left for 48 hrs. Cells 
were treated with Etoposide, Cisplatin and DOX, then MTT assay sperformed after 
48 hrs. PCDNA alone transfected cells (◘), SMP30 transfected cells (■). The data points 
represent the mean ± SD of 3-5 determinations. (* p ≤ 0.05, ** p < 0.01, compared to 
their corresponding values in empty plasmid group).  
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Table 4.2.2.1; summarizes the LC50 in µM values of COS-7 cells with the different 
drugs. When comparing SMP30-transfected and PCDNA-transfected cells and treated 
with Etoposide, Cisplatin and DOX.  
 
 
4.2.2.2 The cytoprotection effect of SMP30 overexpression in HepG2 
To observe the effect of SMP30 overexpression on HepG2 cells, these cells (Figure 
4.2.2.2) were transfected with 1 µg PCDNA or 1µg SMP30 plasmid + 2 µl TR in 1 ml 
and left for 48 hrs. Cells were then treated with DOX at different concentrations and left 
for 48 hrs, then MTT assays were performed to measure the cell viability. HepG2 cells 
shows less cell death with a LC50 40 µM when transfected with SMP30, comparing with 
PCDNA transfected cells (LC50 of 10 µM).  
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Figure 4.2.2.2; the effect of DOX on cell viability of HepG2 cells in the presence of 
empty vector-PCDNA and SMP30. HepG2 cells were grown in 48 well plates in 1 ml 
media and then cells were transfected after getting  to 40-50% cell confluency, 1 µg of 
plasmid and 2 µl of TR were used to transfect cells with empty vector-PCDNA and  
SMP30 then cells were left for 48 hrs. Cells were treated with DOX (0.01, 0.1, 1, 10 and 
100 µM) then MTT assays performed after 48 hrs. Empty vector- PCDNA transfected 
cells (◊), SMP30 transfected (♦). The data points represent the mean ± SD of 3-5 
determinations. (* p ≤ 0.05, ** p < 0.01, compared to their corresponding concentration 
values in the empty PCDNA plasmid group). 
 
4.2.3 The effect of SMP30 on COS-7 cell viability and proliferation 
4.2.3.1 The effect of SMP30 overexpression on COS-7 cells viability 
COS-7 cells were plated on 24 well plates and incubated for 24 hrs, then cells were 
transfected with empty PCDNA or SMP30 (1 µg plasmid/2 µl TR), cells were left for 48 
hrs before MTT assays were undertaken. As shown in figure 4.2.3.1, SMP30 expression 
cells decrease viability by 30 % compared to PCDNA which is significant (p < 0.01). 
This suggested the possibility of overexpressing SMP30 had a suppressor role in cell 
129 
 
proliferation. However it could also have effect on mitochondrial reductase which is 
what the MTT assay actually measures.  
 
 
Figure 4.2.3.1; the effect of SMP30 plasmid on COS-7 cell viability. COS-7 seeded 
on 24 well plate, after 24 hrs cells were transfected with empty PCDNA or SMP30 
(1 µg plasmid/2 µl TR). After 48 hrs of transfection, MTT assay was performed. The 
data points represent the mean ± SD of 3-5 determinations. (** p < 0.01, compare to the 
empty PCDNA group).  
 
4.2.3.2 The effect of SMP30 overexpression on COS-7 cell proliferation 
As previous studies showed SMP30/RGN decreased cell proliferation. A series of 
experiments to test this were undertaken. Cells were plated in 48 well plates for 24 hrs 
at 37 ˚C, day after cells were transfected with SMP30 or empty PCDNA and left for 
48 hrs. Crystal violet assays were performed to measure the number of cells in each 
group (a more direct measure of cell proliferation). Figure 4.2.3.2 shows the decrease in 
cell number with significance at p < 0.05 in the SMP30 group as compared to PCDNA 
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group. Therefore it is most likely that SMP30 decreased by 20% the proliferation of 
COS-7 cells. 
 
 
Figure 4.2.3.2; the effect of SMP30 overexpression on COS-7 cell proliferation. 
COS-7 cells were seeded on 48 well plates, after 24 hrs the cells were transfected with 
empty PCDNA or SMP30 (1 µg plasmid / 2 µl TR). After 48 hrs of transfection, crystal 
violet assays were performed. The data points represent the mean ± SD of 3-5 
determinations. (*p < 0.05, compared to the PCDNA group). 
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4.3 RGN-GFP, Overexpression, Detection, Cytoprotection and 
Microscopy studies 
4.3.1 Optimization of the transfection efficiency in COS-7 cells 
COS-7 cells were seeded on 6-well tissue culture plates (to 50-60 % confluency). Three 
different concentration of turbofect transfection reagent (TR) and RGN-GFP plasmid 
(see figure 4.3.1A) were used to optimize the transfection efficiency. As shown in 
figure 4.3.1B and C after the cells were incubated for 48 hrs and at 72 hrs, the 
transfection efficiency was calculated according to the average percentage of the 
number of green fluorescent cells compared to total number of cells and three replicates 
for each condition was undertaken. Figure 4.3.1C illustrates the optimal condition for 
RGN-GFP transfection in COS-7 cells with condition 3 (1 µg DNA: 2 µl TR) for 72 hrs 
being the best.  
 
 
Figure 4.3.1A: shows the Origene vector with RGN-C-tagged Human Variant 1. 
Plus human RGN (RGN-GFP). The RGN gene was inserted within the multiple cloning 
site between the restriction site Sgf1 and Mlu 1.  
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Figure 4.3.1B; COS-7 cells transfected using three conditions of plasmid and 
turbofect transfection reagent. Condition (1) refers to (2 µg DNA:4 µl TR), condition 
(2) refers to (1 µg DNA:4 µl TR) and condition (3) refers to (1 µg DNA:2 µl TR) ratio. 
The transfection efficiency was calculated after 48 and 72 hrs of transfection using 
fluorescence microscope. 
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Figure 4.3.1C; illustrates the optimal condition of RGN-GFP transfection with 
(1:2) (1 µg Plasmid RGN-GFP: 2 µl transfection reagent) in COS-7 cells. COS-7 
cells were cultured in 6-well plates and transfected 24 hrs later. Transfected cells were 
viewed with a fluorescence microscope at 200x magnification. Picture was taken using 
an Astrovid StellaCam-EX camera connected to the microscope at 48 and 72 hrs after 
transfection.
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4.3.2 Detecting RGN at protein level in kidney and liver cell line 
Figure 4.3.2 shows the presence of RGN protein in kidney (COS-7, HK2) and liver 
(HepG2) cell lines, using a primary rabbit anti-RGN antibody and anti-Rabbit 800 IR 
Dye secondary antibody. Cells (COS-7, HK2 and HepG2) were grown in 10 cm 
diameter Petri dish then lysed in 500 µl of Lysis buffer. All three cell lines had ahown 
low levels of endogenous RGN protein. 
 
 
Figure 4.3.2; western blot to detect RGN detection in cell lysates of kidney and 
liver cell lines. A primary anti-RGN antibody was used. Lane 1, 2, 3 refers to HepG2, 
COS-7 and HK2 cells, respectively. All cell samples loaded at 200 µg with 10 µl of 
250 KDa marker.  
 
4.3.3 Effect of overexpression of RGN-GFP on COS-7 cell viability following 
treatment with Doxorubicin 
To determine whether overexpression of RGN-GFP in COS-7 cells can protect against 
DOX-induced cell death, MTT assays were undertaken on the cells after transfection. 
As transfection efficiency reached 60%, cells were treated with DOX over a range of 
concentrations, as carried out previously. PCDNA was empty vector and used for the 
control group. Figure 4.3.3 shows the cell viability of COS-7 cells which were 
PCDNA-transfected compared to cells transfected with the RGN-GFP plasmid. The 
LC50 of PCDNA-transfected cells was 7±3 µM, while the LC50 for the RGN-GFP 
transfected cells was 20±2 µM. Therefore, RGN-GFP shows a protective role, which 
was statistically significant at 10 and 100 µM (p < 0.05).This protection is similar to 
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that seen with SMP30 overexpression suggesting that the GFP part of the protein has 
only a little effect on the function of RGN. 
 
Figure 4.3.3; effect of DOX on COS-7 cell viability in the present or absence of 
RGN-GFP expression. Cells were transfected with RGN-GFP or PCDNA alone and 
then treated with the drug. MTT assays were carried out to determine the cell viability 
in both PCDNA-transfected (ᴏ) and RGN-GFP transfected cells (). The data pointed 
represent mean ± SD of 3-4 determines. (* p < 0.05, compared to PCDNA transfected 
cells). 
 
4.3.4 The effect of RGN-GFP on COS-7 cell proliferation 
In order to determine whether RGN-GFP also caused a reduction in cell proliferation, 
COS-7 cells were transfected with (PCDNA or RGN-GFP) to determine the effects of 
this protein on cell number using the crystal violet assay. Cells were seeded in 48 well 
plates, then after 24 hrs the cells were transfected with both plasmids (PCDNA and 
RGN-GFP), and then left for 48 hrs to express the protein, after which the crystal violet 
assays were performed. The results in figure 4.3.4 shows a significant difference in cell 
number at p ≤ 0.001 in RGN-GFP transfected cells as compared with transfected with 
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empty PCDNA transfected cells, which suggests that RGN-GFP appears to maintain it 
is suppressor effect on cell proliferation. 
 
 
Figure 4.3.4; the effect of RGN-GFP and PCDNA on COS-7 cell number, Cells 
were transfected for 48 hrs with both plasmids. Crystal violet assays were used to 
measure cell numbers, where absorbance directly related to cell numbers. The data 
points represent the mean ± SD of 3-5 determinations. (*** p < 0.001, compare to 
empty PCDNA group). 
 
4.3.5 Microscopy studies of RGN-GFP treated with Doxorubicin 
4.3.5.1 Time-lapse experiments with COS-7 and DOX 
After exploring the protective function of RGN-GFP in COS-7 cells, it was interesting 
visualize this protein under the fluorescence microscope, in order to determine its 
subcellular localization and whether this changes during cell stress caused by DOX. 
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Therefore, time-lapse experiments were undertaken. COS-7 cells transfected with RGN- 
GFP for 24 hrs, then cells were visualized under the fluorescence microscope.    7 µM of 
DOX was added to the media and then the cells recorded for 30 min (a total 60 images). 
As shown in figure 4.3.5.1 is initially a widely distributed fluorescence location is 
observed, which then appears to focus around the cell body at the centre of the cells, 
following adding DOX. Therefore, this could suggest that RGN-GFP moves toward the 
nucleus under cell stress induced by DOX.   
 
 
Figure 4.3.5.1; time-lapse of RGN-GFP transfected COS-7 cells treated with 7 µM 
DOX. The figure shows the time points (in minutes) using 20X lenses power. A single 
cell is presented for clarify, but this was typical of some other cells observed.   
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4.3.5.2 Co-localization of RGN-GFP with COS-7 cells 
4.3.5.2.1 Co-localization of RGN-GFP in COS-7 cells with mitochondria and 
nuclei and the effects of Doxorubicin 
The co-localization of RGN-GFP with mitochondria and nuclei was undertaken further 
understand the role of RGN. Confocal microscopy was used with the Hoechst dye for 
nucleic staining and Mitotracker-red for mitochondria staining. In addition, DOX was 
also added to determine wether RGN-GFP changed location within the cells. 
Cells were seeded in coverslips of in 6 well plate overnight, cells were then   transfected 
with RGN-GFP for 48 hrs, cells then stained with 0.5µM Mitotracker for 30- 40 min. 
PBS was used to wash the cells and the cells were fixed with 4% paraformaldehyde for 
15 min, then 1 µg/ml of the Hoechst stain was added to the cells for 30 min to stain the 
nucleus. The cells were examined under the confocal microscope, for treated cells, cells 
were initially treated with 5 µM DOX for two hrs before staining. 
Image statistical analysis were performed using ImageJ with the statistical plugin 
JACOp, this tool is used for localization analysis of two images and which calculates 
Pearson’s coefficient, most common correlation coefficient-based tool used to assess the 
co-localization (Bolt and Cordelieres, 2006). In the analysis, Pearson’s correlation 
coefficient was used to evaluate the correlation between the RGN-GFP (green channel) 
and mitochondria (red channel) or nuclei (blue channel). Based on the correlation 
coefficient estimation, values in the ~0.5-1 range indicate a significant overlaps and co-
localization between two channels.  
Figure 4.3.5.2.1A shows fluorescence images of control (non-treated) cells, transfected 
with RGN–GFP and then stained with Mitotracker and Hoechst, visualized with green, 
red and blue filters, respectively. The average Pearson’s correlation coefficients was 
0.192 (SD±0.073) for the RGN-GFP co-localisation with the mitochondria (see figure 
4.3.5.2.1B) and 0.564 (SD 0.036) for the RGN-GFP with the nuclei (see figure 
4.3.5.2.1C) .This analysis suggests, under control conditions RGN-GFP co-localises to 
some extent with the mitochondria (and probably the cytosol), but shows little co-
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localisation with the mitochondria. Analysis of several other images showed similar 
results. 
 
 
Figure 4.3.5.2.1A; fluorescence images with confocal microscopy of untreated 
COS-7 cells. (a) blue channels (for Hoechst i.e. nuclei), (b) green channels (for RGN-
GFP); (c) red channels ( for  Mitotracker); (d) merged image of (a), (b) and (c). 
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Figure 4.3.5.2.1B; colocalization data analyzed with JACOps plugin for COS-7 
cells of red and green channels. Co-localisation with RGN-GFP and Mitotraker® 
Deep RedFM. Scatterplot of red and green pixel values gives a with Pearson’s 
correlation coefficient value of 0.265 (For this specific image).  
 
 
 
141 
 
 
Figure 4.3.5.2.1C; colocalization data with JACOps plugin for COS-7 cells of blue 
and green channels. Co-localisation RGN-GFP and nuclei. Scatterplot of blue and 
green pixel values gives a Pearson’s correlation coefficient value of 0.596 (For this 
specific image).  
 
Figure 4.3.5.2.1D shows DOX treated COS-7 cells during late apoptosis (as the cells 
shows nuclear condensation, cell shrinkage and membrane blebbing). The cells were 
transfected with RGN–GFP and pretreated with DOX (3 hrs) then stained with 
Mitotracker and Hoechst and visualized with green, red and blue filters, respectively. 
The average Pearson’s correlation coefficients was 0.8 (SD±0.0817) for the RGN-GFP 
colocalisation with the mitochondria (see figure 4.3.5.2E) and 0.412 (SD±0.048) for the 
RGN-GFP with the nuclei (see figure 4.3.5.2.1F). This analysis indicates that RGN-GFP 
were strongly co-localised with the mitochondria, and with possibly some colocalisation 
with nuclei.  
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Figure 4.3.5.2.1D; fluorescence images of late apoptotic COS-7 treated with DOX. 
(a) blue channels (with Hoechst  i.e. nuclei); (b) green channels (for RGN-GFP); (c) red 
channels (with Mitotracker), (d) merged image of (a), (b) and (c ).Cells were first 
transfected with RGN-GFP then treated with 7 µM DOX, and then followed by staining 
with Mitotracker and Hoechst before fixing the cells. 
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Figure 4.3.5.2.1E; colocalization data analysed with JACOPs plugin. Scatterplot of 
red and green pixel values of doxorubicin treated cells, Pearson’s correlation coefficient 
value of 0.921 (For this specific image).    
 
Figure 4.3.5.2.1F; colocalization data analysed with JACOPs plugin, scatterplot of 
blue and green pixel values of doxorubicin treated cells, Pearson’s correlation 
coefficient value was 0.463  (For this specific image).  
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4.3.5.2.2 Co-localization of RGN-GFP with COS-7 cells and Etoposide 
Once, the co-localization and the overlap of RGN has been demonstrated with DOX, 
similar experiments were done with etoposide to investigate whether a different drug 
causes a similar effect. 150 µM as Etoposide was used to treat the cells. COS-7 cells 
were plated on 6 well plates with coverslips and attachment allowed over 24 hrs. Cells 
were transfected with RGN-GFP for 24 hrs. Next day, cells were treated with etoposide 
(150 µM.) for 3 hrs then stained with Mitotracker and Hoechst stain. Images below in 
figure 4.3.5.2.2A shows apoptotic COS-7 cell with Hoechst nuclear staining (A), RGN-
GFP stainig (B), Mitro-traker staining (C) and the three merged images (D) of COS-7 
cells treated with etoposide for 2hr. 
The average Pearson’s correlation coefficeints (PCC) was 0.795 (SD±0.145) for the 
RGN-GFP colocalisation with the mitochondria (see figure 4.3.5.2.2B) and 0.421 
(SD±0.103) for the RGN-GFP with the nuclei (see figure 4.3.5.2.2C). This analysis 
suggests that RGN-GFP strongly co-localised with the mitochondria, but not with the 
mitochondria. This suggested increased co-localization of RGN to the mitochondria 
during chemotherapy drugs treatment compared to untreated cells, which suggests that 
RGN might be involved in reducing apoptosis via the mitochondria.  
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Figure 4.3.5.2.2A; treated COS-7 cells with Etoposide (150 µM). (A) Blue channels 
(for Hoechst ie nuclei), (B) green channels (for RGN-GFP); (C) red channels (for Mito-
tracker) and (D) overlay of the three channels.   
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Figure 4.3.5.2.2B; colocalization data analysed with JACOps plugin for Etoposide 
(150 µM) treated COS-7 cells in the red and green channels. RGN-GFP and 
Mitotracker® Deep RedFM (mitochondria) scatterplot of red and green pixel values, 
with average of Pearson’s correlation coefficient value of 0.782 (For this specific 
image).  
 
Figure 4.3.5.2.2C; colocalization data with JACOps plugin for Etoposide (150 µM) 
treated COS-7 cells in the blue and green channels. RGN-GFP and Hoechst 
scatterplot of red and green pixel values with Average of Pearson’s correlation 
coefficient value of 0.435.    
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4.3.5.2.3 Co-localization of RGN-GFP within COS-7 during the early stages of 
Doxorubicin treatment 
Figure 4.3.5.2.3A shows control (non-treated) COS-7 cells. Cells were transfected with 
RGN-GFP and stained with both Hoechst and Mito-tracker before fixing. It is obvious, 
that the RGN-GFP location in control cells is distributed around the cell body and can 
be seen in nuclei, cytoplasm and mitochondria. As shown earlier, the average PCC 
values is 0.354 (SD±0.044) for the RGN-GFP co-localisation with the mitochondria and 
0.608 (SD±0.065) for the RGN-GFP co-localisation with nuclei (which is similar to data 
presented in 4.3.5.2.1B and C).   
 
 
Figure 4.3.5.2.3A; merged image of fluorescence images obtained by confocal 
microscopy. COS-7 cells transfected with RGN-GFP but untreated with drug and fixed 
and then stained with Hoechst (Blue) and Mito-tracker (Red) at 1 µg/ml and 0.5 µM, 
respectively.   
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Figure 4.3.5.2.3B RGN-GFP transfected cells which were then treated with DOX 
(7 µM) for approximately 1hrs and then stained with fluorescence dyes (Hoechst and 
Mito-tracker). These cells were considered at the early stage of cell death and no 
obvious morphological changes can see that the RGN-GFP is strongly localise to the 
nuclei and possibly accumulated around the nucleolus. The average of PCC values 
shows a limited correlation of 0.32 (SD±0.016) of RGN-GFP with mitochondria and a 
very positive correlation OF PCC value 0.653 (SD±0.06) for RGN-GFP with nuclei. 
Figure 4.3.5.2.3C and D plotted the overlap of green-red and green-blue pixels channels, 
respectively.  
 
Figure 4.3.5.2.3B; fixed Fluorescence emerge images taken by confocal microscope 
for DOX treated COS-7 cells at early stage of apoptosis. Cells expressed RGN-GFP 
and then treated with (7 µM) DOX for 1 h and then stained with 1 µg/ml Hoechst (blue) 
and 0.5 µM Mito-tracker red stain.    
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Figure 4.3.5.2.3C and D; colocalization analysis of RGN-GFP transfected COS-7 
cells treated with DOX for a short time of period. (C) scatter plot of green and red 
pixel intensities (PCC 0.301), D scatterplot of green and blue pixel intensities (PCC 
0.605), of RGN-GFP transfected COS-7 cells and treated with DOX.   
 
150 
 
4.3.6 Treating HepG2 cells with different calcium concentration 
4.3.6.1 Measuring RGN expression by western blot 
The level of liver RGN was shown to increase when rats were fed with a diet of high 
calcium (Misawa and Yamaguchi, 2002; Yamaguchi, 2009). In these experiments we 
aimed to investigate whether calcium levels in the media could affect RGN levels in 
HepG2 cells. Therefore, HepG2 cells were seeded on 6 well plate and left for 24 hrs to 
attach to the surface, then cells were treated with media containing different calcium 
concentrations (0 mM, 1.8 Mm, and 10 mM). After 48 hrs the cells were washed with 
PBS and cell lysates were prepared and the protein concentration estimated. Western 
Blot were performed, each lane loaded with the same amount of protein (30 µg), and 
labelled with the anti-RGN primary antibody. The results in figure 4.3.6.1shows that 
with no Ca
2+
 in the media the intensity of band for RGN which is considerably lower 
than cells in group (1.8 mM Ca
2+
) or (10 mM Ca
2+
) respectively. Therefore, these 
results indicate that increasing the calcium concentration in the media could increase the 
level of RGN expresses in HepG2 cells.  
 
 
Figure 4.3.6.1; western blotts of RGN expression in HepG2 cells. 30 µg cell lysate 
were resolved on a 10% SDS-PAGE gels then transferred on to nitrocellulose. The anti-
mouse RGN was used to probe the membrane. (1) indicated cells grown with no Ca
2+  
media, (2) cells grow in 1.8 mM Ca
2+
 media, while group (3) cells  grown in  10 mM 
Ca
2+
 media.    
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4.4 Discussion 
In this chapter I investigated the role of regucalcin (RGN) in protecting against cell 
death using two different versions of human RGN (SMP30, RGN-GFP). The study 
started by testing the role of RGN in decreasing the nephrotoxicity of the chemotherapy 
drugs (Etoposide, Cisplatin, and DOX) in COS-7 cells and the hepatotoxicity of DOX in 
HepG2 cells. Later, the effect of RGN on the cells viability, cell proliferation and 
localisation were studied. 
We found that COS-7 cells that overexpressed SMP30 (without the GFP tag) had the 
ability to decrease the toxicity of the chemotherapy drugs such as Etoposide, Cisplatin, 
and DOX. The LC50 of PCDNA alone transfected cells were 200, 50 and 3 µM, 
respectively, and these were shifted to > 500, > 300 and 20 µM in SMP30 
overexpressing cells treated with Etoposide, Cisplatin, and DOX, respectively.  This 
therefore suggests the protective role for RGN in cell death. Our findings is supported 
by other studies, which showed a suppressive effect of RGN on apoptosis in kidney 
cells treated with TNF-, LPS, Bay K 8644 or thapsigargin (Nakagawa and Yamaguchi, 
2005 b). Accordingly, RGN has an important role in minimizing the amount of 
apoptotic cell through various signaling factors (Yamaguchi, 2013). Since TNF- 
enhanced the mRNA expression of caspase-3 in cloned normal rat kidney proximal 
tubular epithelial cells (NRK52E), and the overexpression of RGN shows suppressor 
effect, therefore, RGN might also cause a decrease of the caspase-3 mRNA expression.  
This could support, in part, our findings that these chemotherapy drugs causes apoptosis 
via activating caspase-3 protein and RGN could reduce this. In accordance to our 
previous funding in chapter 3, it was shown that these drugs mediate various types of 
cell death (apoptosis, necrosis and autophagy), we therefore hypothesis that RGN might 
also play a role in protecting cells not just through apoptosis but also through the other 
forms of  cell death (necrosis and autophagy) as well. This has not been suggested 
before and could open up new research into how this protein controls these other types 
of cell death.  
COS-7 cells transfected with either RGN-GFP or SMP30 showed a significant decrease 
in cell number compared to PCDNA alone transfected cells (p > 0.001). Therefore, 
RGN shows it has a role to play in suppressing/slowing down cell proliferation and this 
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finding is supported by several other studies (Yamaguchi, 2012) that have suggested 
that cell proliferation may be regulated by RGN by causing cell cycle arrest at G1 and 
G1/M phase (Nakagawa et al., 2005).  
Co-localization experiments and time-lapse photography to visualize the movement of 
RGN under cell stress (figure 4.3.5.1) has shown the movement of RGN towards the 
cell body when DOX was added to COS-7 cells within a very short time of about 25 
min. Therefore, more detailed experiments were necessary, to investigate this behaviour 
further. The results in figure 4.3.5.2.1A show that RGN is normally distributed within 
the cytoplasm and nucleus, but limited within the mitochondria. COS-7 cells treated 
with DOX and in late apoptosis showed a very significant co-localisation with 
mitochondria, but only limited-colocalisation within nuclei (see figure 4.3.5.2.1D, E and 
F), and this also was the case when cells were treated with Etoposide. This suggests that 
RGN is usually distributed mostly in cytosol and nuclei in normal conditions, however 
this protein appear to move from the nuclei to the mitochondria during the latter stage of 
apoptosis possible trying to protect cells from cell death, by potentially altering 
mitochondrial mediated processes. 
Cells in the early stages of apoptosis which is still have a normal structure, appeared to 
show possibly more colocalisation within nuclei, these results could be explained by the 
fact that RGN is a transcription factor regulator and participates in gene regulation at the 
nuclear level (Yamaguchi et al., 2003, Sawada et al., 2005). This observation appears to 
be the first reported case that RGN can translocate to the mitochondria during severe 
cell stress. RGN is able to increase Ca
2+
 uptake in mitochondria, which could also 
contribute to cell death (Takahashi and Yamaguchi, 2000 and Omura and Yamaguchi, 
1999). Such a translocation of RGN from the cytoplasm to mitochondria could explain, 
the fact that as both DOX and etoposide induce oxidative stress (Kanchana Gang et al., 
2013;  Deaval, 2012 and Zhou 2001), therefore, RGN going to the mitochondria may be 
trying to control this oxidative stress (Ichikawa and Yamaguchi, 2004). 
Another interesting observation, in RGN-transfected cells that have been treated with 
DOX to a limited extent, is that although the cells show a normal cell structure, these is 
appears to be clear accumulation of RGN around the nucleolus (see figure 4.3.5.2.3B). 
This finding is also novel and could suggest the involvement of RGN in some of the 
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roles of the nucleolus, such as ribosome biogenesis, regulation of mitosis, cell cycle 
progression and proliferation (Michel-Boisvert et al., 2007, Lempiäinen and Shore, 
2009). However, further study is required to assess this in more detail.  
After demonstrating the protective role of RGN to drug-induced toxicity, a more natural 
approach to increasing the expression of RGN was considered. As previous studies had 
shown that treating rats with a high Ca
2+
 diet caused an increased the expression of 
RGN in rat liver (Shimokawa and Yamaguchi, 1992), we tested the effects of Ca
2+
 in 
the media on RGN expression in cells in culture.  
In cultured HepG2 cells, the results presented here clearly shows that Ca
2+
 in the culture 
media can affect the level of RGN expression, although the response appears to saturate 
after 2 mM Ca
2+
, which is the normal range seen in plasma. Further experiments are 
required to assess whether other factors such as hormones (i.e. Calcitonin) can elevate 
RGN levels in cells (Isogai and Yamaguci, 1995). If modulation of RGN levels  in 
patients could be achievd by simple means such as increasing serum Ca
2+
 by ingestion 
and the use of hormones, this could potentially have beneficial effects, since a recent 
study on patients with pancreatic cancer showed a better prognosis if the tumor biopsy 
showed elevated level of RGN (Yamaguchi and Murata, 2015).  
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CHAPTER 5 
SERCA and SPCA expression in 
COS-7 cells and drug treatment 
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5 SERCA and SPCA expression in COS-7 cells and drug treatment 
5.1 Introduction 
Calcium ions are second messengers, involved in various cellular function including cell 
proliferation and death (Chemaly et al., 2013). It is well documented that interfering 
with the sequestration of Ca
2+
 into intracellular can trigger apoptosis as a part of a stress 
response (Orrenius et al., 2003), and many chemotherapy drugs such as Cisplatin can 
lead to this stress response (Foufelle and Froment, 2016). Several recent studies using 
Cisplatin and Doxorubicin have shown that they are able to cause a rise in intracellular 
[Ca
2+
] levels (Shen et al., 2016; Bartlett et al., 2016; Al-Taweel et al., 2014). This rise in 
intracellular [Ca
2+
] levels has been potentially attributed to their effects on a number of 
Ca
2+
 transporters such as the voltage operated Ca
2+ 
channels (Al-Taweel et al., 2014); 
IP3 receptors (Shen et al., 2016; Splettstoesser et al., 2007); Ryanodine receptors (Hanna 
et al., 2014); SERCA2a Ca
2+
 pumps (Hanna et al., 2014) and plasma membrane Ca
2+
 
pumps, PMCA2 (Peters et al., 2016).  
A recent study in heart has shown that overexpressing SERCA2a can reduce the 
cardiotoxicity induced by Doxorubicin (Mattila et al., 2016). In the Michelangeli lab a 
similar effect was also noted, where the toxic effects of a number of environmental 
pollutants on neuroblastoma cells could be reduced if the cells were transfected to 
overexpress SERCA (Al-Mousa, PhD theis 2010). 
In this study, the focus is on determining whether elevated Ca
2+
 plays a role in 
Cisplatin- and Doxorubicin-induced cell death in COS-7 cells. In addition, this chapter 
also focusses on whether overexpressing endoplasmic reticulum Ca
2+
 pump (SERCA 1b 
and 2b) as well as the Golgi localized secretory pathway Ca
2+
 pump (SPCA1 and 
SPCA2) in COS-7 cells (a kidney-derived cell line), can reduce the toxicity caused by 
Cisplatin and Doxorubicin, which are known to be nephrotoxic (Miller et al., 2010 and 
Lahoti et al., 2012). 
In order to more easily assess the expression levels of these Ca
2+
 pumps, as well as 
determine their intracellular localization, green fluorescent protein constructs of SERCA 
and SPCA were used. The plasmids used for the expression of these fluorescence 
versions of the various Ca
2+ 
pumps have already been characterized in detail and shown 
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to produce functional Ca
2+
 pumps with respect to Ca
2+
 dependent ATPase activity and 
or Ca
2+
 uptake (Newton et al., 2003; Wootton, 2004; Lai, 2009, Al-Mousa, PhD thesis, 
2010, Baron et al., 2010).  
5.2 Effect of BAPTA-AM on DOX-induced cell death in COS-7 cells 
To determine whether cell death caused by DOX is via calcium-mediated process, 
BAPTA-AM, an intracellular calcium chelator, was used. Figure 5.2 shows COS-7 cells 
were incubated with BAPTA-AM (10 µM) for 5 hrs and then the cells were exposed to 
DOX (10µM). The Cells were then incubated for 48 hrs and then MTT assays were 
performed. This figure that pre-incubation with BAPTA has little effect upon cell 
viability. Also shown is that 10 µM DOX causes a decreases in cell viability of approx. 
60%. However, if the cells were first pre-treated with BAPTA-AM, then significantly 
more cells remained viable (p < 0.05).  
 
Figure 5.2; shows the effects of Doxicubicin with and without BAPTA-AM pre- 
treatment in COS-7 cells. The cells were pretreated with or without BAPTA-AM 
(10 µM) for about 5 hours and then exposed to DOX (10 µM) for 48 hrs at 37°C. Data 
represents the mean ± S.D of 3-4 determinations. (* value points were significant 
different from the controls, p ≤ 0.05), using the t-test.  
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5.3 The effects of BAPTA-AM on Cisplatin-induced cell death in 
COS-7 cells 
Again in order to determine whether cell death caused by Cisplatin is calcium-
dependent BAPTA-AM was used. Figure 5.3 shows COS-7 were pre-treated with 
BAPTA-AM (10µM) for 5 hr and then treated with cisplatin (65 µM) at 37 ˚C for 
48 hrs. BAPTA-treated cells had significantly higher cell viability than cells treated with 
cisplatin alone, under the same conditions (p< 0.05).  
Taken together, these results with BAPTA-AM pre-treatment would suggest that both 
Cisplatin and DOX causes COS-7 cell death, at least in part, through a Ca
2+
-dependent 
process and is therefore consistent with the previous findings that also suggested a role 
for Ca
2+
 in the toxicity by DOX and Cisplatin (Mattila et al., 2016, Shen et al., 2016 and 
Al-Taweel et al., 2014). 
 
Figure 5.3; shows the effects of Cisplatin with and without BAPTA-AM pre- 
treatment in COS-7 cells. Cells were exposed to the Cisplatin (65 µM) for 48 hrs at 
37 °C. Data represents the mean ± SD of 3-4 determinations. (* value points were 
significant different from the controls, p ≤ 0.05,), using the t-test. 
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5.4 SERCA detection, over-expression and cytoprotection 
Two different SERCA isoforms were used (SERCA 1b and SERCA2b) tagged with 
GFP. For these studies the COS-7 cell line was used because we already had a 
substantial amount of data with regards the nephrotoxicity of the chemotherapy drug 
and they were also the easiest and most consistent to culture and transfect.  
The mammalian expression plasmids for the Ca
2+
 ATPases used were as follows:   
pcDNA3.1 Rabbit SERCA1b-N-GFP (Newton et al., 2003, Wotton, PhD thesis 2005, 
Al-Mousa, PhD thesis, 2010) 
pcDNA6.2 Human SERCA2b-N-GFP (Baron et al., 2010) 
pcDNA6.2 Human SPCA1a-N-GFP (Baron et al., 2010)  
pcDNA6.2 Human SPCA2-N-GFP (Baron et al., 2010)                          
The plasmid identities were confirmed through diagnostic restriction enzyme analysis. 
 
5.4.1 SERCA detection in normal cells 
Figure 5.4.1 shows successful detection of SERCA expression in normal (un-
transfected) HepG2 and COS-7 cells. The cell lysates were prepared and the extracts run 
by SDS-PAGE transferred onto nitrocellulose membranes and then probed with the pan-
SERCA primary antibody (Y1F4 at 1/1000 dilution). These cells clearly expressed 
SERCA of the correct MW i.e. approximately 100KDa. Since natural levels of SERCA 
were already relatively high in these cells, it was decided that GFP tagged Ca
2+
 ATPases 
be used for over-expression studies so that cells expressing higher SERCA levels could 
be clearly identified post transfection. 
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Figure 5.4.1; western blot of HepG2 (1) and COS-7 (2) cell lysate for SERCA. Total 
amount of protein loaded into each cell was 100 µg. The cells were incubated with the 
pan –SERCA primary mouse antibody, Y1F4.  
 
5.4.2 Overexpression of SERCA 
COS-7 cells were transfected with SERCA1-GFP and SERCA2b-GFP expressing 
plasmids. The cells were seeded on to 6 well plates and then transfected with two 
different conditions (1 µg DNA+4 µl TR; condition 1:4) and (1 µg DNA+ 2 µl TR; 
condition 1:2). The transfected cells were examined under fluorescence microscopy 
after 24 and 48 hrs. After counting the total number of cells compared to those that were 
fluorescent, condition 1:2 was found to be the best condition and therefore used for the 
series of next experiments. Figure 5.4.2 shows COS-7 cells transfected under different 
SERCA1-GFP conditions, 24 hrs after transfection. Table 5.4.2 shows the transfection 
efficiency using both conditions, for both SERCA1-GFP and SERCA2b-GFP 
expression.   
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Figure 5.4.2; transfected of COS-7 cells with the two different condition of 
SERCA1-GFP plasmid. Ratio of 1 µg SERCA1-GFP/2 µl TR and 1 µg SERCA1GFP/ 
4 µl TR were used to transfect cells. Fluorescence micrographs and light micrographs of 
the same field-of-view were used to determine the percentage of transfected cells 
(transfection efficiency).  
Table 5.4.2; the transfection efficiency of the two different conditions of SERCA 
plasmid. Condition (1:2) and (1:4) refer to (µg DNA plasmid+ µl TR). The transfection 
efficiency was determined by counting the percentage of fluorescent cells against the 
total number of cells in the white light field. The data are from average of three different 
field-of-views in three replicate wells.  
Transfection condition 1 µg+2 µl 1 µg+4 µl 
Transfection efficiency % % 
SERCA1-GFP 45 33 
SERCA2B-GFP 35 25 
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5.4.3 High resolution visualisation of the localisation of SERCA-GFP using 
fluorescence   microscopy 
Both Ca
2+
 pump proteins (SERCA1 and SERCA2b) used in this project contained a 
GFP tag, which allowed for their localisation in the cell to be observed. COS-7 cells 
were transfected on to glass-bottomed dishes for high-magnification microscopy 
purposes. The nuclei were also stained with Hoechst 33342 stain. Figure 5.4.3 shows the 
location of SERCA1 and SERCA2b. The SERCAs showed a diffused distribution 
throughout the cytoplasm, as well as on the outside of the nuclear membrane, which is 
consistent with an ER location. 
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Figure 5.4.3; fluorescence images showing the localisation of SERCA1-GFP and 
SERCA2b-GFP in COS-7 cells. The cells were transfected with plasmid and the nuclei 
were also stained with Hoechst stain, allowing the nucleus to be visualised using the 
DAPI filter. The cells were visualised at 600x magnification. SERCA1-GFP and 
SERCA2b-GFP showed diffuse staining in the cell that resembles ER localisation. 
(These images were taken in association with Shi Ern, an MSc student).  
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5.4.4 The effects of SERCA-GFP overexpression on COS-7 cell viability 
5.4.4.1 The effect of SERCA1-GFP overexpression on COS-7 cell viability when 
treated with chemotherapy drugs 
To investigate whether SERCA1-GFP overexpression would decrease the 
nephrotoxicity of chemotherapy drugs COS-7 cells were overexpressed with SERCA1-
GFP and PCDNA (empty vector) for 48 hrs with (1µg plasmid + 2µl TR), later on the 
cells were treated with different concentrations of either Cisplatin or DOX. MTT assays 
were then performed after 24 hrs of treatment.  
Figure 5.4.4.1A shows the effects of DOX on cell viability were significantly different 
between the two groups (PCDNA and SERCA1-GFP) with a p < 0.05 at both 1 µM and 
10 µM DOX concentrations. Therefore, this suggests that SERCA1 overexpression is 
reducing the toxicity by this drug.  
 
Figure 5.4.4.1A; the effect of DOX on COS-7 cell viability in the present of 
(SERCA1-GFP and PCDNA). Cells were transfected with SERCA1-GFP and then 
treated with DOX. MTT assays were carried out to determine the cell viability in both 
groups. The data pointed represent the mean ± SD of 3-4 determines. (* p < 0.05, 
compared to PCDNA transfected cells). 
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Figure 5.4.4.1B shows the effects of Cisplatin on the viability COS-7 cells as measured 
using the MTT assay. In this case there was no significant different between the two 
groups (PCDNA and SERCA1-GFP) at all concentrations tested. Therefore, this 
suggests that SERCA1 overexpression does not affect the toxicity by this drug.  
 
Figure 5.4.4.1B; the effect of Cisplatin on COS-7 cell viability in the presence of 
(SERCA1-GFP and PCDNA alone). Cells were transfected with SERCA1-GFP or 
PCDNA alone, when cells reached transfection efficiency 60% the cells were treated 
with the drug. MTT assay were then carried out to determine the cell viability in both 
groups. The data represent the mean ± SD of 3-4 determines.  
 
5.4.4.2 The effect of SERCA2b-GFP overexpression on COS-7 cell viability when 
treated with chemotherapy drugs 
Figure 5.4.4.2A shows COS-7 cells were transfected with SERCA2b-GFP and PCDNA 
alone using the (1:2) ratio condition for 48 hrs, then cells were treated with DOX at 
different concentrations (0.1, 1, 10 and 100 µM). After 24 hrs, MTT assays were 
performed to measure the cell viability. The results show that SERCA2b significantly 
increased the viability of cells treated with DOX (p<0.05).  
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Figure 5.4.4.2A; the effect of DOX on cell viability of COS-7 cells in the present of 
SERCA2b. COS-7 cells were grown in 48 well plates and then cells were transfected 
after achieving 40-50% cell confluency. 1 µg of plasmid and 2 µl of TR (turbofect) were 
used to transfect cells with either SERCA2b or PCDNA plasmid, then cells were left for 
48 hrs. Cells were then treated with DOX (0.1, 1, 10 and 100 µM), followed by MTT 
assays after 24 hrs. The data points represent the mean ± SD of 3-5 determinations, (* p 
≤ 0.05, compared to their corresponding values in empty plasmid group).   
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Figure 5.4.4.2B shows the viability COS-7 cells following transfection with SERCA2b-
GFP or PCDNA empty vector and then treated with Cisplatin. The results show that no 
protective effect was seen with this drug.  
 
Figure 5.4.4.2B; shows COS-7 cell viability in the presence of SERCA2b-GFP or 
PCDNA and treated with Cisplatin. Cells were first transfected with SERCA2b-GFP 
or PCDNA empty plasmid and then treated with the drug. MTT assays were performed 
to determine the cell viability. The data pointed represent mean ± SD of 3-4 determines. 
 
5.5 SPCA transfection, detection and cyto-pretection 
5.5.1 Overexpression of SPCA 
Kidney cells (COS-7 cells) were transfected with SPCA1a-GFP and SPCA2-GFP. Cells 
were seeded in 6 well plates and then transfected with two different conditions (1 µg 
DNA+ 4 µl TR) and (1µg DNA+ 2 µl TR). Transfected cells were visualized under the 
fluorescence microscopy at 48 hrs. After counting the cell proportions under fluorescent 
and white light, condition 1:2 ratio was found to be the best and used for the next 
experiments. Table 5.5.1 shows the transfection efficiency for both conditions.  
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Table 5.5.1; the transfection efficiency of SPCA plasmids after 24 hrs .Two different 
conditions (1:2) and (1:4) (µg DNA plasmid: µl TR) were used. The transfection 
efficiency was determined by counting the percentage of fluorescent cells compared to 
the total number of cells in bright-field. The data represent the average of three 
replicates. 
Transfection condition 1 µg+2 µl 1 µg+4 µl 
Transfection efficiency % % 
SPCA1a-GFP 43 21 
SPCA2-GFP 45 43 
 
 
5.5.2 The visualisation of the localisation of SPCA-GFP using fluorescence 
microscopy 
Expression of GFP tagged SPCAs were used in these experiments, which allowed their 
localisation in the cell to be observed. COS-7 cells were transfected in glass-bottomed 
dishes for high-magnification microscopy purpose. The nuclei were also stained with 
Hoechst 33342 stain. Figure 5.5.2 shows the location of SPCA1a and SPCA2 which 
appear to be more highly distributed around the nuclei, which is consistent with the 
location of the Golgi Apparatus. This is consistent with other studies of SPCA location 
(Wootton et al., 2004, Baron et al., 2010).  
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Figure 5.5.2; fluorescence images shows the localisation of SPCA1a-GFP and 
SPCA2-GFP in COS-7 cells. The cells were transfected with plasmids and the nuclei 
were also stained with a Hoechst stain, allowing the nucleus to be visualised using the 
DAPI filter. SPCAs appeared to be concentrated around the nucleus consistent with a 
Golgi Apparatus location.  
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5.5.3 The effect of overexpression of SPCA-GFP on COS-7 cells treated with 
chemotherapy drugs Doxorubicin and Cisplatin 
5.5.3.1 The effect of overexpression of SPCA1a –GFP on COS-7 cells treated with 
Doxorubicin and Cisplatin 
Figure 5.5.3.1A shows SPCA1a-GFP transfected COS-7 cells treated with different 
DOX concentrations for 24 hrs. The results show no significant change in cell viability 
in the presence of SPCA1a-GFP even with low concentrations compared to cells 
transfected with PCDNA alone. Figure 5.5.3.1B shows overexpressed cells with 
SPCA2b and transfected with cisplatin for 24 hrs, the results shows also no effect of this 
plasmid on protecting cells. 
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Figure 5.5.3.1A and B; the effects of DOX and Cisplatin on cell viability of COS-7 
cells overexpressing SPCA1a-GFP or PCDNA alone. COS-7 cells were grown in 48 
well plates in 1 ml media and then the cells were transfected, (1 µg of plasmid and 2 µl 
of TR in 0.5 ml). The transfect cells (either PCDNA or SPCA1a-GFP) were left for 
48 hrs to allow for expression. Cells were then treated with DOX or Cisplatin and then 
MTT assays performed after 24 hrs to determine cell viability. The data points represent 
the mean ± SD of 3-5 determinations.  
 
5.5.3.2 The effect of SPCA2-GFP overexpression on COS-7 cells treated with 
Doxorubicin and Cisplatin 
Figure 5.5.3.2A and figure 5.5.3.2B show COS-7 cells were transfected with SPCA2b 
and PCDNA for 48 hrs and treated with DOX and Cisplatin, respectively. Cells were 
treated with the drugs for 24 hrs and then MTT assay was carried out. Both figures were 
showed no changes in cell viability after drug treatment.  
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Figure 5.5.3.2A and B; the effects of Doxorubicin and Cisplatin on COS-7 cell 
viability, in cells overexpressing SPCA2-GFP. COS-7 cells were transfected with 
SPCA2b-GFPor PCDNA alone for 48 hrs, then the cells were treated with different 
concentrations of DOX or Cisplatin for 24 hrs and then MTT assays were carried out. 
The data points represent the mean ± SD of 3-5 determinations.  
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5.6 The effect of Ca2+ concentrations in the culture media on SERCA 
expression 
An investigation on whether changing calcium concentrations in the media surrounding 
COS-7 cells could have an effect on the SERCA expression was undertaken. COS-7 
cells were seeded in 6 well plates and left for 24 hrs to attach, then cells were incubated 
with DMEM media  containing different calcium concentrations; 0 mM , 1.8 mM and 
10 mM. After 48 hrs the cells were washed with PBS and cell lysates were prepared and 
the protein concentrations estimated. SDS-PAGE was performed with the lanes loaded 
with the same amounts of cell lysate proteins (100 µg) from the cells grown in different 
conditions. Following transfer onto membranes, Western Blotting was undertaken using 
the anti-SERCA antibody Y1F4 to detect SERCA levels. The results in figure 5.6 shows 
that with no Ca
2+
 present in the media, SERCA was present in the cell lysate (lane 1, 
which is noted as 100%), although at lower levels than in cell lysates prepared in the 
presence of Ca
2+
 in the media.  
Analysis of the bands using imageJ to determine band intensity showed that when the 
cells were grown in normal media containing 1.8 mM Ca
2+
, the relative intensity had 
increased to 145% of that in the absence of added Ca
2+
 (lane 2). Upon increasing the 
Ca
2+
 level in the media to 10 mM, the relative increase in SERCA was shown to 
increase further to 161% of that observed in the absence of added Ca
2+
. This result 
suggests that increasing Ca
2+
 concentrations within the media is causing an increase in 
SERCA expression within the cells.  
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Figure 5.6; detection of SERCA in COS-7 cells incubated in media with different 
calcium concentrations. Cells were incubated for 48 hrs with (0 mM, 1.8 mM, and 
10 mM) calcium in the media. Lane 1 = No Ca
2+
 in media, Lane 2 = 1.8mM in media 
and Lane 3 = 10 mM in media). Western blots were used with anti-SERCA YIF4 mouse 
primary antibody and anti-mouse 800 secondary antibody. ImageJ was used for analysis 
of band intensity.  
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5.7 Discussion  
Doxorubicin (DOX) is widely used in treating various cancer such as Hodgkin and non-
Hodgkin lymphomas, Kaposi’s sarcoma, soft tissue sarcomas and osteosarcomas 
(Minotti et al., 2004; Al-Saedi et al., 2015). Cisplatin is another commonly used cancer 
drug that is used to treat lymphomas, head and neck carcinomas and bladder cancers 
(Dasari and Tchnounwou, 2014). However, the nephrotoxicity of these drugs is well 
documented as they are known to accumulate in kidney as well as liver, small intestines 
and heart. DOX is also well known to cause severe cardio-toxicity as a serious side-
effect (Deman et al., 2001, Boonsanti et al., 2006, Mattila et al., 2016).  
In this study it has been shown that the toxicity caused by both DOX and Cisplatin, is at 
least in part, by a Ca
2+
-dependent process in kidney-derived COS-7 cells. These findings 
are consistent with other recent studies on these drugs using a variety of cell types (Shen 
et al., 2016, Bartlett et al., 2016, Al-Taweel et al, 2014). Since other studies have 
reported that both these drugs can affect a range of Ca
2+
 transporters within cells, here 
an investigation of the effects of these drugs on cell viability was undertaken in COS-7 
cells overexpressing the intracellular Ca
2+
 pumps SERCA and SPCA. 
In this study it was shown that SERCA1b and SERCA2b overexpression in COS-7 cells 
were able to reduce the cytotoxicity of DOX. One of the major reported side-effects of 
DOX is that it causes abnormalities within the sarcoplasmic reticulum (SR) (Fischer et 
al., 1991) and induces abnormal increases in cytosolic concentration of Ca
2+
 in cells 
(Kim et al., 2006; Olson, et al., 2005; Mattila et al., 2016). Since SERCA transfers 
calcium from the cytosol to the lumen of the ER in the cell, this can prevent any 
excessive rise in cytosolic Ca
2+
 which could lead to overload of calcium in the 
mitochondria leading to mitochondrial-mediated death via the intrinsic pathway of 
apoptosis (Pinton et al., 2008). Ca
2+
 transporters that have been shown to be specifically 
affected by DOX include both Ryanodine receptors (RyRs), which is activated, (Zorzato 
et al., 1985, Hanna et al., 2014) and SERCA, which is inhibited (Hanna et al., 2014, 
Vile and Winterbourn, 1990, Zhang et al., 2014 and Ondrias et al., 1990). However, 
since studies on COS-7 cells have shown that they do not express RyRs (Treves et al., 
2002, Al-Mousa and Michelangeli, 2009), the most likely effect of DOX could be 
inhibition of SERCA. Therefore overexpressing SERCA would likely afford some 
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protection against Ca
2+
-dependent cell death, by increasing the capacity to remove Ca
2+
 
from the cytosol into the ER. However, this cannot be the full explanation since 
overexpression of SPCA does not protect against DOX-induced cell death. It is known 
that the Ca
2+ 
uptake activity of SPCA is not as high as SERCA (Wuytack et al., 2002 
and Wootton et al., 2004), which could explain this observation or it could also be that 
the ER-associated Unfolded Protein Response (UPR) cell stress pathway (which is 
activated upon Ca
2+
 depletion of the ER, Bravo et al., 2013), also plays a role, since 
SPCA would only refill the Golgi with Ca
2+
 and not the ER. Therefore further 
experiments to distinguish these possibilities would be required. 
As shown here and in other studies (Chen et al., 2016), Cisplatin-induced cell death is 
partially through a Ca
2+
-dependent process, however, the results presented here has also 
shown no protection when SERCA1a and SERCA2b are overexpressed. This was also 
the case when overexpressing SPCA as well. This would appear to be at odds with the 
previous explanation, except that Cisplatin appears to cause a rise in intracellular Ca
2+
 
levels by directly activating the IP3 receptors (IP3Rs) (Shen et al., 2016; Splettstoesser 
et al., 2007). It is known that COS-7 cells have an abundance of the type III isoform of 
the IP3R (Hattori et al., 2004). The capacity of IP3Rs to release Ca
2+
 into the cytosol 
from the ER is considerably high (i.e. approximately 1.5 million Ca
2+
/sec/channel) 
(Taylor and Traynor, 1995), compared to SERCA which can only transport about 20 
Ca
2+
/sec/pump (Taylor and Traynor, 1995) in the opposite direction. Therefore even 
increasing the level of SERCA massively, would have little effect in reducing cytosolic 
Ca
2+
 levels, of the cell, or refilling of the ER lumen, especially if the IP3R channels 
remained open (Figure 5.7). Therefore the addition of IP3R channel blockers such as 2-
APB (Bilmen et al., 2002), should protect against Cisplatin-induced, Ca
2+
-mediated cell 
death, which is what has been observed in HeLa cells (Splettstoesser et al., 2007). 
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Figure 5.7; the effect of Cisplatin on ER. Cisplatin causes IP3R channels to open and 
decreases Ca
2+
 concentration inside the ER and this can causes elevation of cytosolic 
Ca
2+
.  
In this chapter we have also shown that increasing Ca
2+
 concentration in the media 
appears to increase SERCA expression in COS-7 cells. The levels of expression were 
determined to be about 60% higher than the SERCA levels in Ca
2+
 free media. Some 
studies have linked the expression and regulation of SERCA to many different factors 
such as; excessive muscle contraction, hormonal regulation (via thyroid hormone) and 
age (Periasamy et al., 2008), but not on external calcium concentration, which we have 
shown. We and others have shown that increased extracellular Ca
2+
 levels can increase 
the expression of regucalcin (Shimokawa and Yamaguchi, 1992) and elevated 
cellular regucalcin levels has recently been shown to also increase the expression of 
SERCA (Lai et al., 2011). Therefore more experiments to test this idea are required. It 
would also be interesting to see whether increased plasma Ca
2+
 concentrations could 
also induce higher levels of SERCA expression in whole organs within an organism, 
which could then provide protection against the effects of some cytotoxic drugs. 
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6 General discussion and future works  
6.1 General discussion  
Despite cancer chemotherapy treatments having undergone many considerable advances 
in recent years which have led to significant improvements in the patient’s survival, 
however, hepatotoxicity and nephrotoxicity remains an important complication of some 
of these drugs.  
Four of the most commonly used chemotherapeutic drugs were chosen in this study, 
Methotrexate, Etoposide, Cisplatin and Doxorubicin. MTX drug was shown to have 
limited toxicity and mostly affected cell proliferation rather than cell death, because this 
drug inhibits the enzyme tetrahydrofolate reductase which is important for DNA 
synthesis (Weinsterin, 1990). However, other drugs showed a significant toxicity in 
both liver and kidney cell lines and they were able to cause cell death involving several 
pathways (ie apoptosis, necrosis and autophagy) (see table 6.1A). DOX drug was the 
most toxic drug compared to the others tested, showing potent toxicity at very low 
concentrations (see table 3.2). Cisplatin also showed toxicity in all cell lines used but at 
higher concentrations, and Etoposide was the least toxic of the drugs used in this study. 
Interestingly, in this study we found that Etoposide has a weak effect on cells with 
regards to apoptosis, necrosis and autophagy, compared to Cisplatin, which has showed 
a very strong effect on apoptosis, necrosis and autophagy for most cells tested. While 
DOX, has a reasonably strong effect on apoptosis (especially kidney cells), no effect on 
necrosis and some effect in autophagy as shown in the table 6.1A. 
To summarize, chemotherapy drugs causes cell death in both liver and kidney cells by 
different pathways. Therefore clinicians must be aware with the hepatotoxicity and 
nephrotoxicity that these drugs may induce and we recommend a relationship between 
the oncologists and both nephrologist and hepatologist when it comes in treating any 
cancers with these drugs. 
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Cell lines 
Table 6.1A; summary of the different cell death pathways and different 
chemotherapeutic drugs used in this study.  
Cell death Apoptosis Necrosis Autophagy 
Drugs 
Etop Cisp DOX Etop Cisp DOX Etop Cisp DOX 
COS-7 + + + + + + + + + + + + _ + + + + + + 
HK2 + + + + + + + _ + + _ ND ND ND 
HepG2 + + + + + + + + + + _ + + + + + + + 
Huh7.5 + + + + + + + _ + + + _ ND ND ND 
 
 -            = Little or no effect 
+            = A small but significant effect 
+ +        = A substantially significant effect 
+ + +    = A strong effect 
ND        = Not determined 
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The cyto-protective role of RGN has been known for a while. More recently a study 
reported the role of RGN in protecting against cardiotoxicity caused by DOX (Miyata et 
al., 2013). Based on the results of this study, I have also shown the protective role of 
RGN against several other chemotherapeutic drugs (Etoposide, Cisplatin and DOX) to a 
significant level (see table 6.1B), in both liver and kidney cell lines. The mechanism by 
which RGN protects cells from death is unknown. It is known that RGN is a 
transcription factor regulator and can be located within the nuclei and cytoplasm in 
normal cells. However, in my studies, when cells undergo stress through the treatment 
with chemotherapeutic drugs, RGN most likely moves to the mitochondria to possibly 
protect cells from mitochondrial mediated death. My data has also shown some 
accumulation of RGN around the edge of the nucleolus, which is a novel finding and 
suggests that this protein could also be involved in ribosome formation and therefore 
translation. I have also shown that increasing Ca
2+
 concentration in the media 
surrounded HepG2 cells increases the expression of RGN, which supports previously 
studies, which have shown that in rats treated with the calcitonin hormone and Ca
2+
 rich 
diet enhanced the expression of RGN by up to 300% (Isogai and Yamaguci, 1995). 
Furthermore, looking at my data in detail, since cisplatin causes cell death by apoptosis, 
necrosis and autophagy, I therefore also suggest that RGN could not only protect cells 
from apoptosis but possibly necrosis and autophagy cell death as well (Figure 6.1C). 
Therefore, RGN could be a new therapeutic target protein to reduce the hepatotoxicity 
and nephrotoxicity when patients are treated with these chemotherapeutic drugs, 
although further animal studies are required, to see if increased RGN in living 
organisms also has a protective role. 
The nephrotoxicity of chemotherapy drugs is well documented and many studies have 
demonstrated that DOX can accumulate in kidney, liver and heart (Deman et al., 2001, 
Boonsanti et al., 2006). In this study I have shown that the nephrotoxicity of DOX and 
Cisplatin are calcium dependent, consistent with other studies. Both increases in 
expression of SERCA1 and SERCA2b have the ability to reduce the cytotoxicity of 
DOX but not cisplatin (see table 6.1B). DOX has be shown in several studies to cause 
SERCA inhibition (Hanna et al., 2014, Vile & Winterbourn, 1990, Zhang et al., 2014 
and Ondrias et al., 1990), and therefore overexpression of this protein would help 
minimize this effect and aid removal Ca
2+
 from the cytosol to the ER. However, SPCAs 
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showed no protection against DOX toxicity, possibly because SPCA activity is much 
less that SERCA activity (Wootton et al., 2004 and Wuytack et al., 2002), or possibly 
that low ER [ Ca
2+
] could cause the ER stress response (Mekahli et al., 2011). 
Cisplatin toxicity was shown not to be protected by either SERCAs or SPCAs 
overexpression. This could be explained by the fact that this drug can cause a rise 
intracellular Ca
2+
 level through opening the IP3R (Shen et al., 2016; Splettstoesser et al., 
2007), therefore even  by increasing SERCAs level substantially would have little effect 
upon Ca
2+
 leakage from the ER.  
Another observation that can be made from the results presented here is that SERCA 
overexpression could have a protective role in apoptosis cell death but not necrosis, 
since DOX induce cell death by apoptosis, but not necrosis (Figure 6.1C). 
 
Table 6.1B; summarized the different Ca
2+
 binding proteins and their protection, 
against chemotherapy drugs in COS-7 cells. 
Proteins 
Drugs SMP30 RGN-GFP SERCA1 SERCA2b SPCA1a SPCA2b 
DOX + + + + _ _ 
Cisplatin + ND _ _ _ _ 
Etoposide + ND + ND ND ND 
 
    _     = No effect 
     +     = Positive protective effect 
   ND  = Not determined 
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Figure 6.1C; schematic showing summary of this study.Increasing the expression of 
RGN in COS-7 cells, protect cells from apoptosis and necrosis cell death, induced by 
either DOX or Cisplatin.While SERCA overexpression in the same cells can inhibit 
apoptosis, but not necrosis, when cells exposed to such drugs. 
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6.2 Future Works   
Since this study has shown different cell death mechanisms, between a range of cell 
lines that have originated from different organs when responding to the same chemical 
stresses induced by chemotherapeutic drugs, I think it will be a good idea to try a more 
extensive range of cells (both cell lines and primary cells) from different organs to see 
whether they also utilize the same cell death mechanisms. It will be also interesting to 
use a more extensive range of different chemotherapeutic drugs to see whether they also 
utilize different cell death mechanisms. As one of the key novel findings from this study 
is that some of the more commonly used chemotherapeutic drugs can cause autophagic 
cell death, it will be much better if this could be further confirmed by using other 
different techniques such as investigating the effects of autophagy inhibitors to see 
whether they can reduce chemotherapy drug induced cell death. 
Regucalcin, was shown to protect cells from some chemotherapy drug toxicity, and this 
study could be extended to incorporate a wider range of drugs, to see if all cytotoxic 
drug classes are protected by RGN. In addition, compounds that are known only to 
cause cell death by a single pathway (ie apoptosis, necrosis or autophagy), could also be 
used to see how efficient RGN is at protecting against specific pathways. Given the fact 
that from my studies it was shown that RGN localizes around the nucleolus, it would 
also be interesting to investigate whether RGN affects any of the functions carried out 
by this intra-nuclear structure. 
The research that has been discussed in chapter 5 has explored that increased expression 
of SERCAs, but not SPCAs, can protect COS-7 cells from DOX –induced cytotoxicity. 
Other questions that can be easily addressed include: Is this protection also seen in other 
cell types? Which other drugs can increased SERCA expression, protect against?  Does 
the cell death pathway protected by increased SERCA, involve ameliorating the effects 
of elevated cytosolic [Ca
2+
] levels or decreased ER luminal [Ca
2+
] levels or both?  
Finally, are the cyto-protective effects of RGN and SERCA additive? Can increasing the 
expression of both these Ca
2+
 binding proteins, in patients through dietary and hormonal 
means, protect them from drug induced toxicity? 
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